A comparison of classical bioequivalence analysis techniques with simulated annealing algorithm optimised sampling times and population pharmacokinetic modelling by Cudjoe, Senyo Frank Kofi
A Comparison of classical Bioequivalence
analysis techniques with Simulated annealing
algorithm optimised sampling times and
population pharmacokinetic modelling
School of Statistics and Actuarial Science
BY
Senyo Frank Kofi Cudjoe
937561
Supervisor
R Krommenhoek
A Dissertation submitted to the Faculty of Science,
University of the Witwatersrand, Johannesburg, in
fulfilment of the requirements for the degree of Master of
Science
October, 2017
Declaration
By submitting this dissertation for the qualification of Master of Science degree
in Mathematical Statistics at the University of the Witwatersrand, I declare
that the entirety of the work contained therein is my own, original work and
that I am the authorship owner thereof ( unless to the extent explicitly) and
I have not previously in its entirety or part submitted it for obtaining any
qualification at another university. I further declare that all sources cited or
quoted are indicated and acknowledged by means of a list of references. I fur-
ther cede copyright of this dissertation to the University of the Witwatersrand.
Signed:
Date:
i
Abstract
Bioequivalence (BE) studies are conducted to demonstrate that two drug for-
mulations produce similar bioavalabilities or therapeutic effect and safety when
used. During this study, drug concentrations are obtained several times over
a given period of time and a concentration vs. time graph is constructed. For
a generic drug to be approved, this BE studies are conducted and the generic
drug must be demonstrated to be therapeutically equivalent to the innovator
drug.
This study utilised a standard 2× 2 crossover design to randomly assign sub-
jects to each of the two sequences. Statistical methods such as confidence in-
tervals, Schuirmann’s two one-sided and Wilcoxon-Mann-Whitney tests were
used to assess average bioequivalence (ABE). However, there are concerns that
the use of ABE alone is not appropriate for drugs with high intra-subject and
inter-subject variabilities. Under such a circumstance, population bioequiv-
alence (PBE) and individual bioequivalence (IBE) are proposed. This study
employs the PBE approach but not the IBE as it is not possible to perform
IBE on the available data. Results indicated that the generic drug is average
bioequivalent to the innovator drug although Cmax was outside the regulatory
range set by the Food and Drug Administration (FDA).
Most biological data are modelled using nonlinear fixed effect models. Popula-
tion pharmacokinetic (PK) modelling has been used in clinical pharmacology
to identify the sources of PK variability in the target population. This study
was conducted to determine the characteristics of the PK parameters of the
orally administered antibiotic given to pigs using a population approach. A
population PK model was developed using a nonlinear mixed effects model
(NLMEM) with a one-compartment model using different residuals. For the
NLMEM, the stochastic approximation expectation maximisation (SAEM) al-
gorithm was implemented in MONOLIX. The models were used to estimate
ii
the population PK parameters and diagnostic plots obtained for model eval-
uation. The results showed that the combined residual error model fitted the
data better than the constant error model.
In addition, this study sought to find optimal sampling times which will min-
imise the number of blood samples required for pharmacokinetic study. The
optimal sampling times were generated from a one compartment model and
implemented in MATLAB. The parameters used in the optimisation were es-
timated from the population PK model. These sampling times were generated
using the simulated annealing (SA) algorithm.
Keywords: Bioavailability, Bioequivalence, generic drugs, reference drugs,
average bioequivalence, population bioequivalence, individual bioequivalence,
pharmacokinetics, pharmacodynamics, therapeutic window, confidence inter-
val, nonlinear fixed effects model, two one-sided tests, maximum likelihood,
population parameters, optimal sampling design, concentration-time curve,
model evaluation, Visual predictive checks (VPC), Normalised prediction dis-
tribution errors (NPDE), Stochastic approximation expectation maximisation
(SAEM) algorithm.
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Chapter 1
Introduction
1.1 Background of the study
Some patients live most of their lives on drugs in order to control certain con-
ditions or cure illnesses. Some of these patients suffer from conditions such
as epilepsy or asthma which require regular use of drugs. These patients take
drugs to relieve pains which they feel most often. Whenever drugs are pre-
scribed by medical doctors and given by pharmacists to subjects, a schedule
of the quantity and time during which the drugs should be taken is prescribed
and generally referred to as dosage regimen. Dosage regimen refers to a sched-
ule of doses of a therapeutic agent per unit of time including the time between
doses, for example, every 2 hours or time the doses are to be taken, for exam-
ple, 9am and 5pm daily, or the amount of medicine, for example, number of
capsules, to be given at each specific time (Rowland and Tozer, 1995). The
duration of the drug therapy and the dosage regimen depends on the objective
which could be a prevention of the disease, cure or reduce the severity of the
disease.
Answers to therapeutic questions were obtained using a trial and error ap-
proach in the past (Rowland and Tozer, 1995). With the trial and error ap-
proach, the dose, the interval between the dose and the route of administration
are selected by the pharmacist. The medical doctor then follows the effect of
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the drug on the subject, takes note of the desired effects of the drug such as
pain relief and any complex issues arising from it. The dosage regimen may
then be adjusted until a suitable balance is obtained between the desired ef-
fects and the dose of the drug which may be harmful to the body. After a
substantial experimentation on a large number of subjects, a dosage regimen
which seems to be reasonable is established. In order to prevent the drugs
from being toxic to the body or being ineffective when taken when using the
trial and error approach, it is very important to examine what happens after
a drug is administered to a subject. In order to administer a drug optimally,
one needs to understand or have knowledge of the mechanisms of the drug
absorption, distribution, elimination and also the kinetics of these processes,
i.e. pharmacokinetics (Rowland and Tozer, 1995).
Drug administration can be divided into two phases, namely pharmacokinetic
phase and pharmacodynamic phase (Rowland and Tozer, 1995). In the phar-
macokinetic phase, dose, dosage form (tablet, capsule, solution, etc), frequency
and route of administration are related to drug level-time relationships in the
body and in the pharmacodynamic phase, concentration of drug at the site(s)
of action is related to the magnitude of the effect(s) produced (Rowland and
Tozer, 1995). Pharmacokinetics (PK) is the study of the time course of the
absorption, distribution, metabolism and excretion (ADME) of a drug after
its administration to the body (Bauer, 2008). PK deals with the movement
of the drug in a body after its administration while pharmacodynamics (PD)
is the study of the relationship between the concentration of a compound at
its site of action, where the therapeutic targets are located and the magnitude
of the pharmacological response (Fan and de Lannoy, 2014). In simple terms,
PK describes what the body does to the drug while PD describes what the
drug does to the body (Abel-Rahman and Kauffman, 2004).
After a drug is administered into the body, it normally undergoes four dif-
ferent stages before being eliminated from the body. These four stages are
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known as ADME: Absorption (process where the drug is taken by the body
through the mouth), distribution (the process where the drug is carried by
the body through blood to action site), metabolism (the breaking of the drug
substance into by-products), and elimination (dispersion of the drug product
by the body).
In PK studies, after a drug is administered, the subjects are monitored for a
period and a certain number of blood samples are drawn to measure the time-
course of the plasma drug concentration (Choi, Caffo and Rohde, 2007). An
approximation of the concentration-time curve (CTC) is constructed. PK pa-
rameters such as area under the curve (AUC), maximum concentration (Cmax)
and time to reach maximum concentration (Tmax), are then estimated using
the observed drug concentration profile for each person. Optimisation of the
sampling times increases the accuracy of the PK parameters and reduces the
number of blood samples which are drawn from the subjects (Asyali, 2010).
This enables an optimum number of blood samples to be taken, which may
give better results and prevent inconvenience on the part of the subject.
Since the basic concepts of PK are common to all drugs, information from
the PK of one drug can be used in anticipating or projecting the pharmacoki-
netics of another drug. Knowledge of the pharmacokinetics of a drug helps
the pharmacist to predict the optimal dosage regimen for individual patients
and also what happens when a dosage regimen is altered (Rowland and Tozer,
1995). Whenever a new drug is discovered, an appropriate dosage form must
be developed for the drug to be distributed efficiently to the body so that the
body can obtain beneficial results from the treatment (Chow and Liu, 2008).
Different dosage forms could be designed for a drug to serve a specific pur-
pose. For example, liquid dosage forms may be appropriate and convenient for
different categories of individuals such as children and elderly people. Gener-
ally, most drugs are administered orally which are often in solid forms. These
solid drugs have to be dissolved in the blood or the tissues in the body after
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administration of the drugs in order to be absorbed by the body.
1.2 Definition of Bioequivalence studies
Bioequivalence (BE) studies are conducted by a generic pharmaceutical indus-
try as well as pharmaceutical companies that seek access to market generic
drugs of brand formulations when their patent expires. The PK parameters of
the CTC are used to demonstrate the safety and efficacy of the generic drug
(bioequivalence) instead of performing a clinical trial which is usually more
expensive and time consuming. These studies are usually conducted to reveal
that two drugs are similar to each other in terms of safety (non-therapeutic
side effects) and efficacy (therapeutic benefit) and therefore very important in
drug development (Patterson, 2003). They are carried out to meet regulatory
standards that are set by bodies such as the Food and Drug Administration
(FDA), European Agency for the Evaluation of Medicinal Products (EMEA)
and the South African Medicine Control Council (SAMCC) and are the main
focus of this dissertation.
A bioequivalence study is performed on the test drug to assess the clinical or
psychological effect. The motivation for this study is to assess the expected
in vivo biological equivalence of two proprietary preparations of a drug. If
two products are bioequivalent, it means that they would expect to be, for all
intents and purposes, the same.
1.3 Statement of the Research problem
When the right to produce and sell a drug expires, the company that devel-
oped the original drug (a base measurement for others) may try to develop a
new formulation with the same active ingredients (Rebull, Sanchez, Pla and
Pla, 2008). During the development period of the new drug formulation, BE
studies is used to address the issue of high costs of drugs as this study produces
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drugs which cost less compared to the reference drug. This is mostly done to
reduce the price of the drugs in the market and thereby making it affordable
to the general public whilst serving the same purpose as the reference drug.
Other companies may also try to develop a generic drug that is comparable in
dosage form, quality and strength to the original drug.
A generic (test) drug is a drug which has more or less the same chemical com-
position and is as effective, after it has been administered to a patient, as the
original (reference). To obtain approval to produce the test drug, the FDA,
SAMCC and other agencies require proof of equivalence between the reference
and test drug. The test drug, however, ought to be identical to the reference
drug in terms of efficacy, safety and usage. For the test drug to be accepted
and sold in the market, it needs to meet standards set by the FDA and other
agencies.
This concept, which is termed BE, is used to describe two drugs with two dif-
ferent dosage forms, yet have similar bioavailability and are pharmaceutically
equivalent both in terms of efficacy and safety after administration (Chow
and Liu, 2008). BE attracts global attention particularly in the pharmaceuti-
cal industry but is also of major concern to government agencies, healthcare
providers and individuals. BE addresses a typical question: ”Can a test drug
be prescribed for a subject who previously has been receiving the reference
drug without any significant change in therapeutic effect”?
A BE study is performed on the test drug to assess the clinical or psycholog-
ical effect. This study is done to enable drug switching to reduce the cost of
the drugs and to compare the test drug’s performance to that of the reference
drug. The motivation for this study is based on the urgent need to address
drug affordability as well as to have test drugs that have the same therapeutic
effect as the reference drugs.
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The concept of bioavalability (BA) refers to the rate and extent by which the
drug is available at the site of action (Chow and Liu, 2008; Rebull et al.,
2008). BA is expressed by several parameters obtained from the curve of the
concentration-time graph of each subject after a single dose administration
of a drug. The main BA parameters are Tmax, Cmax, AUC0−t, and AUC0−∞
(Chow and Liu, 2008).
The problem can be addressed by designing a study to compare formulations
of a reference drug with a generic drug with respect to pharmacokinetic pa-
rameters such as AUC, Cmax and Tmax. It is also desirable to determine the
optimal times blood samples are collected from subjects for the purpose of hav-
ing a better and precise estimate of the PK parameters and possibly reduce
the cost of the study and the inconveniences brought upon the subjects in the
study. During the design phase of BE studies, blood samples are drawn over
time from subjects administered with drugs and PK parameters are estimated.
The pharmacokinetic parameters often estimated or measured are AUC, Cmax
and Tmax. Based on the values of the PK parameter estimates, the drug could
be accepted as the test drug for the reference drug or rejected. The main aim
of this study is to determine if bioequivalence can be obtained using different
classical approaches and to determine the optimal sampling times for such a
study. This helps to reduce the cost of the bioequivalence study and reduce the
inconveniences to the subjects on whom the study is conducted. The findings
will help pharmaceutical companies to manufacture test drugs which can be
used to treat the same or similar conditions the reference drugs could do but
being more cost effective.
In most cases, modelling biological data involves fitting nonlinear models to
the available data. In PK, a subject’s reaction to a drug is studied which
usually is a quick increase in the concentration after the drug is given and a
gradual nonlinear decrease as it moves through the body to the action site
and eventually eliminated from the body. There are a number of methods
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and software which are used in modelling population PK but are not able to
diagnose the model fit properly. This is addressed in this dissertation through
developing different models using a one-compartment model and checking the
model assumptions and goodness of fits for the models and visualising the
model diagnostics. Parameter estimates were determined which were used
from the optimal sampling times to determine bioequivalence.
1.4 Significance of the study
The rate and extent of BA could be affected or influenced by any small change
in the contents of the formula and compaction of the drug into tablets (Patter-
son, 2003). The use of test drugs as substitutes for the reference drugs enables
the market to be provided with inexpensive, efficacious and safe drugs without
necessarily repeating the entire clinical development of the drug, which drives
the need to conduct BE studies.
The cost of healthcare has been increasing over the past decades and the price
of drugs was identified as the main cause (Chow and Liu, 2008; Midha and
McKay, 2009; Kamerow, 2011). According to Gray (2009), a commission of
inquiry was established in South Africa in 1961, 1978 and 1985 to investigate
the escalating costs of healthcare which included medicines. The recommen-
dations of the three commissions of inquiry, namely the Snyman, Steenkamp
and Browne commissions, stated that patent legislation was the main cause of
high prices of drugs in the South African pharmaceutical market and identified
test drugs as a way to save the cost of healthcare (Gray, 2009).
The reference and test drugs are both available in the market; however, the
reference drugs are more expensive than the test drugs. The availability of
the test drug in the market helps to create competition between the reference
and the test drug which eventually results in a significant drop in the price of
the drugs resulting in making the drug affordable. However, for the test drug
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to be accepted and sold in the market, it needs to meet regulatory standards
which are set by regulatory bodies such as FDA, MCC and others.
According to Henry and Lexchin (2002), lack of access to the most important
drugs is not only a problem that faces less developed countries but also people
in the developed countries. Some of the people, especially elderly people and
people without medical insurance, are not able to afford the drugs they need
due to the high prices of these drugs. The introduction of the test drug form of
Omeprazole, as stated by Henry and Lexchin (2002), in the Australian market
saw a significant drop of 43% in the price of the reference drug Losec within a
period of 2 years and also a 97% drop in the price of the test drug form of the
combination antiretroviral drugs after being marketed by a test drug producer.
These significant price drops in the prices of the two drugs are illustrated in
Table 1.1.
Table 1.1: Effect of test drugs on the prices of drugs.
Omeprazole(Australian) Antiretroviral Combination Therapy
Generic product Branded product Generic product Branded product
Date
Price
(US$)
Date
Price
(US$)
Date
Price
(US$)
Date
Price
(US$)
November
1998
N/A
November
1998
43.28
July
2000
230.59
September
2000
869.92
November
1999
30.86
November
1999
31.27
September
2000
66.67
October
2000
77.58
November
2000
30.01
November
2000
30.63
February
2001
29.17
March
2001
59.33
November
2001
24.10
November
2001
24.51
August
2001
24.58
August
2001
59.33
The motivation for this dissertation is based on the urgent need to address the
issue of drug affordability as well as to have test drugs with similar therapeutic
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effects as the reference drugs. The findings will help inform pharmaceutical
companies to manufacture test drugs which can be used to treat similar con-
ditions to those treated by the reference drug but at an affordable price.
According to Karim, Pillai, Ziqubu-Page, Cassimjee and Morar (1996), the
escalation in the health care cost in South Africa is partly due to the high
costs of drugs. They further stated that test drugs have been identified as
a mechanism for healthcare cost reduction. This has led the Pharmaceutical
Society of South Africa (PSSA) to introduce the Maximum Medical Aid Price
(MMAP) as a payment option in the private sector to encourage the use of
test drugs. The study reviewed 1570 prescriptions which had 4086 items and
found that 45.7% of the total prescriptions had at least an item with a test
drug equivalent. However, only 0.3% of the prescribers were against test drug
substitutions. The reference drugs’ prices were 9.9% greater than their test
drugs’ prices (Karim et al. 1996) as indicated in Table 1.2.
Table 1.2: Prices of prescription (in Rands) received by 10 Pharmacists on 4
selected days.
Price of all 1570
Prescriptions
Mean price
Reference drug 189042.56 120.49
Test drug 172038.68 109.65
1.5 Aims
The aims of the study are to:
• Determine the optimal times blood samples could be taken from subjects
after administration of test drug formulations in order to estimate PK
parameters such as AUC, Cmax and Tmax;
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• Establish bioequivalence between the reference (R) and test (T) drug for-
mulations for both the original measurement and the simulated results;
and
• Do population Pharmacokinetic modelling.
1.6 Objectives
The key objectives of the study are to:
• Test for carryover effect, period effect and direct drug effect;
• Perform Analysis of variance (ANOVA) and use the results from the
ANOVA in the confidence interval to determine if the two formulations
are bioequivalent;
• Perform a Schuirmann’s two one-sided t-test (TOST) to assess average
bioequivalence (ABE) between the two formulations for AUC and Cmax;
• Carry out a non-parametric test i.e Wilcoxon-Mann-Whitney test on the
Tmax;
• Perform population bioequivalence;
• Determine the power of Schuirmann’s TOST for the hypothesis of for-
mulation effects, determine the size effect of the TOST;
• Use the nonlinear mixed effect model to develop a population pharma-
cokinetic model using a one-compartment model and estimate population
pharmacokinetic parameters;
• Determine optimal sampling times using simulated annealing algorithm;
• Perform BE studies using the optimised sampling times and the concen-
trations; and
• Compare the results of the classical methods obtained from the original
data to the optimised data.
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1.7 Dissertation Organisation
This dissertation consists of five chapters. The next chapter (Literature Re-
view) provides details of the history of BE studies and some of the methods
used in the assessment of bioequivalence studies. A further background of op-
timisation techniques which are used to obtain optimal sampling times in BE
studies are reviewed in this chapter. The research methodology as well as the
optimisation method for estimating sampling times using simulated annealing
algorithm are explained in Chapter 3. The results of the methods described in
Chapter 3 are presented and discussed in Chapter 4. Chapter 5 discusses the
conclusion and provides recommendations.
1.8 Limitations of the study
In this dissertation, the 2×2 crossover design which is widely used was adapted
even though it is not optimal. Higher crossover designs usually give better re-
sults compared to the 2× 2 design as they test for within and between subject
variability. The higher crossover design was not available for the data used in
this dissertation. This therefore led to the inability of performing IBE which
requires the higher order design.
The cost of the reference and test drugs were also not known so comparison to
ascertain if the test drug is cheaper than the reference drug was not carried out.
Other characteristics of the subjects such as weight and gender were not avail-
able for the population modelling and hence these covariates were not included
in the modelling.
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Chapter 2
Literature review
2.1 Introduction
The theory of BA and BE have attracted so much attention from academia,
health authorities and pharmeceutical industries over the past 30 years due
to its importance and implementation to test drugs (Hauschke, Steinijans and
Pigeot, 2007). This research is necessary due to the high cost of healthcare
particularly the high cost of drugs. This has prompted regulatory bodies to
start formulating requirements that are necessary for approving test drugs as
substitutes for the reference drugs. In the early 1970s, BE was generally tested
using the 75/75 rule (Hauschke et al., 2007). This rule used the ratio of AUC
of the test drug formulation to the AUC of the reference drug formulation in
the BE study and states that it must be between 75 and 125 per cent in order
to declare that the two drugs are bioequivalent (Buehler and Director, 2010).
However, this approach of assessing the bioequivalence between two formula-
tions received a lot of criticism. It was therefore used together with the power
approach in the early 1980s. The power approach is a method of testing in-
terval hypothesis of no difference using a standard two-sided t test at the 0.05
level of significance (Schuirmann, 1987). If the null hypothesis of no difference
under the power approach is rejected, then µT and µR are not considered to be
equivalent and if the hypothesis of no difference is not rejected, the power of
the test is being questioned. The power should be at least 0.80 before failure
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to reject the hypothesis of no difference may be taken as evidence that µT and
µR are equivalent.
According to Midha and McKay (2009), the FDA started to research the BA
of new drugs which led to the formation of a BE study panel by the Office of
Technology Assessment (OTA). This office was mandated to study the thera-
peutic and chemical equivalence of two drug formulations. The United States
of America congress then enacted the Drug Price Competition and Patent Ter-
m Restoration Act of 1984 authorising the FDA to accept test drugs for use
when there is evidence of BA and BE studies (Midha and McKay, 2009). The
activities of the FDA are the examination, acceptance or rejection of the test
drugs application. A core objective of the act was to ensure that even though
less expensive test drugs are produced, the quality was not compromised so as
to ensure the safety and efficacy whenever it is taken by patients. The FDA
frequently publishes guidelines on how BA and BE studies can be conducted
on test drugs. These guidelines provide the different statistical methods that
are approved by the FDA and their acceptance criteria.
BE studies are important in assessing the efficacy, safety and clinical effect of
test drugs. They enable effective switchability between the reference and test
drugs thereby making the test drug affordable to most people. The ability to
collect blood samples from subjects at optimal times save cost of BE studies
and reduce the inconvenience caused to the subjects. The next section is a
review of literature on BE studies.
2.2 History of Bioequivalence
Clinical trials that are used to register drugs into the market place use small
samples of the total population of people who will eventually take the drugs.
Due to this, not all the patients will benefit from it and experience the same
level of safety while taking the drug. However, the risk should be minimised
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or held at an acceptable level with regards to the policies. When the patent
period of a drug expires, new formulations (test) could be marketed which
generate profit for the companies that produce them and offer benefits as well
to the general public (lower costs) (Strom, 1987). However, there were reports
of failures of some of the test drugs in the United States which received pub-
lic attention leading to establishing standards and requirements for test drugs
to be accepted into the market especially drugs which have a very narrow
therapeutic index (drugs which result in large change response with a small
change in dose) (Rheinstein, 1990; Calvert, 1996). There are other examples
of bioinequivalence for Carbamazephine as stated in Welty et al. (1992).
The FDA was then given the authority by the Drug Price Competition and
Patent Term Restoration Act of 1984 to generate a procedure of approving test
drugs which needed to be introduced into the marketplace. The FDA in 1985
approved one hundred and twenty two test drugs whose patent periods ex-
pired for marketing (Strom, 1987). According to Patterson (2003), crossover
designs were very important and of general interest in clinical trials in the
1960s through to the 1980s. In a crossover design there is a random allocation
of subjects to different sequences where each sequence receives different treat-
ments (Jones and Kenward, 2014). A further discussion on crossover design is
conducted in Chapter 3.
Jones and Kenward (2014) indicated that the history of BE studies started
in the 1960’s. Also, bioequivalence studies, according to Midha and McKay
(2009), have been ongoing for the past decades and are accepted as the mea-
sure of approval for test drugs to be marketed and sold at reduced costs. BE
studies are conducted to demonstrate that drug products are equal in rate and
their extent of absorption (Patterson, 2001). Patterson further stated that
bioequivalence studies dated back to the 1970’s through to the 1990’s with
average bioequivalence being the accepted standard for the approval of test
drugs. Chow and Liu (2008) also indicated that bioequivalence studies, which
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dated back to 1970’s, could be divided into four stages.
The first stage, which dates back from the early 1970’s to 1984, during which
the Drug price Competition and Patent Restoration Act was passed, gave the
authorization to the FDA to accept test drugs when there were BA and BE
studies available. The second phase began from 1984 to 1992 and provided
companies with guidance on how the data should be analysed and presented.
The third phase started in 1992 and addressed population and individual bioe-
quivalence concepts as well as statistical methods used for each. The fourth
phase started at the beginning of the twenty-first century. It was based on
research conducted in the past three decades in the twentieth century prompt-
ing the FDA to issue and implement guidelines for the statistical methods for
bioequivalence studies.
Test drugs in South Africa are controlled and regulated by the Medicines Con-
trol Council which was formed in the 1970s (MCC, 2003). It was constituted
under the Medicines and Related Substance Act 101 of 1965 to monitor and
regulate the manufacturing of test drugs. The MCC is mandated to ensure
that drugs that are marketed and used in South Africa are safe for public con-
sumption.
Kong and Gonin (2000) use an optimisation technique for calculating the opti-
mal time design for one compartment model. This was to select the sampling
times optimally in order to improve the accuracy of the AUC estimates in a BE
test. In the article they consider a compartment open model while assuming
that the drug follows a first order absorption. The compartmental model in
Equation 2.1 has the concentration-time curve given as
Ct =
DKa
V (Ka −Ke)(e
−Ket − e−Kat), (2.1)
where D, V , Ka and Ke are positive constants, 0 ≤ t ≤ ∞ where t is the
time the blood samples are drawn, D denotes the dose of the administered
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drug, the volume of drug distribution is denoted by V, and the absorption and
elimination rate constants of the drug are denoted as Ka and Ke, respectively.
The dose administered as well as the volume of distribution were considered
to be constants for healthy subjects, whereas the elimination rate constant de-
pended on the drug formulation and subjects, but was assumed to be constant
due to its low variability.
Kong and Gonin (2000) conducted simulation studies using different values of
Ka and Tf (final sampling time) and found that the proposed optimisation
technique improves the regular design. From the empirical results, the unex-
plained AUC mean percentage for the regular design is -1.1 with a standard
deviation of 1.5 while the unexplained AUC mean percentage for the optimal
design is 0.001 with a standard deviation of 0.9. The study suggested six to
eight sampling points to be the best number of sampling times in BE studies.
The proposed optimal design method which was used in the study induces
little bias in the estimation of the total AUC and the calculated AUC is more
reliable.
Choi et al. (2007) in their article investigated the appropriate time to choose
samples in order to evaluate the AUC. They explored the advantages of several
objective functions and suggested an objective function which addressed the
inadequacies of the existing objective functions. A simulated annealing algo-
rithm (SA) was used in this minimisation process. A new objective function
based on squared bias was used to estimate AUC as well as a Monte Carlo
integration approach which was used to simplify the calculations. They dis-
cussed two methods for defining the objective functions. The first uses the
mean squared error (MSE) for estimating AUC while the second uses MSE
for estimating the concentration time curve using linear interpolation to define
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the objective function. They proposed an objective function
ObjG(t; β) =
m+1∑
j=1
{[
E(Aˆ
g(j−1)(1)
tj−1 )− Ag(j−1)(1)tj−1
]2
+
nj∑
k=2
[
E(Aˆ
g(j−1)(k)
g(j−1)(k−1))
− Ag(j−1)(k)g(j−1)(k−1)
]2
+
[
E(Aˆ
tj
g(j−1)(nj))− A
tj
g(j−1)(nj)
]2}
.
(2.2)
which divides the number of divisions between the time intervals tj−1 and tj
equally based on the interval length. This makes it possible to estimate the
errors made in approximating the AUC and the true AUC for every division
after which the results are to be summed up.
Gibaldi and Perrier (1982) used a one-compartmental pharmacokinetic model
which has a first-order elimination kinetic and first-order absorption which is
similar to the one in Equation 2.1.
Asyali (2010) used the cubic spline approximation approach to the concentration-
time curve and initiated a global optimality criterion whose main focus was to
determine how close all the PK parameter estimators were to their true values
simultaneously. He investigated a one compartmental model with a first order
absorption rate which is the same as the one in Equation 2.1. Asyali (2010)
proposed the global optimality criterion (GOC) which uses the euclidean norm
as a measure of closeness of the estimated values to the actual values to indicate
the accuracy of AUC0−24 (area under the concentration time curve from zero
to 24 hours), Cmax (peak drug concentration) and Tmax (time required to reach
peak drug concentration). The GOC is given as GOC(t1, t2, ...tN) =‖ θˆ−θ ‖2=(
ˆAUC0−24 − AUC0−24
)2
+(Cˆmax−Cmax)2 +(Tˆmax−Tmax)2. The optimal sam-
pling times are determined by minimising the GOC with respect to t1, t2, ...tN ,
where N is the last sampling time. In the study, he considered several ways
to enhance the spline approximation in order to obtain the optimal sampling
times by minimising the GOC using another optimisation technique known as
sequential quadratic programming (SQP). The SQP is a method for numerical
solution of constrained nonlinear optimisation problems. It is a conceptual
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method from which numerous specific algorithms have evolved and is backed
by a theoretical and a computational foundation. The SQP method finds an
approximate solution of a sequence of quadratic programming subproblems in
which a quadratic model of the objective function is minimized subject to the
linearised constraints. It is established that this approach gives more precise
estimates of PK parameters with a small number of samples.
Jones et al. (1999) described a method which is used to construct D-optimal
designs for a nonlinear mixed effect model (NLMEM) in crossover PK studies
based on a model which uses generalised least squares. The variables, such as
the parameter values as well as the design points, are specified in the model
while samples are simulated under the simulation approach. The performance
of the design is assessed using the estimated model parameters and their corre-
sponding variances. A nonlinear mixed model (NLMMs) in Equation 2.3 with
random and fixed effects was used to analyse the data,
yijq = f(tq, θij) + εijq, (2.3)
with yijq being the concentration for the ith subject in period j at time
q, f(tq, θij) is a nonlinear function representing the mean pharmacokinet-
ic response, the measurement time represented as tq, and θij represents a
vector of pharmacokinetic parameters for the ith subject in the jth period.
εijq ∼ N(0, σ2e) is a random measurement error. The pharmacokinetic param-
eters were estimated using Equation 2.4:
θij = Xijβ + µi, (2.4)
where Xij = xij ⊗ Im, Im is an m ×m identity matrix, xij represents a 1 × l
covariate vector which constitutes the crossover design, ⊗ represents the Kro-
necker product, β represents an lm × 1 vector of coefficients for the period,
mean, and treatment effect and µi ∼ N(0, σ2) is a subject effect vector.
Jones et al. (1999) used the D-optimality criterion which makes the determi-
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nant of the information matrix to be as large as possible. The values for the
mean, period, treatment effect, and variability of the data are determined us-
ing Equation 2.3 to fit the within-subject model to each individual subject and
Equation 2.4 to estimate parameters. The optimal design criterion changed
significantly when period effects were included or excluded.
D’Argenio (1981) used a procedure which adopts a sequential estimation ap-
proach for the optimal selection of the sampling times to estimate the parame-
ters of the model. This technique used parameter estimates from previous sub-
jects to estimate the optimal times for the next subject in the group. Monte
Carlo simulations were used to compare the estimated parameters using the
optimal sequential estimation method for the parameter estimates versus using
the conventional method of choosing the sampling times. He assumed that the
kinetics of the drug can be represented by a first order ordinary differential
equation given in Equation 2.5:
x˙ = f(x, α∗, r, t), x(0) = g(α∗), (2.5)
where x is a vector representing compartmental concentration, r represents the
piecewise constant input vector, the independent variable is represented as t, α∗
denotes the true but unknown constant parameter vector, and x(0) represents
the initial condition vector which could be a function of the unknown parameter
as well. From the results obtained by D’Argenio(1981), the mean and standard
deviation of the optimal sampling experiment were smaller than that of the
conventional sampling type (sampling points chosen randomly) from empirical
results obtained. The optimal method produced smaller parameter estimate
standard deviations as compared to the conventional approach. The average
percentage bias was 18% for every parameter when using the optimal sampling
approach while it was 56.5% for both Kel (elimination rate constant) and
Kcp (central to peripheral rate constant) (D’Argenio, 1981). The conventional
method gave a larger average percentage bias compared to the optimal method.
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2.3 Bioavailability and Bioequivalence
2.3.1 Introduction
Bioavailability and bioequivalence are important to both the producer of the
reference drug and the test drug for marketing the drug. FDA approval of any
test drug requires proof of bioequivalence, usually ABE between the reference
and test drug.
2.3.2 Bioavailability(BA)
According to Chow and Liu (2008), BA is the amount of a substance that be-
comes available to an organism’s body for bioactivity when introduced through
ingestion, inhalation, injection or skin contact. Rate of bioavailability depends
on factors such as type of the substance, whether fat soluble or water soluble
and the composition of the diet. Whenever a drug is administered either orally
or through any other route, an adequate quantity of the administered drug is
absorbed over a period of time before its effect can be felt. The BA for oral
drugs that are delivered into the body system can be considered a measure
of both the rate and total amount of drugs reaching the general circulation
from an administered dosage form (Welling, 1984). This assesses the process
whereby the drug is delivered from the dosage form and moves to the part of
the body where the drug effects are expected and therefore the drug’s absorp-
tion, distribution, metabolism and the elimination processes can be determined
(Kimura and Higaki, 2002).
The major parameters measured in BA are (Terry et al., 1982):
• Cmax - the peak plasma drug concentration used to determine the rate
of drug BA;
• AUC - the area under the concentration time curve which is a measure
of the extent of drug BA; and
• Tmax - the time required to reach maximum drug concentration after the
administration of the drug.
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The extent and rate of oral absorption of a drug is vital in pharmacokinetics
as it is responsible for the physiological action of the drug and thus referred
to as drug bioavailability (Caccia and Garattini, 1990). A certain fraction of
the drug is metabolised while passing through the liver or other organs. Only
a portion of the consumed drug reaches the site of action and this can result
in ineffectiveness of the drug in treating the illness. A comparative BA study
compares the BA of different drug formulations of drugs which are similar
(Chow and Liu, 2008).
2.3.3 Bioequivalence (BE)
Two drugs are considered as pharmaceutically equivalent whenever they con-
tain interchangeable quantities of similar active ingredients but not necessarily
of the same amount or dosage (Chow and Liu, 2008). Comparing the thera-
peutic performance of two drug formulations is important to assess the chances
of using a similar drug product (test) as an alternative to another (reference).
These two drugs could either be produced by the same manufacturer or by
different manufacturers. The BE can be measured in at least three ways:
chemically, biologically, or therapeutically (Asyali, 2010).
The BE assessment is an issue which is of great concern to the biopharma-
ceutical industry (Metzler, 1974). A test drug may be used as a substitute
for the reference drug if it complies with regulatory requirements and meets
certain criteria in a particular country. The use of pharmacokinetic concepts
and parameters have made BA and BE studies now acceptable for expensive,
complicated and lengthy clinical trials.
There are three reasons for conducting BE studies. These are:
• when the dosage form that is proposed for the market is totally different
from the one used during the clinical trials;
• when there are important changes during the process of manufacturing
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a marketed formulation; or
• where a new test formulation is being tested against the reference for-
mulation (Chow and Liu, 2008).
Ghosh and Rosner (2007) explained that whenever the rate and degree of
absorption of the reference formulation and its test formulation show similar
drug concentration-time profiles, they exhibit similar therapeutic effects. Test
drugs need to show BE with the reference drugs, in vivo, in order to be ac-
cepted in the market as therapeutically effective. There are three kinds of
bioequivalence methods: average bioequivalence (ABE), population bioequiv-
alence (PBE) and individual bioequivalence (IBE) (Chow and Liu, 2008).
2.4 Decision Rules and Regulatory Aspects
2.4.1 Average Bioquivalence
The ABE is a recommended method by regulatory bodies including the FDA
for comparing BA measures in BE studies (FDA, 2001). It mainly compares
the population averages of a BE measure rather than the variances of the mea-
sure for the test (T) and reference (R) drugs (Chow and Liu, 2008). In order
to show that an R drug and the T drug are average bioequivalent, it becomes
necessary to prove that the Cmax and AUC for the T drug is not significantly
different from the Cmax and AUC of the R drug.
However, ABE does not consider the variability of the T drug and R drug.
The advantage of ABE is that it is easier to interpret to patients, pharmacists
and physicians (Ghosh and Rosner, 2007). In a BE trial, a T drug is compared
to an R drug in subjects who are healthy volunteers and have to meet certain
criteria such as being older than 18 years and have a body mass index (BMI)
in the range of 18.5 to 30 kg/m2. The most frequently used statistical design
for ABE comparison is the two sequence, two period crossover design (Chow
and Liu, 2008). In a standard 2×2 crossover design, each subject in the s-
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tudy is randomly allocated to either sequence TR (test drug in the first period
followed by reference drug in the second period) or RT (reference drug in the
first period followed by test drug in the second period) separated by a sufficient
time period between each dosage for the drug which was administered in the
first period to be totally removed from the body (Jones and Kenward, 2014).
Normally at least five elimination half-lives are necessary to achieve this. A
half-life is the period required for the drug concentration in the body to be
reduced by one-half. Chow and Liu (2008) defined the washout period as a
time interval between treatments during which the effect of one treatment is
not carried over to the other. This, however, is dependent on the type of drug
and the half-life, which is usually the time in which half of the drug is removed
from the body. A drug formulation with a k -order carryover effect is one in
which the effects of a drug administered in the first period persists up to the
kth treatment period (Chow and Liu, 2008). A first-order carryover effect lasts
only one treatment period. In this research, a first-order carryover effect is
considered.
The ABE is determined by using the confidence interval approach or a two
one-sided test procedure (Schuirmann, 1987). The ABE considers equivalence
between the population means of the PK parameters for the R and T drugs.
The 75/75, 80/20, 20% and 80/125 rules were proposed by the FDA for testing
bioequivalence and are explained in the next sections (Purich, 1980).
2.4.1.1 75/75 Rule
Bioequivalence is declared for two drugs if at least 75% of the relative BA of
the T drug to the R drug formulation of each subject falls within (75%, 125%)
limits (Chow and Liu, 2008). The merits of the 75/75 rule, according to Chow
and Liu (2008), are its ability to compare the relative BA within a specific
subject, removal of heterogeneity of variability within subjects and applying it
is easy. This rule was heavily criticised by many researchers including Haynes
(1981) who revealed that the rule was responsive to certain drugs with huge
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intra-subject variabilities although the mean AUC for both the T and R drug
formulations may be exactly equal.
This rule may dismiss about 56.3% of the T drug as inadequate whenever the
variability of the inter-subject is substantial, according to Metzler and Huang
(1983). Cabana (1983) also indicated that the rule was not valid especially
whenever the inter-subject coefficient of variation (CV) of the subjects involved
is 60% and the intra-subject CV ranges from 20% to 30%. According to Cabana
(1983), this rule works best whenever the inter-subject CV is below 40% for
both the T and R drugs while the intra-subject CV is at a maximum of 30%.
Also, the 75/75 rule is no more a requirement for BE assessment because it is
not statistically meticulous.
2.4.1.2 80/20 Rule
A condition underlying this rule indicates that the study should be large to
be able to deliver a minimum of 80% of detecting correctly any difference of
20% in the average BA (Chow and Liu, 2008). This rule relies on testing an
assumption of equality for a single variable instead of testing for equivalence.
When there is no statistically significant difference in the means of the R and
T drugs and the power for any recognition of 20% difference of the R drug
average is 80%, one can conclude that the two drugs are bioequivalent (Chow
and Liu, 2008).
2.4.1.3 20% Rule
For bioequivalence to be concluded using this rule, the average BA of the T
drug formulation ought to be within ±20% of the R drug. A T drug could
exhibit about 20% of variability in average BA with an R drug using the ±
20% rule (Chow and Liu, 2008). However, according to Levy (1986), the ±
20% rule does not take into consideration the effect of safety and efficacy of
the drug. Interchangeability of the drug formulations can be problematic when
using this rule. Interchanging the T drug with the R drug can lead to a more
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than 20% difference from one subject to another (Chow and Liu, 2008).
2.4.1.4 80/125 Rule
For any drug formulations to be declared as bioequivalent using this rule, the
average BA of the T formulation should be within the FDA’s criterion of (80%,
125%) of the R drug, mostly at 90% confidence level (Chow and Liu, 2008). It is
advised that the logarithmic transformation of the AUC and Cmax parameters
should be used. However, EMEA and the World Health Organization (WHO)
accept a wider confidence interval of (75%, 133%) for the Cmax under certain
conditions. The SAMCC also accepts the same wider confidence interval for
the Cmax just as the EMEA and WHO do.
2.4.2 Population and Individual Bioequivalence
The ABE for drugs with a small therapeutic index (thus drugs for which a
small change in the dosage will be able to cause large changes in response to
treatment) becomes very complicated (Benet and Goyan, 1995). Drugs such
as Warfarin normally show very small within-subject variability (coefficients of
variation less than 10%) (Patterson, 2003). However, the sample size require-
ment for high variabilty drugs (coefficient of variation greater than 30%) is high
(greater than or equal to 30) in order to demonstrate 90% power of average
BE in a two period cross-over design (Phillips, 1990). A widened equivalence
limit, 0.7 to 1.43, as allowed by the EMEA, for Cmax has been suggested by
Midha, Rawson and Hubbard (1997) to allow such drugs access to the market
easily. The power to demonstrate average bioequivalence reduces whenever
the variability of the drug increases and it is therefore advisable to have a very
large sample size so that it is sufficient to demonstrate bioequivalence.
The ABE only considers the population means of the R and T drug formula-
tions where variation between subjects is not considered. It is therefore not
able to address the concept of switchability of the drugs and therefore did not
meet sufficient requirements for public consumption (Patterson, 2003). The
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ABE assesses the difference in the means of the formulations and does not
account for the variance of narrow therapeutic drugs and can not account
for subject-by-formulation relations. Hauck and Anderson (1992) and Wellek
(1993) argued that it is not enough to only show ABE in certain situations as
it does not indicate relevance to the individual subject and therefore proposed
the PBE and the IBE. The PBE addresses the question, “can I safely and
effectively start on the R or T drug?”. The IBE was introduced to answer the
question “can I safely and effectively switch between the R and T drug?”. For
a T drug to gain approval for access into the market, PBE is required while
IBE is required for switchability.
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Figure 2.1: Concentration profile for T
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Figure 2.2: Concentration profile for T
formulation in sequence 2.
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Figure 2.4: Concentration profile for R
formulation in sequence 2.
The T and R formulations in Figure 2.1 and Figure 2.3 show interchangeable
rates of absorption and variability while the T formulation in Figure 2.2 ex-
hibits more variability than the R formulation in Figure 2.4. According to
Hauschke et al. (2007), the two drugs in Figures 2.2 and 2.4 can be bioequiv-
alent though with high variability and thus can lead to different effects. ABE
has not been able to address this effect leading to a new concept known as
PBE which was introduced by Hauschke and Anderson (1992).
The PBE addresses the between-subject variability of the two formulations.
One other concept that ABE and PBE do not address is the safety and ef-
ficacy of subjects when they switch from one formulation to another. This
has to do with the subject-by-formulation interactions (Hauschke et al., 2007).
This concept is known as IBE and considers the subject-by-formulation inter-
actions. The PBE and IBE both consider the means and the variability of the
bioavailabilities of the subjects.
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One of the important issues which affect BE studies is whether patients who
are being treated with a T drug will experience similar results in terms of
safety and efficacy as patients who are using the R drug. In practise, each
subject responds differently to the same drug. Hence it becomes imperative
to compare the variability of bioavailability (Chow and Liu, 2008). The ex-
changeability between the two drugs is questionable whenever the variability
within the T drug is greater than the R drug even though the two drugs may
be equivalent in average bioavailability. This is a cause of concern for the T
drug. The PBE takes into account inter-subject variability (inter-subject vari-
ance) and hence solves the issue of interchangeability for subjects who need to
start either treatments. If PBE is satisfied, a patient who has not received any
of the formulations can be safely prescribed either the reference or test drug
formulations.
After a drug is marketed, the safety and efficacy might be discussed when
a drug substitution is made. This situation is related to interchangeability
or switchability. IBE considers intra-subject and subject-by-formulation vari-
ances which address changes in treatment whenever an R drug is substituted
by its T drug. IBE also allows for a precise evaluation of BE for drugs which
have very high PK variability and with narrow or large therapeutic range (En-
drenyi and Midha, 1998).
The IBE considers the possibility of switching a patient who is using the R drug
to the T drug or from the T drug to the R drug (Byron and Kenward, 2003).
It considers the within-subject variability of the subjects as well as subject-
by-formulation relations. Chow and Liu (2008) defined an assessment criteria
for PBE and IBE to be probability based and moment based as described in
the next section.
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2.4.2.1 Moment Based Criteria
This approach uses the loss of the expected squared error of the within subject
differences of BA for subjects who receive the T and R drug formulations as
well as the variability within each subject which is expressed as the loss of the
expected squared error of subjects who receive the R formulation at different
times (Chow and Liu, 2008). The moment based criterion consists of the ratio
between intra-subject variability of the R and the within subject variability of
the T drug, variability of the interaction between subject and drug formulation
and the distinction in average BA (Chow and Liu, 2008). The difference ratio
(DR) (Equation 2.6) was suggested by the FDA as a statistical approach for
establishing bioequivalence.
DR =
Difference between T and R formulations
Difference between two formulations
. (2.6)
2.4.2.2 Probability Based Criteria
This criterion assumes that the probability of the variability due to the within
subjects of BA in subjects that receive the T formulation and the R formulation
on different occasions is within a pre-determined limit (Chow and Liu, 2008).
However, this approach will not be considered in this research as it is not
recommended by the FDA (Hauschke et al., 2007).
2.4.3 Population Bioequivalence Using Moment-Based
Criteria
The creation of the benchmark for BE requires the comparison of BA endpoints
(AUC, Cmax); differences between the R and the T as well as R with itself
(Chow and Liu, 2008). Let YT , YR and Y
′
R represent bioavailabilities of the
T drug being administered once and the R drug administered twice. Also,
YT − YR and YT − Y ′R refer to the between-subject differences when doing an
assessment for PBE with YT , YR and Y
‘
R being independent (Hauschke et al.,
2007). Taking the expected squared differences and comparing the discrepancy
29
gives
E(YT − YR)2 = E(Y 2T )− 2E(YTYR) + E(Y 2R)
= (E(Y 2T )− µ2T ) + (E(Y 2R)− µ2R)− 2E(YTYR) + µ2T + µ2R
= σ2BT + σ
2
WT + σ
2
BR + σ
2
WR − 2µTµR + µ2T + µ2R
= (µT − µR)2 + σ2T + σ2R,
where µT − µR represents the difference between the means of the T and the
R drugs, σ2BR + σ
2
WR = σ
2
R and σ
2
BT + σ
2
WT = σ
2
T , E(YR − Y ′R) = 2σ2R, σ2R and
σ2T represent the total variability for the R formulation and T formulation,
respectively.
For a T drug and R drug to be declared as PBE, the equation below must be
satisfied:
Θpop =
(µT − µR)2 + σ2T − σ2R
max(σ20, σ
2
R)
< θpop, (2.7)
where θpop is the predetermined value used to determine PBE for the moment-
based criterion. The maximum variability difference that can exist between
the T and R formulation, i.e., σ2T −σ2R, is fixed at 0.02 by the FDA (1997) and
σ20 is fixed at 0.04.
The population difference ratio (PDR) is used to provide a motivation for the
choice of 0.04 as indicated below,
PDR =
√
E(YT − YR)2
E(YR − Y ′R)2
=
√
(µT − µR)2 + σ2T + σ2R
2σ2R
. (2.8)
θpop =
average bioequivalence limit+ variance allowance
scaled variance
=
[ln(1.25)]2 + 0.02
0.04
= 1.74483
PBE is therefore concluded if Θpop < θpop. However, if the assumption of
differences in the variance of the T and R formulations is not met, this criterion
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of assessment of the PBE reduces to ABE. That is, if σ2T = σ
2
R (
σ2T
σ2R
= 1), then
θpop is
θpop =
[ln(1.25)]2
0.04
= 1.24483,
which gives a linearized criterion of
(µT − µR)2 + σ2T − σ2R −max(σ2o , σ2R)θpop < 0
(µT − µR)2 −max(σ2o , σ2R)θpop < 0
(µT − µR)2 − 0.04[ln(1.25)]
2
0.04
< 0
(µT − µR)2 < [ln(1.25)]2
[− ln(1.25)] < (µT − µR) < [ln(1.25)]
0.8 <
exp(µT )
exp(µR)
< 1.25.
For any statistical assessment of PBE, the estimators of Θpop are derived using
ANOVA or the restricted maximum likelihood (REML) method using mixed
effects models. To solve the population bioequivalence problem, an appropriate
statistical approach has to be derived:
H0 : Θpop ≥ θpop
H1 : Θpop < θpop.
(2.9)
In order to conclude PBE or otherwise, a statistical approach is used where
PBE can be declared when the null hypothesis shown in Equation 2.9 is reject-
ed at the 5% level of significance. However, the FDA (1997) recommends the
two-sided 90% confidence interval method or the one-sided upper 95% confi-
dence interval method for Θpop.
The PBE looks at whether either the R or T drug can be prescribed for a
subject who is not on either of the two drugs (Jones et al., 1999). This can be
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assessed using the aggregate metric in Equation 2.10:
(µT − µR)2 + σ2T − σ2R
max(0.04, σ2R)
, (2.10)
where σ2T = σ
2
WT + σ
2
BT and σ
2
R = σ
2
WR + σ
2
BR which tests the hypothesis in
Equation 2.11,
H0 : νPBE = σ
2 + σ2T − (1 + cFDA)σ2R ≥ 0 for σˆ2R > 0.04
H0 : νC.PBE = σ
2 + σ2T − σ2R − (cFDA)0.04 ≥ 0 if σˆ2R > 0.04,
(2.11)
where σ2T and σ
2
R represent the subject variances of the T and R drugs, re-
spectively. The aggregate statistic could be formulated using a mixed model
approach based on a two period crossover design.
If the upper bound of the 90% CI for the BA parameters of interest (AUC
or Cmax) is below a pre-determined regulatory value of 1.74, PBE can be
established for the metric under consideration.
2.4.4 Individual Bioequivalence Using Moment-Based
Criteria
In order to declare that the T and R formulations are individually bioequiva-
lent, the equation given below must be satisfied,
Θind =
(µT − µR)2 + σ2D + σ2WT − σ2WR
max(σ2W0, σ
2
WR)
< θind, (2.12)
where σ2D = σ
2
BT +σ
2
BR−2ρσBRσBT and Θind denotes the predetermined bound
for the moment-based criterion for IBE assessment. However, YT , YR and Y
‘
R
are no longer independent since only a replicate COD is used in IBE.
Similarly,
E(YT − YR)2 = var(YT − YR) + E[(YT − YR)]2
= var(YT ) + var(YR)− 2Cov(YT , YR) + (µT − µR)2
= (µT − µR)2 + σ2BT + σ2WT + σ2BR + σ2WR − 2ρσBRσBT
= (µT − µR)2 + σ2WT + σ2WR + σ2D,
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and E(YT − Y ′R)2 = 2σ2WR.
Again, the FDA (1997) recommended 0.04 for σ2W0, 0.02 being the maximum
difference for the within-variances of the T and R formulations, i.e σ2WT −σ2WR,
and a maximum value of 0.03 for interaction between subject and formulation,
i.e σ2D. The value of σ
2
W0 is dependent on the individual difference ratio (IDR).
The FDA guidance suggests the individual difference ratio (IDR) which is given
as:
IDR =
√
(µT − µR)2 + σ2D + σ2WT + σ2WR
2σ2WR
. (2.13)
The largest tolerable value of the IDR is given as 1.25 by the FDA. Assuming
the 80/125 rule with a certain probability, gives ln(1.25) as the upper bound
for µT − µR. This results in the value of θind:
θind =
average bioequivalence limit+ variance allowance
scaled variance
=
[ln(1.25)]2 + 0.03 + 0.02
0.04
= 2.49
The IBE is a statistical method which is used to decide whether a patient being
treated with the R drug can be switched to the T drug (Byron and Kenward,
2003). It takes into consideration the variability within each subject and the
subject-by-formulation interaction. The aggregate metric is an approach used
for the assessment of IBE (FDA, 1997):
(µt − µR)2 + σ2D + σ2WT − σ2WR
max(0.04, σ2WR)
, (2.14)
which is used to test the following linearised null hypotheses:
H0 : νIBE = σ
2 + σ2D + σ
2
WT − (1 + cFDA)σ2WR ≥ 0 if ˆσ2WR > 0.04
H0 : νC.IBE = σ
2 + σ2D + σ
2
WT − σ2WR − 0.04(cFDA) ≥ 0 if ˆσ2WR ≤ 0.04,
(2.15)
where σ2WT and σ
2
WR denote within-subject variability for the T and R drug for-
mulations, respectively, σ2BR and σ
2
BT denote the variabilities between subjects
for the R and T formulations, respectively, σ2D = σ
2
BT + σ
2
BR − 2ρσBTσBR de-
notes the subject-by-formulation interaction with ρ being the between-subject
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correlation of the T and R drugs, and µT and µR denote the means of T and
R whilst δ = µT − µR denotes the difference between the means of the T and
the R drugs.
The metrics in Equation (2.15) are scaled using the within variance σˆ2WR and a
constant value of 0.04. Whenever the metric is scaled using σˆ2WR, it is referred
to as reference-scaled and it is called a constant scale when it is scaled using
0.04. The value of cFDA is the regulatory value of 2.49 which is set by the FDA.
The cFDA assumes a within-subject variance for R of 0.04 and is calculated as
follows:
cFDA =
[ln(1.25)]2 + 0.03 + 0.02
0.04
,
= 2.49,
which allows for a difference in means of ln(1.25) and a variance allowance of
0.03 for the subject-by-formulation interaction and an allowance of 0.02 for
the difference in within-subject variances (FDA, 1997).
If the upper bound of the 90% CI for the BA parameters of interest, either AUC
or Cmax, is below a pre-determined regulatory value of 2.49, bioequivalence can
be established for the metric under consideration.
2.5 Pharmacokinetic Parameters
The concentration time curve (CTC) is used to study the absorption and e-
limination rate of a drug in a blood sample in a comparative BA study (Chow
and Liu, 2008). At various time points, blood samples are taken after a drug is
administered. There are other pharmacokinetic metrics but they only provide
support information and are not used to approve the new formulation. It is
argued that AUC and Cmax are insufficient to provide evidence that a T drug
is bioequivalent to the R drug; however, regulatory bodies have depended on
and used the AUC and Cmax as the main metrics for bioequivalence approval
of drugs (Lacey et al., 1995; Steinijans et al., 1995; Rescigno and Powers,
1998). AUC is a PK parameter which determines the magnitude of absorp-
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tion of a drug, thus, the total quantity of the drug that is absorbed by the body.
The AUC is regarded as the best standard measure for extent of BA while the
Cmax as a measure of the rate of BA is criticized for not characterizing the
rate of BA appropriately (Cartwright, 1991; Herchuelz, 1996; El-Tahtawy et
al., 1998). The Cmax is heavily dependent on the sampling scheme and has
more variability than the AUC and therefore poses problems for assessment
of bioequivalence (Buice et al., 1996; Tsang et al., 1996; Patterson, 2003).
Despite these shortfalls of the Cmax, it is still used as one of the metrics of
bioequivalence studies because it performs better than other measures (Bois et
al., 1994). During bioequivalence studies, each of these endpoints are analysed
separately and are generally log-transformed (Westlake, 1979; Midha et al.,
1993). The normality of the AUC and Cmax are not tested after log transfor-
mation, as stated in FDA (1992) and statistical analysis is also not conducted
on the original metrics even if there is evidence that the data are not normally
distributed.
During the sampling stage, the plan outlined for taking the blood samples
should be designed properly for suitable evaluation of the pharmacokinetic
parameters for both rate and absorption. These pharmacokinetic parameters
are mostly determined either directly (model-based approach) or indirectly
(concentration-time profile approach). An example of the concentration - time
graph approach is illustrated in Figures 2.5 and 2.6. Methods for estimating
the AUC as suggested by Chow and Liu (2008) include linear interpolation
which uses the trapezium rule, a planimeter, spline and lagrange methods and
a physical method. However, the linear interpolation technique is the most
widely used. For the linear interpolation method using the trapezoidal rule,
let C0, C1, ...Ck be the blood concentrations obtained at times 0, t1, ...tk. Then
AUC0−tk is obtained using Equation 2.16,
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AUC0−tk =
k∑
i=2
(
Ci−1 + Ci
2
)
(ti − ti−1). (2.16)
Although the AUC is normally calculated from time zero to time t, Hauschke
et al., (2007), suggested that AUC from zero to infinity in a single-dose study
should be determined. Martinez and Jackson (1991) articulated that a fraction
of area under tk to infinity may be large, should the level of blood at tk be sig-
nificant. The AUC from time zero to infinity, which is represented as AUC0−∞,
is approximated using the equation shown in Equation 2.17 (Rowland, 1980;
Chow and Liu, 2008),
AUC0−∞ = AUC0−tk + (
Ck
λ
). (2.17)
This serves as the extent of absorption in single-dose studies. After the drug
is administered, Ck is the concentration of blood which occurs at the last
sampling time point, λ is the elimination rate constant and given as λ =
−2.303 × gradient of the terminal segment of the log concentration time curve
(Chow and Liu, 2008). The time interval for the calculation of each λ as
well as AUC0−t/AUC0−∞ is indicated in Table 2.1. According to Hauschke et
al. (2007), the percentage ratio of AUC0−t/AUC0−∞, as shown in Table 2.1,
should exceed 80% for each subject. This is important not to over extrapolate
the AUC0−∞. From Table 2.1, only one subject had the percentage ratio to
be 78% while the rest are above 80%. The values for the percentage ratio,
AUC0−t/AUC0−∞, therefore confirms that the choice of the ultimate section
of the logarithm concentration time curve used to calculate the lambda value
is consistent and accurate.
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However, there are challenges in estimating the terminal portion of the log-
linear plot for the concentration-time graph as indicated in the concentration
time graph (Figures 2.5 and 2.6).
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Figure 2.5: Concentration profile for
T and R formulations of subject 860
in sequence 1.
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Figure 2.6: Concentration profile for
T and R formulations of subject 861
in sequence 1.
The choice of the range of the terminal portion affects the estimation of the
extrapolated AUC to infinity. A very suitable range should be selected either
using a mathematical algorithm or by a clinical pharmacokineticist together
with the person who determined the concentrations of the subjects.
f.dose = clearance.AUC0−∞, 0 < f ≤ 1, (2.18)
From Equation 2.18, it can be established that the fraction, f, of a dose ab-
sorbed is proportional to the AUC0−∞ where clearance is a proportionality
factor. Clearance, as defined by Rowland and Tozer (1995), is the apparent
volume of blood that is completely removed of drug per unit of time.
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For a compartment model in Equation 2.19 with first-order absorption and
elimination kinetic, the rate of constant of absorption is estimated with the
residuals method (Gibaldi and Perrier, 1982),
Ct =
(
KaFDo
V (Ka −Ke)
)(
e−Ket − e−Kat) , (2.19)
where Ct represents the concentration, Ka represents the rate of constant of
absorption, Ke represents the rate of constant of elimination, Do represents
the quantity of the dose that is administered, F represents the proportion of
the dose that is absorbed or gets to the systemic circulation and V is the
distribution volume. Cmax, which is the maximum concentration, is defined
mathematically as Cˆmax = max(c0, c1, ..., ck). Tmax, in Equation 2.20, is the
time needed to attain maximum concentration and is defined as the estimated
time at which Cmax, in Equation 2.21, is observed.
Tmax =
2.303
(Ka −Ke) log
(
Ka
Ke
)
(2.20)
Cmax =
(
KaFDo
V (Ka −Ke)
)
(e−Ketmax − e−Katmax) (2.21)
The half-life (t1/2) and the elimination rate constant (Ke) are often the param-
eters which are studied during the elimination phase of a drug, according to
Chen and Pelsor (1991) and Chow and Liu (2008). The elimination half-life of
a drug is explained by Chow and Liu (2008) as the time which it takes for the
concentration of the drug to reduce by one-half from the body. The t1/2 can
be derived with the assumption that the reduction in concentration of blood
is of first order, as shown in Equations 2.22, 2.23 and 2.24,
log(D) = log(Do)− Ket
2.303
, (2.22)
where D represents the quantity of the drug in the body and is given asD =
Do
2
(t = t 1
2
),
log
(
1
2
)
=
−Ket 1
2
2.303
, (2.23)
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t 1
2
=
0.693
Ke
, (2.24)
where Ke = −2.303
(
dlogD
dt
)
.
Knowledge of half-life is necessary to determine the frequency of administration
of a drug so as to get the desired plasma concentration. It is independent of
the dose administered.
2.6 Power of a Test
When planning bioavailability analysis, it is very important to choose the right
sample size as this affects the power of the study (Wang and Bakhai, 2006).
The sample size, according to bioequivalence studies, is the total number of
subjects involved in the study. This number, as stated by Hauschke et al.
(2007), is determined by the amount of variability in the PK characteristic,
the power of the test, the level of significance and the expected deviation of
the T from the R formulation. A larger sample size has a better power and
has the ability to detect any treatment effect while a small sample size has
less power and could necessarily not be able to accurately detect a treatment
effect. That is, by taking larger samples, the ability to find a difference in
means of the two formulations, if they do exist, is improved. Also, the power
of the test decreases as the population variance reduces and as the difference
in the means increases, the power also increases.
The power of the test, according to Chow and Liu (2008) and Hauschke et
al. (2007), is defined as the likelihood of rejecting the null hypothesis of
bioinequivalence between an R and a T drug, while the alternative hypoth-
esis of bioequivalence is true.
H0 : bioinequivalence
H1 : bioequivalence.
(2.25)
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This implies that the power of a test is the likelihood of concluding correct-
ly that a drug is effective and bioequivalent when it is. According to Owen
(1965), power in BE studies is the likelihood of demonstrating that two drugs
are bioequivalent correctly when the two drug formulations are indeed bioe-
quivalent.
power = 1− β,
= P (reject H0 when H0 is false),
where β = P (type II error).
The power (1 − β) of the decision rule is the chance of correctly concluding
bioequivalence.
There are two types of errors that depend on the sample size and the power
of the test. The two types of errors are used when testing the null hypoth-
esis against the alternative hypothesis for average bioequivalence. In ABE,
there are chances of incorrectly establishing that two drug formulations are
bioequivalent when they are not. This phenomenom is referred to as making
a Type I error. A Type I error is perpetrated whenever the null hypothesis
(bioinequivalent) is rejected whilst it is indeed true and a Type II error occurs
when the null hypothesis is false but it is not rejected. The two types of errors
are shown in Table 2.2 (Chow and Liu, 2008).
Table 2.2: Type I and Type II errors for a hypothesis test.
The null hypothesis is
True False
Fail to reject
null hypothesis
Correct decision Type II error β
Reject null
hypothesis
Type I error α Correct decision
Usually the sample size used in bioequivalence studies, as stated by Chow and
Liu (2008), is chosen based on a power function which tests the null hypothesis
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of bioequivalence between the two formulations (µT = µR). In every BE study
it is important to choose the sample size while considering the Type I error rate
as well as the equivalence criteria, the power (normally 90%) and the intra-
subject variation (Patterson, 2003). Whenever the intra-subject coefficient of
variation (CV) increases beyond 30%, the sample size required for BE increases
as shown in Table 2.3 (Patterson, 2003).
Table 2.3: Sample sizes producing 90% power in BE for Two period crossover
design(COD).
CVw% Two period COD∗ Two period COD
30
40 50
54 60
112 124
45
84 90
112 120
230 244
60
140 146
184 194
384 404
75
200 206
264 276
554 574
Two period COD∗ assumes subject-by-formulation interaction is negligible.
Two period COD assumes subject-by-formulation interaction is non-negligible.
Patterson (2003) indicated that the number of samples needed for BE studies
reduces by half when using replicate designs with high intra-subject variabil-
ity. However, when the variability is low, a non-replicate two period COD is
preferred as the replicate design does not improve precision drastically.
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In order to test for bioequivalence between an R and a T drug, two types
of hypothesis approaches are used, namely direct and indirect bioequivalence
testing (Hauschke et al., 2007). The indirect bioequivalence testing uses the
hypothesis in Equation 2.26,
H0 : bioequivalence
H1 : bioinequivalence.
(2.26)
The major shortcoming of this indirect approach, according to Hauschke et al.
(2007), is the fact that the chances of judging bioinequivalence mistakenly is
regulated and therefore is not accepted by the regulatory authorities.
Table 2.4: Type I and Type II errors for indirect bioequivalence testing.
The null hypothesis of bioequivalence is
True False
Fail to reject
null hypothesis of bioequivalence
Correct decision Consumer risk β
Reject null hypothesis of
bioequivalence
Producer risk α Correct decision
The ultimate regulatory concern for regulatory bodies is to control consumer
risks, thus limiting the chances of concluding incorrectly bioequivalence (Hauschke
et al., 2007). Due to this, the direct approach is the approved method by the
regulatory bodies as in Equation 2.25.
The producer and consumer risks for the direct method of BE assessment are
illustrated in Table 2.5.
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Table 2.5: Type I and Type II errors for direct bioequivalence testing.
The null hypothesis of bioinequivalence is
True False
Fail to reject
null hypothesis of bioinequivalence
Correct decision Producer risk β
Reject null hypothesis of
bioinequivalence
Consumer risk α Correct decision
In ABE, Type I error is defined as the likelihood of deciding that two drug
formulations are bioequivalent. This probability is also known as alpha, con-
fidence or regulatory risk.
The relationship between a Type I and a Type II error for a bioequivalence
study, as illustrated by Chow and Liu (2008), is shown in Table 2.6. The
power is determined based on a hypothesis and the outcome. There are four
possible outcomes with hypothesis testing, two of which are correct decisions
while the other two are incorrect, as shown in Table 2.6. The inferences which
are incorrect are the errors. The two types of errors, Type I and Type II, in
some cases, are referred to as consumer’s risk and producer’s risk, respectively,
as explained in Table 2.6 (Patterson, 2003).
Table 2.6: Type I and Type II errors.
True State H0
Bioinequivalent Bioequivalent
Bioinequivalent Right decision Type II error
Bioequivalent Type I error Right decision
The power of the test is not the main issue of this study but rather the com-
parison of the formulation means and shall not be investigated further.
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2.7 Simulated Annealing Algorithm
Many problems in computer science, engineering and manufacturing can be
modelled as minimisation or maximisation of a cost function or objective func-
tion over a finite set of discrete variables (Aarts and Korst, 1990). This class
of combinatorial optimisation problems has received attention over decades
and major achievements have been made in its analysis (Papadimitriou and
Steiglitz, 1998). Solving such combinatorial optimisation problems amount to
finding the optimal solution among a finite number of alternative solutions.
According to Aarts, Korst and Michiels (2005), combinatorial optimisation
problems are separated into subclasses. The first class contains problems that
can be solved efficiently using known algorithms (linear programming) and the
second class contains problems that are difficult to solve and are formally re-
ferred to as nondeterministic polynomial time (NP) hard. There is no known
algorithm that gives an optimal solution for an NP-hard problem. Many com-
binatorial optimisation problems belong to the NP-hard group. The travelling
salesman problem (TSP) is one of the well known combinatorial optimisation
problems. In a TSP, a salesman starts from his home city and must visit each
city once on a prescribed list of cities to be visited and return home while min-
imising the tour length and total cost of travelling (Aarts and Korst, 1990).
Solving combinatorial optimisation problems aim at finding the minimum or
maximum value of a function (cost or objective function).
Annealing is the physical process of heating up a solid until it melts followed
by cooling it down until it crystallises into a state with a perfect lattice (Aarts
and Korst, 1990). The atoms in the material have high energies at high tem-
peratures and have freedom to restructure themselves. The atomic energies
decrease until a state of minimum energy is obtained. Whenever the cooling
process is rapid (quenching), it results in defects in the crystal structure (Pham
and Karaboga, 2012). According to Aarts and Korst (1990), the cooling pro-
cess must be done cautiously in order not to get trapped in a local optimal
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solution. This process can be formulated in a combinatorial optimisation as
a problem of finding a solution with minimal cost among a potentially large
number of solutions. By creating a link between the cost function and the
free energy, and between the solutions and the physical states of the atoms, a
solution method in combinatorial optimisation based on the simulation of the
physical annealing process is used (Aarts and Korst, 1990). This method is
known as Simulated Annealing. The annealing concept in combinatorial op-
timisation was introduced in the early 1980’s (Kirkpatrick, Gelatt and Vecchi
,1983).
2.7.1 Metropolis Algorithm
Annealing is a thermal process for obtaining low energy states of a solid in
a heat bath (Aarts and Korst, 1990). The annealing process consists of the
following two steps (Kirkpatrick et al. 1983):
1. increase the temperature of the heat bath to a maximum value at which
the solid melts; and
2. decrease carefully the temperature of the heat bath until the particles
arrange themselves in the ground state of the solid.
Metropolis et al. (1953) introduced a simple algorithm that can be used to
provide an efficient simulation of a collection of atoms in equilibrium at a given
temperature. The algorithm is based on Monte Carlo techniques and generates
a sequence of states of the solid. Given a current state i with energy Ei, a
subsequent state j is generated by applying a perturbation mechanism which
transforms the current state into the next state. The energy of the state j is
denoted by Ej. If the difference in energy, Ej −Ei ≤ 0, the state j is accepted
as the current state. However, if Ej − Ei > 0, the state j is accepted with a
probability which is given as
exp(
Ei − Ej
kBT
),
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where T represents the temperature of the heat bath and kB is a physical
constant known as the Boltzmann constant. This acceptance rule is known as
the Metropolis criterion. When the temperature is sufficiently slowly lowered,
the solid can reach thermal equilibrium at each temperature (Aarts and Korst,
1990). This process is achieved in the Metropolis algorithm (MA) by gener-
ating a large number of transitions at a given temperature. The Boltzmann
distribution, which is a characteristic of thermal equilibrium, gives the proba-
bility of the solid being in a state i with energy Ei at temperature T, and is
represented by
PT{X = 1} = 1
Z(T )
exp
(−Ei
kBT
)
,
where X denotes a stochastic variable representing the current state of the
solid and Z(T) represents the partition function which is defined as
Z(T ) = Σjexp
(−Ej
kBT
)
,
where the summation extends over all possible states. The Boltzmann distri-
bution plays an important role in the SA algorithm analysis.
2.7.2 Simulated Annealing
The MA can be applied to create a sequence of solutions of a combinatorial
optimisation problem by assuming the following equivalences between a phys-
ical many-particle system and a combinatorial optimisation problem (Aarts
and Korst, 1990):
1. solutions in a combinatorial optimisation problem are equivalent to states
of the physical system; and
2. the cost of a solution is equivalent to the energy of a state.
Metropolis et al. (1953) suggested the MA for simulation of a solid in a heat
bath to simulate thermal equilibrium based on the Monte Carlo approach.
Each state has a distinct level of energy which is defined by the objective
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function. A difference between the new state and old state, ∆E = Ej − Ei,
is calculated and the new state is chosen with a likelihood of e
−∆E
KT . However,
should the new state have a lower energy than the current state (∆E < 0), the
new state is accepted as the starting point with a likelihood that is dependent
on the energy level difference as well as the current temperature shown in
Equation 2.27,
P (accept) =
1 if ∆E ≤ 0,e−∆EKT if ∆E > 0, (2.27)
where P represents the acceptance probability and T denotes the control pa-
rameter. The algorithm has the ability to escape the local minimum based
on the acceptance of the worst state. This acceptance is referred to as the
Metropolis criterion (Metropolis et al., 1953).
MA was applied in optimisation problems by Kirkpatrick et al. (1983) who
named it the Simulated Annealing (SA). SA is a stochastic global optimization
method which was described first by Metropolis et al. (1953) who developed a
Metropolis algorithm to simulate a collection of atoms at a given temperature.
Kirkpatrick et al. (1983) showed how the model for simulating the annealing
of solids, proposed by Metropolis et al. (1953), can be used for solving opti-
misation problems where the objective function to be optimised is similar to
the energy level of a solid. SA consists of two nested loops. The decremen-
t of the temperature from an initial high to a final low temperature is the
outermost loop which is also known as the cooling schedule. The innermost
loop repeats the process over a specified Monte Carlo simulation. The SA
algorithm initially begins with a high temperature where so many states are
accepted. However, as the temperature decreases, only few states are accepted.
The chances of accepting a bad state is done by comparing it with a random
number generated uniformly from [0,1]. The temperature is reduced when the
Metropolis iteration loop is completed and the process is repeated until the
stopping criterion is met.
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The MA starts from an initial energy level, x, and the system is disturbed at
random to a new energy level, y, in the neighbourhood of x. The value of
the objective function fy is calculated. If the change, ∆fxy = fy − fx, is a
reduction in the objective function value, the new state is accepted. However,
should the change be an increase in the value of the objective function, the
new state is accepted with a likelihood ∆fxy
T
with T being a control parameter.
The SA algorithm is seen as an iteration of MA which is evaluated at decreasing
values of the control parameter that takes on the role of temperature. The main
attributes of the SA algorithm are its general applicability (or usefulness) and
ability to obtain solutions without being trapped in a local minimum (Aarts
and Korst, 1990). This is done by not only accepting better solutions but also
worse solutions with a given probability. The SA algorithm has the ability
to find high-quality solutions which do not necessarily depend on the choice
of the initial solution and therefore is regarded as a very effective and robust
algorithm (Aarts and Korst, 1990).
The flowchart of SA is given in Figure 2.7.
Initial Parameter Set
Evaluate Solution
Accepted?
Update Current
Set
Change
Temperature
Generate New Set
Stop
Terminate
Search?
Decrease
Temperature
Y
N
N
Y
N
Y
Figure 2.7: The SA Flowchart.
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If the current solution (fnew) has the value of the objective function lower
compared to that of the previous solution (fold), the current solution is accepted
(in a minimisation situation). The current solution may be accepted if the
Boltzmann distribution in Equation 2.28,
e
−fnew−fold
T , (2.28)
is greater than a uniform random number in [0,1], where T is the temperature
control parameter.
The annealing process consists of a number of steps which are described in the
section below.
2.7.2.1 Initial Population
At each iterative stage a definition of an initial guess for the parameter values is
required. SA does not require the use of several initial solutions. One approach
is to randomly select the initial parameter values given a set of appropriate
boundaries. The closer the initial estimate is to the global optimum, the
quicker the optimisation process.
2.7.2.2 Initial Temperature
The control parameter, T , should be defined with care as it controls the accep-
tance rule defined by Equation 2.28. T should be large to avoid being trapped
in a local minimum but small enough to move off a global minimum.
2.7.2.3 Perturbation Mechanism
This mechanism creates a new solution from the current solution by exploring
the neighbourhood of the current solution and making small changes to the
current solution. When the parameters are continuous variables, a solution
P is defined as a vector P = (x1, x2, ..., xn) which represents a point in the
search space. A new solution is generated using a vector ϕ = (ϕ1, .., ϕn)
of standard deviations to create perturbation from the current solution. A
neighbourhood solution is produced from the current solution by xi+1 = xi +
50
N(0, σ2i ) where N(0, σi) is a random Gaussian number with mean of zero and
standard deviation σi.
2.7.2.4 Objective Function
The objective function or the cost function relates to the parameter that needs
to be minimised or maximised. For example, there may be the need to minimise
the number of sampling times which eventually reduces the cost.
2.7.2.5 Initial Value of Temperature
A basic assumption which underlies the initial value calculations of the control
parameter T (temperature) is that it should be large for the movement between
different energy states to be accepted at this value. It is usually achieved
through generating trials m0 and requires that the initial acceptance ratio,
x = x(T0), is close to one, where x(T ) is the ratio between the number of
accepted transitions and the number of proposed transitions. The initial value
of T is obtained from the expression:
T0 = ∆f+
(
ln
m2
m2x0 + (1− x0)m1
)−1
, (2.29)
where m1 and m2 denote the number of trials (m1 +m2 = m0) with ∆fxy ≤ 0
and ∆fxy > 0 and, ∆f+ the average value of ∆fxy values for which ∆fxy > 0,
and x0 represents the initial configuration.
2.7.2.6 Decrement of the Control Parameter
The new value Tt+1, which is calculated from Tt, is obtained from the expression
Tt+1 = Tt(1 +
Ttln(1 + δ)
3σ(Tt)
), (2.30)
where σ(Tt) is the standard deviation of the cost function values at the points
in the Markov chain (MC) at Tt. The constant δ is the distance parameter
and determines the rate of decrease of the control parameter.
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2.7.2.7 Stopping Criterion
This is based on the idea that the average function value f(Tt) over an MC
decreases with Tt so that f(Tt) converges to the optimal solution as Tt →
approaches 0. The MC stops whenever there are no changes in f(Tt). The SA
algorithm is terminated if ∣∣∣∣df¯s(Tt)dTt Ttf¯(T0)
∣∣∣∣ < εs, (2.31)
where f¯(T0) is the mean value of f at the points in the initial Markov chain,
f¯s(Tt) is the smoothed value of f¯ over a number of chains so as to reduce
the fluctuation of f¯(Tt), and ε is a small positive number called the stopping
parameter.
The proposed SA algorithm steps used in this dissertation is adopted from
Choi et al. (2007):
1. The initial temperature T0, and the number of MC simulations at each
temperature P is set;
2. The initial sampling times t0 = (t1, t2, ..., tn) are set;
3. Generate the new sampling schedule tnew;
4. Estimate the energy of the current solution (Ecurrent) and new schedule
(Enew);
5. Check if the new schedule should be accepted using the acceptance cri-
terion;
6. Repeat the process from steps 3 to 5 for p number of times;
7. Calculate next temperature; and
8. Repeat the process until the stopping criteria is effected.
52
2.8 Population PK
In a traditional non-compartmental approach of bioequivalence, the subjects
are recruited from a homogenous population which makes it difficult to make
an inference about the whole population. The solution to this is through
population pharmacokinetics (PopPK). This approach uses a nonlinear mixed
effects model by building a PK model with fixed effects, between-subject vari-
abilities and residual variabilities. The use of PopPK modelling has several
advantages such as investigating the characteristics of the PK parameters in a
model (Chow and Liu, 2008). The advantages and disadvantages of the PopP-
K method, as stated by Bonate and Steimer (2006), are summarised in Table
2.7.
Table 2.7: Advantages and disadvantages of PopPK method.
Advantages Disadvantages
Subgroups within the population
can be distinguished which may
not have been noticed.
It is very expensive.
Population method can analyse
thinly dispersed data.
It is time consuming.
Essential covariates are used and
may be able to interpret subject
variability.
The methods are not easy to com-
prehend.
The information that are ob-
tained could be used for predic-
tion of dose for individual sub-
jects.
Different PopPK analysts may
develop different models.
It is a model based on promoting
the use of prior knowledge, there-
by enhancing understanding and
statistical power.
Difficult to review.
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PopPK, as defined by Aarons (1991), studies the origins and the variation
in the concentration of drugs in individual subjects who are sampled from a
population and receive a quantity of the drug of interest at a particular time
period. That is, population PK studies the connection that exists between
the quantity of administered dose and concentration of the sampled subjects
as well as the population from which they were sampled. The population PK
parameters are evaluated by fitting a model. There are a number of meth-
ods used to estimate the parameters of the PopPK including the traditional
approach which uses the standard two-stage (STS) method and the nonlinear
mixed effects modelling approach (NLMEM) (Chow and Liu, 2008). These two
methods are discussed in the next section. In this dissertation, the NLMEM
approach is adopted because of its advantages that will be discussed in Section
2.10.
2.8.1 Traditional Two-stage
This approach of estimating the PopPK parameters has two stages, hence the
name: standard two-stage (STS) approach. The PopPK parameters are esti-
mated by fitting each individual subject’s data separately and later combining
the individual estimates (Chow and Liu, 2008).
For each subject, enough dosage is administered and sufficient blood concen-
trations are drawn so that the PK parameters are approximated accurately for
each subject. The estimates of the parameters are acquired using a determin-
istic PK model which could be a one or multi compartment model (Chow and
Liu, 2008).
From the PK parameter estimates which were derived individually from each
subject in the first stage, covariance model analysis is considered to avoid con-
founding effects as well as the interactions that may exist among the covariates
(demographics) and to study the treatment effect (dosage and route of admin-
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istration) and the variation between individuals (Chow and Liu, 2008).
However, this approach has cost and ethical issues as stated by Sheiner et
al. (1977) and also has disadvantages from a statistical point of view. The
variation of each individual is not considered whenever the estimates obtained
from the deterministic model in the first stage are used. It becomes diffi-
cult to obtain reliable and accurate approximations of the PK parameters for
each subject whenever the sampling of the subjects is sporadic (Chow and Liu,
2008). The traditional approach is incapable of describing the attributes of the
population where a number of demographic-, physiological- and behavioural at-
tributes are documented for each individual subject including their age, weight,
sex, and other variables (Chow and Liu, 2008).
2.8.2 Nonlinear Mixed Effects Modelling Approach
The traditional two-stage method described in section 2.9 has several setbacks
and therefore an alternative method, the NLMEM approach, is proposed and
comes highly recommended by the FDA. This method is a nonlinear regres-
sion model which accounts for random and fixed effects. NLME models are
quite similar to the linear mixed effect models (LMEM) but the function in
NLMEM is nonlinear (Bonate and Steimer, 2006). PopPK studies the phar-
macokinetics in a population and it models the data from every individual
subject concurrently, but it is also able to account for within-subject variabil-
ity, between-subject variability and residual variability (Bonate and Steimer,
2006). This method was introduced by Sheiner and Beal (1985) and is the most
widely used method for population studies. During NLMEM the attributes of
the population constitute the mean of the population which is obtained from
fixed effect parameters, the variation, which is within the population, as well
as the variability from the random effect parameters (Bonate and Steimer,
2006).
One objective of a PopPK is to develop a model which connects the concentra-
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tion to the administered dose and other covariates as well as to obtain estimates
of the PK parameters (Bonate and Steimer, 2006). These NLME parameters
are derived using a maximum likelihood estimation (MLE) method. Because
of the nonlinear dependence of the observations it becomes demanding to cal-
culate the likelihood of the data. Hence, two algorithms are widely used: the
first-order (FO) approximation and the stochastic approximation expectation-
maximisation (SAEM). The NLME does not require the data to be necessarily
frequent and does not follow a structured sampling time schedule (Bonate and
Steimer, 2006).
2.8.3 Pharmacokinetic Models
The use of PK modelling in drug development has received much attention
(Sheiner and Steimer, 2000). Teorell (1937) first introduced the PK models
to describe drug absorption, distribution and elimination. He suggested that
organs and tissues be separated into different compartments and are only con-
nected by kinetic rate. In this dissertation, the focus is on compartmental
models even though there are different types of models, including physiologi-
cal models and empirical models, as stated by Shargel et al. (2004).
Consider a single one-compartment model which is a bolus (administration of
a discrete quantity of a drug so as to raise its concentration to an effective
level) intravenous injection (IV), as described by Welling (1997), and given in
Figure 2.8.
D
Ka Ke
A(t)
Figure 2.8: One compartment model with bolus IV.
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Here, A represents the amount of the drug in the body calculated as A = C ×
V, where C is the concentration of the drug in the body and V is the volume of
distribution. Ke represents the elimination rate constant and Ka represents the
absorption rate constant. Using a differential equation, the following equation
is obtained:
dA
dt
= −KeA, (2.32)
with t being the time. After performing integration Equation 2.32 becomes:
C = C0e
−Ket. (2.33)
lnA− lnA0 = −KeA
e
ln(
A
A0
)
= e−Ket
A = A0e
−Ket
The amount of drug A can be expressed as the concentration simply by dividing
it by the volume of distribution, V, of the drug.
2.9 Summary
Bioequivalence studies started in the early 1960s to 1970s to meet the needs
of consumers in having access to inexpensive and efficacious drug products.
The origin of bioequivalence studies was purely for economic reasons and was
driven by legislation across different countries. Therapeutic failures prompted
extensive research in the area of bioequivalence studies and led to the estab-
lishment of techniques and regulations for assessing whether two drug products
were bioequivalent based on the extent of BA between different formulations.
ABE was then introduced as a measure of assessing two drug products and
was adopted by the FDA and other bodies such as SAMCC. ABE, although it
protected the health of the public since it was adopted, could only compare the
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mean rate and extent of BA and does not compare between- or within-subject
variability between the drug formulations. This led to further research on PBE
and IBE.
The literature presented in this Chapter shows that research on bioequivalence
studies employed ABE, PBE and IBE to show that two drug products were
indeed bioequivalent. However, very little is done using IBE since that requires
a higher order COD and most of the designs used are limited to 2× 2 COD.
Population PK studies is one area of research which is gradually coming to the
fore. This method focuses on investigating the population characteristics of
the PK parameters using a modelling technique. Available literature indicates
that different methods, such as the traditional approach, nonlinear mixed ef-
fect modelling technique and others, have been used to model the population
parameters. However, nonlinear mixed effect modelling is widely used and
recommended by the FDA.
The techniques which were discussed in this section form the basis of the
methodology which is discussed in the next Chapter and used in the disserta-
tion.
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Chapter 3
Methodology
3.1 Introduction
For a T drug to be approved as a replacement for the R drug and be marketed,
regulatory bodies, including the FDA, WHO and SAMCC, demand that ABE
between the T and R drugs should be provided (FDA 2001). BE is measured
using Cmax and AUC which measure the extent and the rate of drug absorption,
correspondingly. The scope of this research is to perform statistical analysis
on the PK parameters using the available data, estimate the population- and
individual absorption rate, clearance and volume of distribution of the drug
using a model and also optimise (minimise) the samples of blood taken from
each subject. The 2 × 2 crossover design will be used for this dissertation as
well as the TOST. ANOVA will also be carried out and the results will be used
in the CI approach. A confidence interval approach will be used to determine
bioequivalence using the results obtained from the ANOVA analysis. An SA
algorithm will be used to optimise the blood sampling times taken from the
subjects.
Bioequivalence assessment between the T and R drugs can be assessed through
four main ways (FDA, 2003):
• In vitro studies;
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• Pharmacodynamic studies;
• Comparative clinical studies; and
• Pharmacokinetic studies.
These methods can be used singly or as a combination depending on the type
of treatment formulation or the method of administration of the drugs. Ac-
cording to the FDA, pharmacokinetic studies are the preferred method for
bioequivalence studies. This choice of bioequivalence studies as the preferred
method for bioequivalence studies was supported by Wang and Bakhai (2006).
Pharmacodynamic studies and comparative studies are most recommended
whenever pharmacokinetic studies cannot be applied. In vitro studies are gen-
erally recommended for immediate release (IR) of drugs that are taken orally
and are in a solid form (FDA, 2003).
3.2 Experimental Design
Before BA studies are conducted the type of design to be used, subject se-
lection criteria, the dosing schedules as well as the statistical methods to be
used, are considered (Chow and Liu, 2008). The types of statistical analyses
to be performed depend on the type of design that is used. For example, when
one wants to conduct IBE, the most appropriate design according to the FDA
(2001), is the repeated measures design (preferably two sequence, four period
design) as this enables easy computations of the within and between subject
variabilities and the subject-formulation relations. In general, meaningful sta-
tistical inferences can be drawn from data only when appropriate designs are
used.
When ABE and PBE are the only chosen methods for BE comparisons, a non-
replicate standard two-formulation, two-period, two-sequence COD is used s-
ince using a replicated design will be more expensive and time consuming
(FDA, 2001). During BE studies the study should be properly designed so as
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to distinguish the drug effect from all other effects. Also, there should be an
adequate washout period to avoid carryover effects. Usually a 2 × 2 COD is
used for BE studies. However, other designs such as repeated COD, parallel
design, etc. could be used depending on the study objective. Generally a sin-
gle dose study is preferred with steady-state studies used at certain times only.
A randomised, single-dose, two-period, two sequence COD was used for this
study. The T and R drugs were administered under fasting conditions (subjects
are not allowed to eat 24 hours before drug administration) to the subjects with
a sufficient washout period separating the two treatments. The study was done
at two separate periods. In the first period of the first sequence every subject
was administered a single dose (10 mg of drug) of the R drug and samples of
blood were drawn at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 30, 48
and 72 hours. The choice of the sampling times are influenced by the half-
life of the drug and other pharmacokinetic parameters of the drug such as
the absorption and elimination rates. In the second period each of the same
subjects received another single dose (10 mg of drug) of the T drug and a new
series of blood samples were drawn. Similarly, in the first period of the second
sequence every subject in the second group received the T formulation first
and in the second period, they received the R formulation second. In each of
the periods for both sequences, samples of blood are drawn at the same times
after the administration of the drug (Chow and Liu, 2008).
3.3 Research Data
Blood samples obtained through a 2× 2 crossover design from pigs were used
as the data for this dissertation. The 16 pigs were allocated to two different
sequences. The pigs in sequence 1 were dosed with the T drug first and then
with the R drug. The drugs were administered intramuscularly. The pigs in
the second sequence were dosed with the R drug first and then with the T
drug after the washout period. The data were obtained from Onderstepoort
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Veterinary School. The study at Onderstepoort was executed to obtain BE
between the T and R drugs which were both antibiotics for marketing purposes.
The dose of the drugs for the pig data is 15 mg/kg. The raw data comprise of
the variables listed in Table 3.1.
Table 3.1: A list of the variables in the raw data.
Variable Description
Time Time at which samples are collected (hours).
Sequence The sequence to which each subject belongs.
Period The period to which a subject belongs.
Concentration A measure of the concentration at a particular time.
Treatment An R and T formulation.
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Table 3.2 summarises the data used in this dissertation.
Table 3.2: Data from a Two Period COD with T and R formulations.
Subject Sequence
AUC
Test
AUC
Ref
AUC
T:R
Cmax
Test
Cmax
Ref
Cmax
T:R
1 RT 53.378 62.4935 0.85 4.68 3.3 1.42
2 RT 63.4214 60.244 1.05 2.68 3.16 0.85
3 RT 78.4096 65.0565 1.21 3.32 2.08 1.60
4 RT 56.0545 50.333 1.11 3.24 3.67 0.88
5 RT 38.5985 49.2165 0.78 1.82 2.06 0.88
6 RT 78.99 60.549 1.30 2.99 1.89 1.58
7 RT 71.838 57.7215 1.24 2.15 3.69 0.58
8 RT 54.3085 49.312 1.10 3.88 2.86 1.36
9 TR 56.264 55.291 1.02 5.8 1.95 2.97
10 TR 61.1015 73.1955 0.83 3.02 3.95 0.76
11 TR 59.2165 72.3501 0.82 2.12 3.26 0.65
12 TR 60.798 66.7527 0.91 3.1 10.2 0.30
13 TR 68.9234 85.6995 0.80 9.72 4.39 2.21
14 TR 67.7175 77.544 0.87 9.78 3.32 2.95
15 TR 66.153 59.1085 1.12 2.51 1.86 1.35
16 TR 58.9715 67.0836 0.88 2.37 3.69 0.64
R=Reference, T=Test
The AUC and Cmax data were estimated using a non-compartmental PK
method and analysed using Statistical Analysis System (SAS) version 9.4,
R software version 3.2.2, matrix laboratory (MATLAB) version 8 and Mono-
lix version 2016R1. From the data, some of the observations (concentrations)
were missing but were not imputed since they were only few and not likely to
impact the results significantly. There was no demographic information (age,
weight, height) available for the subjects in the data. There was an equal
number of subjects (8 subjects per sequence) in each of the sequences which
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makes it a balanced design.
3.4 Sample size
The number of subjects to be used in a BE study to establish bioequivalence
between the T and R drugs within meaningful limits is determined by various
factors (Chow and Liu, 2008):
• the level of significance desired;
• the required power; and
• the expected deviation from the R drug which is compatible with bioe-
quivalence.
The analytical and clinical standards required may also determine the total
number of subjects to be used. However, the minimum number of subjects
used for BE is 12. An adequate number of subjects are required to be used
to accommodate for any dropouts since replacing subjects during the study
could complicate the statistical model and analysis. In addition, the number
of subjects should also be adequate to ensure that statistically meaningful
analyses and results are obtained. Table 3.3 shows the minimum sample size
requirements for selected countries.
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Table 3.3: The minimum samples required in some selected countries.
Regulatory
Authority
Minimum Number Sample size specification
South Africa 12 or more subjects for im-
mediate release and 20 for
modified release oral dosage
forms.
The number of subjects
should be justified on basis
of providing 80% power.
USA 12. The number of subjects
needs to provide sufficient
power to conclude bioequiv-
alence.
Europe 12 or more. The number of subjects
should depend on appropri-
ate sample size calculations.
3.4.1 Subject Selection
In BE studies, subjects must be chosen with the aim to minimise variation
and also to allow for easy identification of the differences between the T and R
formulations (Chow and Liu, 2008). The study, however, is usually performed
using healthy subjects. Subjects which are selected for bioequivalence studies:
• are healthy subjects of either sex in the range of 18 to 55 years;
• are subjects with no history of drug or alcohol abuse;
• are of normal weight (weight corresponds to height as determined by
BMI); and
• are subjects that have gone through thorough medical screening before
selection (FDA, 2003).
However, the subject selection normally differs from one country to the next
as indicated in Table 3.4.
65
Table 3.4: Subject selection criteria in selected countries.
Regulatory
Authority
Age Gender BMI
South Africa 18 to 55 years. Male or female. Recommended
BMI or usually
within 15% of
the body mass.
USA 18 years or older. Male or female. Not specified.
Europe 18 years or older. Male or female. 18.5 to
30kg/mˆ2.
When animals are used in BE studies they must be healthy and chosen from
a homogeneous population. Thus, they need to have the same weight, be of
the same breed, same age and same sex. However, when it is difficult to get a
homogeneous group of animals, it is acceptable to use animals from different
populations provided age, sex and weight are controlled (EMEA, 2001).
3.4.2 Standardisation of the study
The subjects involved in the BE studies should preferably fast at least the
night before the administration of the drugs or formulations. The time of the
day where the subjects ingest the drug should be stated. Subjects should not
be permitted to take any other drug before and during the study period.
3.5 Research Design
3.5.1 2 x 2 Crossover Design
A COD is a redesigned, randomized block in which every block receives d-
ifferent formulations of the drug at different periods (Chow and Liu, 2008).
Crossover trials are designed in a way such that subjects receive a sequence of
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treatments in a specified order for a pre-specified length of time with a washout
period between each treatment where no treatments are dispensed (Wang and
Bakhai, 2006). A crossover study should be designed such that the formulation
effect could be separated from other types of effects (Hauschke et al., 2007).
In a COD two or more treatments are compared where a subject switches to
another treatment upon completion of one. This is one advantage a COD trial
has over the parallel design in that subjects become their own controls thereby
requiring fewer subjects to evaluate the effect of different therapies. Subjects
are assumed to have stable conditions which should not vary between the first
and second dosing periods. This assumption must be satisfied for a COD to
be implemented successfully. In addition to this, a COD is favourable for BE
studies because:
• every subject serves as its own control thereby enabling each formulation
to be compared within each subject and evaluating the within subject
formulation;
• inter-subject variability is accounted for; and
• a good and unbiased estimate of the differences between the two formu-
lations is obtained when the subjects are properly randomised.
A COD has the advantage of comparing the individual effects of the treat-
ment and not the sequences. It allows for identifying the individual reactions
of the various formulations as each subject receives each of the formulations
(Senn, 2008). Depending upon the different number of treatments, the aim of
the study and the number of sequences, there could be many sets of possible
sequences which could be utilised in the design.
However, the two-period, two-treatment COD, where every subject is admin-
istered either the T or the R drug formulation first and the alternative as the
second treatment, remains the simplest design. It is not compulsory that the
number of periods should be the same as the number of formulations. The
67
treatment is randomly administered to the subjects. Most often, half the sub-
jects receive one treatment while the other half receives the second treatment
at the same time. For example, in a 2 × 2 COD, each subject is assigned
arbitrarily to either treatment sequence RT or TR at different dosing periods.
Subjects in the COD are administered the R and T formulations in both pe-
riods 1 and 2, respectively, in the first sequence whereas the second group of
subjects also receive the T and R formulations in periods 1 and 2, respectively,
in the second sequence. That is, subjects in the RT sequence receive R for
the first dose and T as the second dose separated by a washout period, while
subjects in the TR sequence receive T for the first dose and R as the second
dose.
The main advantage of a COD trial is the comparison of treatments within
subjects (Jones and Kenward, 2014). In this study, for example, each subjec-
t provides two measurements in R and T, separately. A repeated measures
design has a lot of advantages and a potential disadvantage as well, but it
is not considered in this dissertation. The disadvantage of a repeated design
(carryover or residual effect) is the chance of a treatment effect in a period to
be still present during the start of the next period. This disadvantage, howev-
er, can be reduced when the appropriate design and analysis are used (Jones
and Kenward, 2014). To eliminate this carryover or residual effect a washout
period of sufficient length is usually allowed.
Differences between treatments in one period could also be different from a lat-
er period because of treatment-by-period relations. However, in a well planned
design, the chances of treatment-by-period effect will be minimal. A suitable
design, which allows any such interaction to be easily detected and determine
whether it was as a result of carryover or not, could be used as well (Jones and
Kenward, 2014).
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A 2× 2 crossover design is shown in Figure 3.1 below.
Subject
Sequence 1 Test Reference
Sequence 2 Reference
Period 1
Test
Period 2
R
an
do
m
iz
at
io
n
W
as
ho
ut
Figure 3.1: A standard two-sequence, two-period crossover design.
Generally, a clinical trial with a sequences of treatments delivered over b dif-
ferent periods is referred to as an a× b COD. In a COD, treatment differences
are based on within-subject comparison which results in a low variability with-
in the subjects as compared to a parallel design where treatment differences
are based on between-subject variability resulting in high variability between
subjects.
COD, however, poses a lot of inconvenience to subjects such as pain if it is
intravenous as they have to take multiple treatments which involves a longer
period of observation. This could result in high drop out rates resulting in
an unequal number of subjects completing the trial. One of the challenges of
a COD is the carryover effect (Jones and Kenward, 2014). Carryover effect
is the tenacity of a treatment which is given in one treatment stage of the
study to the next treatment stage or the effect of a drug that remains after the
dosing period is over (Senn, 2008; Chow and Liu, 2008). The carryover effects
(residual effect) and washout should be established in a COD as the existence
of a carryover effect normally affects the inferences that are made about the
BA between the drug formulations (Chow and Liu, 2008). Carryover effects
may lead to biased estimation of the PK parameters.
The washout period should be long enough for the drug formulations to be
completely eliminated from the subjects’ system to avoid carryover effects.
Washout periods normally depend on the type of drug being used in the BE
studies. A first-order carryover effect lasts for one treatment period. The
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period effect is another potential drawback of the COD. The effect of either
the T or R treatment could be affected if it is administered either in the first
or second period. The period effect could be minimised by assigning an equal
number of subjects to each sequence and then adjusted statistically (Jones and
Kenward, 2014).
3.5.2 Statistical Model
The two sequences, two periods COD is mostly recommended for bioequiva-
lence assessment using PK studies. A 2 × 2 crossover model, as presented by
Chow and Liu (2008), is given as follows:
Yijk = µ+ Sik + Pj + Fj,k + Cj−1,k + eijk, (3.1)
where µ represents the overall mean; Sik represents the random effect for each
subject i in the kth sequence, where i=1,2...nk, k=1,2; Pj represents the fixed
effect of the jth period with j=1,...,p and ΣPj = 0; Fj,k is the fixed effect of the
drug formulations in the kth sequence dispensed during the jth period while
ΣFj,k = 0; Cj−1,k is the fixed carryover effect of the formulations in the kth
sequence dispensed at the (j − 1)th period where Co,k = 0 and ΣCj−1,k = 0;
eijk is the within-subject random error; and Yijk is the PK parameter of the
ith subject for each sequence k at each period j.
The assumption is that Sik should be independently and identically distributed
with a mean of zero and variance σ2s , and eijk should be independently dis-
tributed with a mean of zero and variance σ2t , where t = 1, 2, ..., l (the number
of drug formulations). Carryover effects, period effects and direct drug effects
are usually the preliminary tests that are performed before assessing bioequiv-
alence between the T and R formulations.
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All the methods which are used in this study for BE assessment are derived
using the model in Equation 3.2,
Yijk = µ+ Sik + Fj,k + Pj + eijk, (3.2)
where Yijk, µ, Sik, Fj,k, Pj and eijk are defined in Equation 3.1.
3.5.3 Washout and Carryover Effect
Despite the advantage of each subject serving as its own control, COD still
has a disadvantage. This potential problem arises when the first treatment ef-
fect from the first time period is still existing in the next period and therefore
misrepresents the effect of the second treatment. According to Senn (2001) a
carryover effect arises whenever the drug treatment administered in one period
continues to affect subjects in the second period thereby biasing the amount
of drug in the blood sample of a subject. One potential cause of a carryover
effect is the short time between periods before administering the second drug
formulation. The short time between the periods is referred to as a washout
period. Carryover effect could also be as a result of some drugs having longer
half-lives or some subjects having very weak metabolism rates. Washout and
carryover effects (residual effects) need to be addressed in a COD because the
carryover effect affects statistical inference of BA between formulations (Chow
and Liu, 2008).
Whenever the carryover effect is present, the estimate (µT − µR) would be
biased as the effect of the drug which is dispensed in the first period is still
present. A washout period is the resting period between drugs dispensed in the
first period and second period during which the impact of a drug formulation
given at one period does not extend to the next treatment period (Chow and
Liu, 2008).
The duration of the washout period is determined depending on the type of
drug and half-life of the drug. For drugs with a long half-life, their effect may
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still be present even after washout is introduced at the termination of a dosing
period. If this happens it becomes important to differentiate the direct drug
effect from the carryover effect. A direct drug effect can be interpreted as
the effect of the drug being present in the period in which it was dispensed
while carryover effect is the drug effect after the termination of a dosing period
(Chow and Liu, 2008).
In the absence of carryover effects due to adequate washout period, the general
crossover model given in Equation 3.1 reduces to the model in Equation 3.2.
3.5.4 Period Effect
It is preferred that the subjects’ condition and ability to respond to the formu-
lations remain unchanged between the two dosing periods. This is not always
the case as some subjects improve on average or deteriorate before taking the
second treatment. This can cause a problem which affects COD, generally re-
ferred to as the period effect (treatment by period interaction). The effect of R
and T can be influenced depending on the period they were administered. This
could be as a result of physiological and environmental changes which occur
in the subjects. A significant period effect could be as a result of timing and
amount of physical activity and/or the hotness or coldness of the water used
at both periods (Lockyer, Al-Dgither, Al-Gaai, Yousuf and Hammami, 2005).
However, a significant period effect does not influence the BE assessment.
3.6 Outliers
One of the challenges encountered in BA and BE studies is that the data
set sometimes contains either extremely small or extremely large observations
which are referred to as outliers. An outlier is a data point that does not fit
the model correctly. These extremely small or extremely large observations
tend to influence any decisions reached about the bioequivalence of the two
drugs. There are four types of outliers as identified by (Chow and Liu, 2008):
• unexpected observations which appear in the CTC;
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• very small or large observations in a given formulation type;
• subjects unusually having either extremely low or extremely high BA
with respect to R form; and/or
• unusual subjects having extreme BA in both formulations.
Chow and Tse (1991) argued that the decision on bioequivalence is heavily
influenced by the presence of any outliers. When BA studies are conducted
with the inclusion of subjects which are potential outliers, Westlake (1981) and
Schuirmann (1987) stated that this may lead to bioinequivalence whereas the
formulations are indeed bioequivalent. It is therefore very important to iden-
tify any possible outliers in the data and conduct the bioequivalence studies
with and without these outliers.
By doing so it makes it easy to conclude if the possible outlier does have any
effect. Rodda (1986) suggested that outliers (unexpected observations) should
be included in the analysis as they have little effect on the calculation of the
AUC and, consequently, have little effect on BA comparison. It only suggests
that the subjects respond to the formulations differently either due to external
or internal factors. The FDA also believes that outliers should not be excluded
from the analysis (FDA, 2001).
3.6.1 Outlier Detection
The study of the detection of potential outliers in a data set has received much
attention in past decades (Dixon, 1953; Cook, 1977; Draper and John, 1981).
Various methods have been developed to handle outliers in linear regression
problems. However, the data used in BA studies can not be accommodated in
a linear regression framework. The inclusion or deletion of potential outliers
in the BA analysis affects the results obtained and as such need to be consid-
ered. A number of possible techniques have been proposed for the detection of
outliers in BA and BE studies. Cook and Weisberg (1982) proposed the Like-
lihood Distance (LD) approach for identifying outliers while Chow and Tse
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(1990) developed an approach known as the Estimates Distance (ED) method.
Another approach, the Hotelling T 2 statistic (HT), was introduced by Liu and
Weng (1991) to detect outliers.
3.6.1.1 Likelihood Distance and Estimates Distance
The LD and the ED procedures which were proposed to detect an outlier as-
sume no period effect and no formulation effect. In the absence of formulation
and period effects, the model in Equation 3.1 is reduced to Equation 3.3:
Yij = µ+ Si + eij j = 1, ..., n; i = 1, ..., k, (3.3)
where n is the number of formulations, k is the number of subjects and Yij
expresses the measurement value for the ith subject, jth formulation. The
parameters which are of interest include µ, σ2e and σ
2
s . Let θˆ = (θ1, θ2, θ3)
T
where θ1 = µ, θ2 = σ
2
e and θ3 = σ
2
e + nσ
2
a. The log-likelihood function L(θ) for
Equation 3.3 is given as:
L(θ) =
−kn
2
log2pi−k
2
log(θ2θ
n−1
3 )−
1
2θ3
k∑
i=1
n∑
j=1
(Yij − θ1)2−n
2
( 1
θ2
− 1
θ3
) k∑
i=1
(Y¯i−θ1)2.
(3.4)
The maximum likelihood estimator (MLE) θˆ, of θ is obtained through max-
imisation of L(θ) in Equation 3.4 with respect to θ given that θ3 ≥ θ2. The
MLE θˆ = (θˆ1, θˆ2, θˆ3)
T of θ is then,
θˆ1 = Y¯ =
1
nk
k∑
i=1
n∑
j=1
Yij,
θˆ2 = m1,
θˆ3 =
(k − 1)m2
k
,
where
m1 =
1
k(n− 1)
k∑
i=1
n∑
j=1
(Yij − Y¯i)2,
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and
m2 =
n
k − 1
k∑
i=1
(Y¯i − Y¯ )2.
However, if θˆ3 < θˆ2, the MLE of θ2 and θ3 becomes
θˆ2 = θˆ3 =
1
nk
k∑
i=1
n∑
j=1
(Yij − Y¯ )2,
which is obtained by maximising L(θ) under the condition that θ2 = θ3.
Since the log-likelihood function gives a summary of the information concerning
θ for a given data set, it becomes possible to compute the impact of the ith
case based on the difference of the log-likelihood between θˆ and θˆi, where θˆi
represents the MLE of θ when the ith subject is deleted. The difference is
given as
L(θˆ)− L(θˆi), (3.5)
which measures the impact of the ith subject. If the contrast in Equation 3.5
is large (could influence bioequivalence decision), the ith subject is considered
an outlier.
The LD statistic, which is based on the log-likelihood distance, is given by
LDi(θˆ) = 2[L(θˆ)− L(θˆi)],
where θˆi is the MLE of θ when the ith subject is deleted. LDi(θˆ) can be
shown to be asymptotically chi-square distributed with 3 degrees of freedom
(df ) as k (number of subjects) approaches infinity. An ith subject is therefore
considered an outlier if
LDi(θˆ) > χ
2
3(α),
where χ23(α) is the upper α percentile of a central chi-square distribution with
3 df.
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Alternatively, the impact of an individual subject could be studied by delet-
ing that subject and taking note of the changes (Chow and Tse, 1990). The
comparison is then based on the difference θˆi − θˆ. A squared distance from θˆi
to θˆ, which is referred to as Cook’s distance, and is similar to that of linear
regression, was derived by Cook and Weisberg (1982).
The estimates distance can then be defined as
EDi(θˆ) = k
2(θˆi − θˆ)Σˆ−1(θˆi − θˆ),
where Σˆ is the estimate of
∑
=

θ3
n
0 0
0
2θ22
n− 1 0
0 0 2θ23
 , (3.6)
obtained by replacing θ by its MLE θˆ. EDi(θˆ) can be shown to have a chi-
square distribution with 3 df. Therefore, an ith subject is regarded as an
outlier if
EDi(αˆ) > χ
2
3(α),
where χ23(α) is the α percentage point of a χ
2
3 distribution.
3.7 Interval Hypothesis Approach
In reality, no two drug formulations can ever have the same bioavailability
profiles as their profiles would differ by a clinically meaningful limit (Chow
and Liu, 2008). Even though the two drug formulations may not have exactly
the same profiles, they could be considered as equivalent if they differ by a
clinically accepted limit. Due to this, another approach for assessing average
bioequivalence, the interval hypothesis method, was introduced by Schuirmann
(1987). The hypothesis for average bioequivalence is given as
H0 : µT − µR ≤ θL or H0 : µT − µR ≥ θU ,
H1 : θL < µT − µR < θU ,
(3.7)
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where µT and µR are the average bioavailability of the test product and refer-
ence product, respectively, θU and θL are clinically meaningful limits which are
both given as 20% of the unknown reference mean (µR). The null hypothesis
states that µT and µR are not equivalent while the alternative hypothesis states
that they are equivalent. Bioequivalence is concluded if both null hypotheses
are rejected. However, when the natural logarithm of the PK responses is used,
the hypothesis in Equation 3.7 becomes:
H0 : µT/µR ≤ δL or H0 : µT/µR ≥ δU ,
H1 : δL < µT/µR < δU ,
(3.8)
where δL = exp(θL) and δU = exp(θU).
Given that θL=−0.2µR and θU=0.2µR, the interval hypotheses can be rephrased
as
H0 : µT − µR ≤ −0.2µR or H0 : µT − µR ≥ 0.20µR,
H1 : −0.2µR < µT − µR < 0.20µR,
(3.9)
which, if µR > 0, may be changed to
H0 : µT/µR ≤ 0.80 or H0 : µT/µR ≥ 1.20,
H1 : 0.80 < µT/µR < 1.20.
(3.10)
The statistical assumptions of normality and homogeneity of variance are
deemed to be satisfied for the logarithmically transformed bioavailability vari-
ables (Hauck and Anderson, 1984). If the statistical assumptions are true on
the logarithmic scale, the interval hypotheses can be changed to
H0 : ηT − ηR ≤ log(0.80) or H0 : ηT − ηR ≥ log(1.20),
H1 : log(0.80) < ηT − ηR < log(1.20),
(3.11)
where ηT and ηR are the true test and reference means, respectively, of the
logarithmically transformed parameters.
Equation 3.7 can be decomposed into:
H01 : µT − µR ≤ θL versus Ha1 : µT − µR > θL,
H02 : µT − µR ≥ θU versus Ha2 : µT − µR < θU .
(3.12)
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The initial set of hypotheses in Equation 3.12 are used to determine if average
bioavalibality of the T drug is not too low while the second batch tests if the
average bioavailability is not too high (Chow and Liu, 2008). Whenever the
average BA of the T drug formulation is too low, there is an issue of efficacy
and an issue of safety when it is too high. Rejecting H0 in Equation 3.7 is
similar to rejecting H01 and H02 in Equation 3.12 which eventually leads to an
average bioequivalence conclusion.
Thus, when θL < µT − µR and µT − µR < θU , it can be concluded that
θL < µT − µR < θU ,
µT and µR are considered to be bioequivalent.
3.7.1 Two One-Sided Test (TOST)
The logic of hypothesis testing requires that the hypothesis to be demonstrat-
ed be the alternative hypothesis. This, however, implies that the equivalence
hypothesis should be the alternative and not the null hypothesis as demonstrat-
ed in Equation 3.7. Schuirmann (1987) introduced the Two One-Sided Test
(TOST) procedure which consists of decomposing the interval hypotheses in
Equation 3.7 into two sets of one-sided hypotheses,
H01 : µT − µR ≤ θL versus Ha1 : µT − µR > θL,
H02 : µT − µR ≥ θU versus Ha2 : µT − µR < θU .
(3.13)
The TOST procedure consists of rejecting the null hypothesis in the interval
hypothesis (Equation 3.13) and concluding equivalence of µT and µR, if and
only if both null hypotheses (H01 and H02) are rejected at a specified α level of
significance. Under normality assumptions, the two sets of one-sided hypothe-
ses in Equation 3.13 can be tested with ordinary one-sided t tests. Thus, BE
is concluded if
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TL =
(Y¯T − Y¯R)− θL
σˆd
√
1
n1
+
1
n2
 > t(α, n1 + n2 − 2),
TU =
(Y¯T − Y¯R)− θU
σˆd
√
1
n1
+
1
n2
 < −t(α, n1 + n2 − 2),
(3.14)
where Y¯T and Y¯R are the observed average bioavailabilities of the T and R for-
mulations, respectively, θL and θU are lower and upper bioequivalent limits, σˆd
is the pooled standard deviation of period difference from the two sequences,
n1 and n2 are the number of samples in each sequence and α is the level of
significance. The TOST procedure turns out to be operationally identical to
the procedure of declaring bioequivalence only if the (1 − 2α)× 100% CI for
µT − µR is contained in the interval [θL, θU ], where (1− 2α)× 100% CI is the
90% classical confidence interval.
However, regulatory agencies such as the FDA were not necessarily concerned
with the power of bioequivalence but rather with the confidence interval with
which bioequivalence is concluded (Patterson, 2003). According to FDA (1992),
the significance level under the Schiurman’s TOST procedure is set at 5% per
test. The assumptions for bioequivalence assessment using the TOST proce-
dure are as follows:
• Samples should be randomised;
• Homogeneity of variances;
• Addition of the statistical model; and
• Normality and independence of residuals.
The FDA demands that subjects used for the bioequivalence studies must
be allocated at random to a sequence and the model will be fitted to a log
transformed AUC and Cmax. The within- and between-subjects variances are
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assumed to be homogeneous for both formulations while the Cmax and AUC
data are presumed to be log-normally distributed. The goodness-of-fit of the
log-transformed data is assessed using the residuals versus predicted values as
well as normality probability plots (Jones and Kenward, 2014).
3.7.2 Analysis of Variance (ANOVA)
ANOVA has been used as an assessment of bioequivalence in the past, accord-
ing to Pabst and Jaeger (1990), to test a simple hypothesis of the means of
the characteristics of the CTC being equal or not (Westlake, 1981). The null
hypothesis states that the T drug has the same consequence as the R drug.
Rejecting the null hypothesis implies that the T and the R have different effects
whenever they are taken. The hypothesis is given as follows:
H0 : µi − µ = 0 for all i = 1, 2, ..k
H1 : at least two µi − µ are different,
(3.15)
where µi represents the population mean for level i. Quite a handful of re-
searchers have criticised the use of the ANOVA as a method of bioequivalence
assessment (Hauck and Anderson, 1984). However, the ANOVA is needed, as
stated by Rani and Pargal (2004), to estimate the least squares means and the
error variance, σ2. The use of ANOVA enables the researcher to comprehend
the variation within the data through separating the total sum of squares (SS)
into random errors and fixed effects (Chow and Liu, 2008). The model used
in the ANOVA, given by Chow and Liu (2008), is given in Equation 3.16
SSTotal =
2∑
k=1
2∑
j=1
nk∑
i=1
(Yijk − Y¯...)2
=
2∑
k=1
2∑
j=1
nk∑
i=1
(Yijk − Y¯i.k + Y¯i.k − Y¯...)2
=
2∑
k=1
2∑
j=1
nk∑
i=1
(Yijk − Y¯i.k)2 + 2
2∑
k=1
nk∑
i=1
(Yi.k − Y¯...)2
= SSwithin + SSbetween,
(3.16)
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where
Y¯i.k =
1
2
2∑
j=1
Yijk,
where Y¯i.k is the average of Yijk for each sequence, Y¯... is the grand mean,
SSwithin denotes the sum of squares for within subjects and SSbetween is the
sum of squares between the subjects. The number of subjects in sequences
1 and 2 are denoted as n1 and n2, respectively. The total sum of squares
(SStotal) has 2(n1 + n2) − 1 df, the SSwithin has n1 + n2 df and the SSbetween
has n1 + n2− 1 df. The SSbetween is sub-divided into two parts with one being
the carryover effect and the other the inter-subject error. Thus,
SSbetween = SScarry + SSinter, (3.17)
with SScarry being the carryover effects with 1 df and SSinter the inter-subject
error with n1 + n2 − 2 df. SScarry and SSinter are defined below,
SScarry =
2n1n2
n1 + n2
{(Y¯.12 + Y¯.22)− (Y¯.11 + Y¯.21)}2, and
SSinter =
2∑
k=1
nk∑
i=1
Y 2i.k
2
−
2∑
k=1
Y 2..k
2nk
,
The mean squares (MS) is derived by dividing the sum of squares by its df.
To test the carryover effect hypothesis, the test statistic is given by
Fc =
MScarry
MSinter
∼ F (1, n1 + n2 − 2).
If Fc < F (α, 1, n1+n2−2), the null hypothesis is rejected with F (α, 1, n1+n2−
2) being the upper αth percentile for the F distribution with 1 and n1 +n2−2
df (Chow and Liu, 2008).
However, the test statistic Fc is similar to Tc > t(α/2, n1+n2−2) since Fc = T 2c .
In the same way, SSwithin can be written as:
SSwithin = SSdrug + SSperiod + SSintra,
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where
SSdrug =
2n1n2
n1 + n2
{1
2
[(Y¯.21 − Y¯.11)− (Y¯.22 − Y¯.12)]}2,
SSperiod =
2n1n2
n1 + n2
{1
2
[(Y¯.21 − Y¯.11)− (Y¯.12 − Y¯.22)]}2,
SSintra =
2∑
k=1
2∑
j=1
nk∑
i=1
Y 2ijk −
2∑
k=1
nk∑
i=1
Y 2i.k
2
−
2∑
k=1
2∑
j=1
Y 2.jk
nk
+
2∑
k=1
Y 2..k
2nk
,
with 1 df for each of SSdrug and SSperiod and n1 + n2 − 2 df for SSintra.
Whenever the null hypothesis for the carryover effect is not rejected, thus
CR = CT , the null hypothesis for the drug effect testing for no drug effect can
be tested using the statistic
Fd =
MSdrug
MSintra
∼ F (1, n1 + n2 − 2).
The null hypothesis is rejected if Fd > F (α, 1, n1 + n2 − 2). The test statistic
Fd is similar to
Td =
Fˆ
σˆd
√
1
n1
+
1
n2
,
since Fd = T
2
d .
The test statistic below is considered for testing the null hypothesis in a period
effect:
Fp =
MSperiod
MSintra
∼ F (1, n1 + n2 − 2).
The null hypothesis is then rejected if Fp > F (α, 1, n1 + n2 − 2). It could be
shown that
Fp = T0 =
Pˆ
σˆd
√
1
n1
+
1
n2
.
An ANOVA table for the 2× 2 COD is provided in Table 3.5.
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However, to test for inter-subject variability (σ2s), the following hypothesis is
considered:
H0 : σ
2
s = 0,
H0 : σ
2
s > 0.
(3.18)
The test statistic for testing the inter-subject variability is
Fv =
MSinter
MSintra
∼ F (1, n1 + n2 − 2, n1 + n2 − 2).
If Fv > F (α, n1 + n2 − 2, n1 + n2 − 2), the null hypothesis of no inter-subject
variation is rejected.
3.7.3 Wilcoxon-Mann-Whitney Test
A distribution-free rank sum test can sometimes be used on a TOST, according
to Hauschke et al. (2007), with a 2 × 2 COD (Chow and Liu, 2008). This
distribution-free rank sum test is known as a Wilcoxon-Mann-Whitney TOST
(Chow and Liu, 2008). This is a non-parametric approach to the parametric
approach by Schuirmann (1987). When µT − µR in the hypothesis stated in
Equation 3.13 is replaced by θ, the two sets of hypotheses are re-written as:
H01 : θ
∗
L ≤ 0 versus Ha1 : θ∗L > 0
H02 : θ
∗
U ≥ 0 versus Ha2 : θ∗U < 0,
(3.19)
where θ∗L = θ − θL and θ∗U = θ − θU .
Given that i = 1, 2, ..., nk and k = 1, 2, the approximations of θ
∗
L and θ
∗
U are
acquired as a linear function of the differences in the period dik. Let:
bhik =
dik − θh, h = U,L, for the subjects in sequence 1,dik, for subjects in sequence 2, (3.20)
where dik =
1
2
(Yi2k − Yi1k). In the absence of any carryover effect, the expec-
tation of bhik is given as:
E(bhik) =

1
2
[(P2 − P1) + (θ − 2θh)], for k=1,
1
2
[(P2 − P1)− θ], for k=2,
(3.21)
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with h = L,U , i = 1, 2, ..., nk and k = 1, 2. The variance is given by V (bhik) =
V (dik) = σ
2
d =
σ2e
2
. It, however, implies that E(bhi1)−E(bhi2) = (θ − θh) = θ∗h.
Let RL represent the rank sum of the responses for subjects in the sequence 1,
RL =
n1∑
i=1
R(bLi1). (3.22)
The test statistic for H01 is given by:
WL = RL − n1(n1 + 1)
2
. (3.23)
If WL > W (1− α), the null hypothesis (H01) is rejected. W (1− α) represents
the (1 − α)th quantile for the distribution of WL. Similarly, for the second
batch of hypotheses in Equation 3.19, H02 is rejected if:
WU = RU − n1(n1 + 1)
2
< W (α), (3.24)
where RU represents the sum of ranks of bUik for the subjects in the first
sequence. When both sets of hypotheses H01 and H02 are rejected, thus
WL > W (1− α) and WU < W (α), (3.25)
the two drugs are considered to be average bioequivalent. Whenever there are
no ties among the observations, the expectation and variances of WL and WU ,
under the null hypotheses H01 and H02, gives
E(WL) = E(WU) =
n1n2
2
,
V (WL) = V (WU) =
1
12
(n1 + n2 + 1).
(3.26)
However, when there are ties, the WL and WU are calculated by assigning
average ranks. The expected value and variances of WL and WU thus become
E(WL) = E(WU) =
n1n2
2
, (3.27)
and
V (WL) = V (WU) =
1
12
(n1 + n2 + 1−Q), (3.28)
with
Q =
1
(n1 + n2)(n1 + n2 − 1)
q∑
v=1
R(r3v − rv),
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where q represents the frequency of groups that are semantic while rv denotes
the size of the groups that have the same association v.
It could be concluded that W (1 − α) = n1n2 −W (α) since WL and WU are
symmetric about their means, n1n2/2. For a large total number of subjects
(i.e n1 + n2 > 40) and with the ratio of n1 to n2 close to 1/2, Equation
3.25 can be approximated for ABE with a large sample approximation which
uses the standard normal distribution. Bioequivalence could be established if
ZL > Z(α) and ZU < −Z(α) with Z(α) being the αth quantile of the standard
normal distribution and
ZL =
WL − E(WL)√
V (WL)
=
RL −
[
n1(n1 + n2 + 1)
2
]
√
1
12
n1n2(n1 + n2 + 1)
,
ZU =
WU − E(WU)√
V (WU)
=
RU −
[
n1(n1 + n2 + 1)
2
]
√
1
12
n1n2(n1 + n2 + 1)
.
(3.29)
The variances in ZL and ZU are replaced with the one given in Equation 3.28
which assumes no ties.
Statistical methods for assessing average BE between the R and T drugs are
derived with the assumption that Sik as well as eijk are normally distributed
with means of 0 and variances σ2s and σ
2
e . In practise, the challenge faced
when comparing two drugs is the assumption of normality. Whenever the
assumption of normality is violated for both the raw or log-transformed data,
a distribution-free (non-parametric) method is applied. The non-parametric
version of TOST, which is the Wilcoxon-Mann-Whitney TOST, would be used
to test for a difference between Tmax for the R and the T drugs. The statistical
inferences discussed above assumed that the data follow a normal distribution.
The parametric test can then be replaced by Wilcoxon rank-sum tests or the
Mann-Whitney U-test. The non-parametric analysis for a 2 × 2 COD was
described first by Koch (1972) and illustrated later by Cornell (1990). In order
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to use this approach, the subjects must be randomly selected from a population
of healthy subjects, the observations within a sample must be independent of
one another and the two subjects must be independent of one another.
3.7.4 Confidence Interval
For some years, BE studies have been simply done using ANOVA, where a
simple hypothesis of no difference in the means of the R drug and T drug
was tested (Westlake, 1981). The use of the theory of classical statistical hy-
pothesis testing of the equality of any two formulations has been criticised by
many researchers, such as Westlake (1972) and Metzler (1974), as not being
the appropriate statistical method. Both of them suggested that the right ap-
proach is the confidence interval (CI) method for the assessment of average BE.
Westlake (1972) further argued that the hypothesis approach was not relevant
to assess bioequivalence and proposed an alternative method which is based
on the confidence interval. Also, it is not sufficient to say the two drugs are
interchangeable, but that an amount of assurance should be given that the
average quantity of the drug eliminated from the T drug is adequately close to
the quantity eliminated by the R drug. The hypothesis method, however, is
not able to provide this assurance. Metzler (1974) as well stated that it is not
enough to prove that Br 6= Bt (Br is the bioavailability of the R drug and Bt
is the bioavailability of the T drug) but that the difference Br −Bt should be
assessed instead and conclude it is acceptably small and thus non-significant.
Classical hypotheses testing are sometimes not appropriate for BE studies.
The classical hypothesis testing only tests whether the two drug formulations
are identical. Hypothesis testing, however, does not provide this assurance.
The confidence interval approach provides this assurance which is needed to
declare bioequivalence between the R and T drug.
To establish ABE between the R and T formulation, a 90% confidence interval
is constructed on either the natural logarithm or logarithm to base 10 of the
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AUC and Cmax. The two drugs can then be said to be bioequivalent if a classic
(1− 2α)× 100% CI for the ratio of the means of the T to the R drug µT/µR
or the difference between the mean of the T drug and the mean of the R drug
(µT − µR) is within the recommended limits set by the FDA and acceptable
limits of other regulatory bodies (Westlake, 1981). The acceptable limits for
the ratio of µT/µR, according to the FDA (2001), are [0.8,1.25] .
Metzler (1974) and Westlake (1976) stated that the classic CI method is the
most suitable approach for the assessment of ABE. Kirkwood and Westlake
(1981) suggested that when the (1− 2α)× 100% CI for (µT − µR) lies within
the approved limits approved by the FDA and other regulatory agencies, a
conclusion could be made indicating that the T drug is bioequivalent to the
R drug. However, when this condition is not satisfied, the T drug cannot be
said to be bioequivalent to the R drug.
The two CI approaches which will be used in this thesis are the classic CI and
Westlake’s Symmetric CI approaches.
3.7.4.1 Classic Confidence Interval
Given that Y¯R and Y¯T represent the least squares means ( the average means of
each formulation in both periods) of the R and T drugs, respectively, acquired
from the sequence-by-period means, the classic (1− 2α)× 100% CI is deduced
using the t-statistics in Equation 3.30,
T =
(Y¯T − Y¯R)− (µT − µR)
σˆd
√
1
n1
+
1
n2
∼ t(n1 + n2 − 2), (3.30)
where the total number of subjects in sequence 1 and sequence 2 are given by
n1 and n2, respectively, and σˆd denotes the pooled standard deviation of the
sample according to the Student t-distribution with (n1 + n2 − 2) df (Chow
and Liu, 2008). A classic (1−2α)×100% CI for the mean difference, µT −µR,
has limits
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L1 = (Y¯T − Y¯R)− t(α, (n1 + n2 − 2))σˆd
√
1
n1
+
1
n2
,
U1 = (Y¯T − Y¯R) + t(α, (n1 + n2 − 2))σˆd
√
1
n1
+
1
n2
.
(3.31)
Equation 3.31 could be converted to a classic (1− 2α)× 100% approximate CI
for the mean ratio, µT/µR, which results in Equation 3.32,
L2 =
(
L1
Y¯R
+ 1
)
× 100%,
U2 =
(
U1
Y¯R
+ 1
)
× 100%.
(3.32)
Given that θU and θL are, respectively, the upper and lower equivalence limits
for the difference, and δU and δL are the upper and lower equivalence limits
for the ratio, bioequivalence is concluded if
(L1, U1) ∈ (θL, θU),
(L2, U2) ∈ (δL, δU),
(3.33)
where:
• θL = −0.2µR;
• θU = 0.2µR;
• δL = 80%; and
• δU = 120% for the ±20 rule.
The classic (1− 2α)× 100% CI for the mean difference, µT − µR, is a random
interval and the confidence limits which are associated with it are random
variables. The classic (1−2α)×100% CI for µT −µR has a basic concept that,
should the same study be performed a number of times, say n times, then
(1− 2α)× 100% times of the n randomly constructed intervals will normally
cover µT − µR range (Peter and Kjell, 2001).
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However, there is no guarantee that the probability of the classic (1 − 2α) ×
100% CI within the limits of the equivalence limits is at least 1 − 2α (Chow
and Liu, 2008). Thus, the probability,
P [(L1, U1) ∈ (θL, θU)],
cannot be automatically more than or equal to 1− 2α.
3.7.4.2 Westlake’s Symmetric Confidence Interval
The classic (1 − 2α) × 100% CI for the difference in the means of the T and
R drugs, µT − µR, from Equation 3.31, is symmetric around Y¯T − Y¯R but not
around zero (Chow and Liu, 2008). Similarly, Chow and Liu (2008) stated
that, from Equation 3.32, the CI for the mean ratio of the T and R drugs,
µT/µR, is symmetric around Y¯T/Y¯R but not around 1. The classic CI derived
from an unpaired two sample t statistic in Equation 3.30 is
|T | < k or − k < T < k,
where k is the upper αth percentile of a central t distribution with n1 +n2− 2
degrees of freedom. The classic (1 − 2α) × 100% CI for the difference in the
means of the T and R drugs, µT − µR, could be given as:
k1 < T < k2, (3.34)
where k1 and k2 are selected such that the chance from k1 to k2, which is
dependent on a central t-distribution with n1 + n2 − 2 df, is equivalent to
(1− 2α). That is, ∫ k2
k1
Tdt = 1− 2α.
Equation 3.34 reduces to the classic CI Equation 3.31 whenever k1 = −k2.
Westlake (1976) argued that the classic CI needs to be modified so that it is
symmetric around 0 for the mean difference since confidence limits are mostly
stated in a symmetric form and also to make it easier for non-statisticians to
understand.
The CI for µT − µR is given as:
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−∆ < µT − µR < ∆. (3.35)
where ∆ represents Westlake’s symmetric confidence interval.
It is similar to establishing a CI for the T drug formulation (µT ) being sym-
metric about the R mean (µR), thus :
µR −∆ < µT < µR + ∆, (3.36)
where ∆ = −k1σˆd
√
1
n1
+
1
n2
+ (Y¯R − Y¯T ).
This suggests that
(k1 + k2)σˆd
√
1
n1
+
1
n2
= 2(Y¯R − Y¯T ). (3.37)
The T drug can be considered to be average bioequivalent to the R drug
according to the ±20 rule if |∆| < 0.2µR. The values of k1 and k2 could be
obtained by solving Equation 3.38,∫ k2
k1
Tdt = 1− 2α, (3.38)
for k1 and k2 under the constraint conditions in Equation 3.37.
3.7.5 Simulated Annealing Algorithm
Estimation of the AUC after the administration of a drug is one of the chal-
lenges encountered in PK studies. During the design phase of bioequivalence
studies, it is important to arrange the times of observations in order to estimate
accurately the AUC (Westlake, 1979). The choice of the study design affects
the efficiency of the PK studies as well as the precision with estimating the
parameters. According to Katz and D’Argenio (1983), the observation times
should be selected in order to get a minimal expected value of the squared
difference between the quadrature approximation and the exact value of the
integral. The process of finding the best suitable way of arranging the obser-
vation times is a combinatorial optimisation problem which can be achieved
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using several optimisation algorithms like simulated annealing, tabu search,
genetic algorithm, and others (Choi et al., 2007).
A MATLAB program was written to estimate the times, t1, t2, ..., tm, that will
minimise the objective function using the Simulated Annealing algorithm. The
first and last sampling times were fixed and only the interior times were op-
timised. The process starts by fixing the first and the last sampling points
with an iteration process exploring the neighbourhood for the best solution.
The best solution with the least objective function value gives the best op-
timised estimate value of AUC. During the process other parameters of the
drug, such as the volume of distribution, fraction of the absorbed dose which
is administered, the absorption rate, the elimination rate and the dose that is
administered, are also considered. The algorithm stops whenever there are no
improved solutions.
The Simulated Annealing recipe:
1. Select the starting value and initial parameter values;
2. Randomly select a new point in the neighbourhood of the original start-
ing value;
3. Compare the two points using the metropolis criterion;
4. Repeat steps 2 and 3 until the system reaches the equilibrium state; and
5. Stop when system reaches optimal solution.
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3.8 Population Pharmacokinetics(PopPK)
Models
The PopPK model, according to Sheiner et al. (1972, 1977), is an addition to
the PK model but this time integrates the individual variations. This model
is able to quantify the dose response connection using few concentration mea-
surements from each subject in the research as well as other data including
weight, age and sex. Bauer et al. (2007) stated that new algorithms including
NLMEM, the STS and Bayesian hierarchical models have been developed and
used for PopPK modelling. The NLMEM is used in this dissertation.
3.9 The Pharmacokinetic Model
The general pharmacokinetic model is:
yij = f(tij, φi) + g(tij, φi, ξi)εij 1 ≤ i ≤ N, 1 ≤ j ≤ ni, (3.39)
where φi represents the parameter vector of the structural model, f, for each
individual i, N is the number of subjects, and ni is the observation for indi-
vidual i. The residual error model is given by g which could be dependent
on the additional parameter vector ξi. For simplicity in the notation, given
that ψi = (φi, ξi), where ψi are the individual parameters of subject i grouped
together, Equation 3.39 can be written as:
yij = f(tij, ψi) + g(tij, ψi)εij 1 ≤ i ≤ N, 1 ≤ j ≤ ni. (3.40)
The residual errors (εij) have a mean of zero and standard deviation of one.
From Equation 3.39, f(tij, φi) and g(tij, φi, ξi) are the conditional mean and
standard deviation of yij.
That is:
E(yij|ψi) = f(tij, φi),
sd(yij|ψi) = g(tij, φi, ξi).
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3.9.1 The Structural Model
The first step in a PopPK model development is to discover the structural mod-
el that normally describes the data obtained. The structural model is denoted
by f in Equation 3.39. For any subject i and the individual vector parameters
ψ = (φi, ξi), f(tij, φi) gives the observed variable prediction at time tij. As-
suming that there are no errors (εij=0), it is the value that is measured at time
tij. This model predicts the concentration of the drug as a function of time.
The most commonly used structural models include 1-, 2- or 3-compartment
models with different absorption models (Sun, 2010). This model is usually di-
agnosed by plotting the predicted values versus the concentration conditioned
on time, predicted values for random effects versus concentration conditioned
on time, weighted residuals versus time, weighted residuals versus predicted
value, predicted value versus concentration conditioned on covariates, and pre-
dicted values for random effects versus concentration conditioned on covariates
(Sun, 2010). The model could be chosen from literature as a starting point
for the modelling process. However, if there is no known structural model
to start with, one could start with 1-, 2- and 3-compartment models with d-
ifferent elimination and absorption models and choose the best model using
different selection criteria including the Akaike information criterion (AIC),
the likelihood ratio test (LRT), the Bayesian information criterion (BIC) and
diagnostic plots. A basic structural model is usually one without covariates.
The structural model explains the underlying patterns in the data set. In this
dissertation, a one-compartment PK model with a first order absorption rate
and first order elimination rate is provided in Equation 3.41:
C(t, φ) =
DKa
V Ka − Cl (e
−(Cl/V )t − e−Kat), (3.41)
with the PK parameters φ=(Ka, V, Cl). The observed concentration is as-
sumed to be normally distributed with a constant error model given as:
yij|ψi ∼ N(c(tij, φi), a2),
where ψi=(φi,a). The PK parameters (Kai, Vi, Cli) are log-normally distribut-
ed. This model will be used to demonstrate the estimation methods discussed
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in Section 3.12 and the model evaluation methods discussed in Section 3.16.
3.9.2 The Residual Error Model
Although the main aim is to estimate the mean of the population parameters,
the variability of the parameters among the different subjects in the population
should also be observed (Bonate and Steimer, 2006). That is, the study is inter-
ested in how much the value of the obtained parameters vary from one subject
to another in the population. According to Bonate and Steimer (2006), ran-
dom effects are necessary in a NLME model not just because they quantify the
population variation but also determine a subject’s empirical Bayes estimate
(EBE) for parameters. The nature of the data often determines the type of
error model which is appropriate for the data. For any stated structural model
f, the conditional probability distribution of the observation (yij) is given by
the residual error model. In other words, it is given by the probability dis-
tribution of the residual errors (εij) and the standard deviation g((tij, φi, ξi)).
There are different types of residual error models. These include:
• Constant error model: This model assumes that g(tij, φi, ξi) = ai. Then,
ξi = ai and the model in Equation 3.40 becomes
yij = f(tij, φi) + aiεij. (3.42)
• Proportional error model: This model assumes that the standard error
of the residual error is proportional to the prediction, i.e., g(tij, φi, ξi) =
bif(tij, φi). Then ξi = bi and the model in Equation 3.40 becomes
yij = f(tij, φi)(1 + biεij). (3.43)
• Combined error model: This model combines a constant and a propor-
tional model with the assumption that g(tij, φi, ξi) = ai + bif(tij, φi),
ξi = (ai, bi) and
yij = f(tij, φi) + (ai + bif(tij, φi))εij. (3.44)
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3.9.3 The Covariate Model
A covariate can be described as any variable that is distinct to a subject and
could impact how the drug affects the body (Bonate and Steimer, 2006). The
covariates of a subject could be categorised as intrinsic factors (genetically de-
termined) such as weight, age, race or extrinsic factors such as dose or smoking
status (Bonate and Steimer, 2006). These covariates could be continuous or
categorical.
3.10 Parameter Estimation
3.10.1 The Maximum Likelihood Estimation of Popula-
tion Parameters
This is an approach which is used for estimating the population parameters
based on a probability distribution such as the maximum likelihood (ML)
estimation (Lavielle, 2014). The ML estimation of the population parametric
vector, θ is made up of maximising, with respect to θ, the observed likelihood
function which is defined by:
Ly(θ) = p(y; θ) =
∫
p(y,ψ; θ)dψ. (3.45)
Given a parameter vector θ∗ where observations were generated by the mod-
el parametrised by θ∗. According to Lehmann and Casella (2006), the ML
estimation under normal conditions has several attractive properties as the
number of individuals in the study increases. These include:
• consistency: the ML estimates converge to the true parameter values;
• asymptotic normality: as the number of subjects in the study increases,
the ML estimate distribution approaches the normal distribution with
mean θ∗ and covariance matrix equal to the inverse of the Fisher infor-
mation matrix; and
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• efficiency: when the sample size approaches infinity, it achieves the
Cramer-Rao lower bound implying that no estimator has a lower asymp-
totic mean squared error than the ML estimator.
One objective in a population modelling method is the estimation of the dis-
tribution of the individual parameters p(ψi, θ). For instance, if the vector ψi
is normally distributed, ψi ∼ N(ψpop,Ω), the population parameter vector
ψpop as well as the variance-covariance matrix, Ω need to be estimated.
In order to calculate the ML estimate, it requires an algorithm to maximise∫
p(y,ψ; θ)dψ with respect to θ. One algorithm, the stochastic approximation
expectation maximisation (SAEM), is used for the estimation. This algorithm
has been proven to be efficient and converges well (Kuhn and Lavielle, 2005;
Allassonniere et al., 2010).
3.10.2 Expectation Maximisation (EM) Algorithm
An estimator could be determined by maximising the joint distribution p(y, ψ, θ)
if the individual parameters were obtained. According to Dempster et al.
(1977), since the individual parameters are not observed, the EM algorithm
takes the place of ψ by its conditional expectation. An iteration k updates
θEMk−1 to θ
EM
k when initial conditions θ0 are provided in the following two steps:
1. E step: QEMk (θ) = E(logp(y,ψ; θ)|y; θEMk−1); and
2. M step: θEMk = arg max Q
EM
k (θ).
The EM sequence has the ability to converge under mild conditions to a point of
the observed likelihood (Wu, 1983). The relationship between the observation y
and the parameter ψ is usually nonlinear which makes the first step not explicit
for a nonlinear mixed effect model (Lavielle, 2014). This can be addressed by
using the SAEM algorithm as a stochastic approximation which depends on
the simulation of ψ (Delyon et al., 1999).
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3.10.3 Stochastic Approximation of EM (SAEM)
Algorithm
The SAEM algorithm is a stochastic algorithm which is used to estimate the
ML estimates (Lavielle, 2014). This algorithm is implemented in a number of
softwares including Monolix, NONMEM, MATLAB and R. This is an algo-
rithm based on iterations and requires an initial guess of the PK parameters.
The iteration k of SAEM comprises of three stages:
1. the simulation stage:
for i=1,2,...,N, draw ψki from the conditional distribution P (ψi|yi; θk−1);.
2. stochastic approximation:
Update Qk−1(θ) according to Qk(θ) = Qk−1(θ) + γk(logp(y,ψ
k; θ) −
Qk−1(θ)), where γk represents a sequence of decreasing positive numbers
with γ1 = 1; and
3. maximisation step:
Update θk−1 as stated by θk = argmax Qk(θ).
For the SAEM algorithm to converge, the requirement is that
∑∞
k=1 γk = ∞
and
∑∞
k=1 γ
2
k < ∞ (Delyon et al., 1999). This condition is satisfied if, for
instance, γk decreases as 1/k. In order for SAEM to converge, the choice of
step-size (γk) is very important. Choosing smaller step-sizes ensure there is
almost a guarantee of convergence of the algorithm to the ML estimates.
3.11 Model Evaluation
It is very important to evaluate the performance of any model that is developed.
In this, the model should be able to explain a phenomenon and the data used in
the modelling process. Model evaluation, therefore, is concerned with whether
the model best describes the observed data satisfactorily, whether the model
is simple enough for extrapolation and whether the model could be used for
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the reason it has been developed (Comets et al., 2010). It is essential to
check whether the data are in agreement with the model and also if the model
explains the data well (Lavielle, 2014). To be able to do this effectively, model
diagnostics are used to choose the model that best describes the data and
eliminate the models that are not able to reproduce the data (Comets et al.,
2010). These diagnostic plots are able to explain whether the model addresses
every relevant aspect of the data or if the model needs any further attention.
It is also important to be able to conclude if the data best describe a one- or
two-compartment model. A model selection process should be developed to
select the best model. Whenever several models are valid, it is often desirable
to select the model with the simplest assumptions. This selection process is
often done using model diagnostics. Another process could be using selection
tools to compute a criterion for comparing the models with one another. Some
of the criteria which would be used include Akaike information criteria (AIC)
and the Bayesian information criteria (BIC).
3.12 Model Diagnostics
The study examines several diagnostic plots and applies them to the data used
in this dissertation. These model diagnostics plots would be used to select the
best model among the different models which are used. The diagnostic plots
which are used in this dissertation are discussed below.
3.12.1 Spaghetti Plot
This is a plot of the concentration time curve for all subjects plotted on the
same panel. It is a plot that shows the effects of drugs on subjects after
the administration of the drug. This plot can be used to track results of
drugs amongst subjects. Spaghetti plot shows variability between individual
concentration data at a given time. It gives a better picture of the variability
between the individuals in the study. It is easy to select individuals who deviate
from the central tendency with respect to half-life, absorption, distribution,
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clearance,etc. using this plot.
3.12.2 Individual Fits
For the model defined in Equation 3.40, estimating the individual (ψi) and
population parameters ψpop enables the computation for each individual, the
predicted profile which is given by the estimated population model (f(t, ψˆpop)),
and the predicted profile which is given by the estimated individual model,
where ψˆi is an estimate of ψi (Lavielle, 2014).
3.12.3 Observation vs Prediction
The population and individual models enable the calculation of the predic-
tions f(tij; ψˆpop) for the population and f(tij; ψˆ) for each individual at the
observation times tij.
3.12.4 Residuals
There are a number of residuals but two of them are used in this disserta-
tion. The individual weighted residuals (IWRES) and normalised prediction
distribution errors (NPDE).
• IWRES are the estimates of the standardised residual (εij) which is based
on individual predictions:
IWRESij =
yij − f(tij; ψˆ)
g(tij; ψˆ)
.
Whenever the residuals are assumed to be correlated, it can be decorre-
lated by multiplying each individual vector IWRESi = (IWRESij, 1 ≤
j ≤ ni) by ˆR−1/2i , where Rˆi represents the estimated correlation matrix
of the vector of residuals (Lavielle, 2014).
• Population weighted residuals (PWRES) are defined as the normalised
difference between observations and their mean. Let yi = (yij, 1 ≤
j ≤ ni) represent the vector of observations for subject i. Then the
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mean of yi is the vector E(yi) = (E(f(tij;ψi), 1 ≤ j ≤ ni). Let Vi
be the ni × ni variance-covariance matrix of yi. Then the ith vector of
population weighted residuals PWRESi = (PWRESij, 1 ≤ j ≤ ni)
is therefore defined as:
PWRESi = V
−1/2
i (yi − E(yi)).
E(yi) and Vi are unknown but can be estimated by a Monte Carlo sim-
ulation.
• NPDE are a non parametric category of PWRES which depends on rank
statistics (Lavielle, 2014). For any (i, j), let Fij = FPWRESij(PWRESij)
where FPWRESij is the cumulative distribution function (cdf) of PWRESij.
The NPDE are defined as the empirical estimates of Φ−1(Fij) where the
Fij are obtained using Monte Carlo simulation: a large number of repli-
cates y1,y2, ...,yk, of the original data yobs are drawn under the model
and Fij estimated by:
Fˆij =
1
K
K∑
k=1
1ykij≤yobsij .
The NPDE are then defined as the empirical estimation of Φ−1(Fij), that is,
NPDEij=Φ
−1(Fˆij).
3.12.5 Visual Predictive Checks
This is a diagnostic tool which is used for continuous data which summaris-
es the structural models in the same plot by calculating several quantiles of
the empirical distribution of the data used (Lavielle, 2014). Ideally, the vi-
sual predictive check (VPC) diagnoses both the fixed and random effects in
a mixed-effects model. This is done by comparing different percentiles of the
observed data to percentiles of simulated data (Bergstrand et al., 2011). This
is often achieved by grouping the data into bins over a range of intervals. The
VPC is used to compare different models, suggests if the model needs an im-
provement and can also be used to support the appropriateness of a model
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(Karlsson and Holford, 2008). The prediction intervals for the quantiles are
then estimated using the Monte Carlo approach. The model is used to make
repeated simulations of the observations using the original design of the da-
ta. The percentiles of the simulated data are then plotted versus time from
when the treatment started. The same percentiles are then plotted for the
observed data to assist in comparing predictions with the observations. The
percentiles which are often chosen are the 10th, 50th and 90th percentiles. The
percentages of outliers which are outside the prediction interval are estimated
to show that the trends in the prediction interval could be used to identify
model misspecification (Wilkins et al., 2006).
3.12.6 Model Selection
The statistical tools which are often used to select the best model include the
information criteria such as the AIC and the BIC. The AIC and BIC, which
are used together with other diagnostic plots were implemented in MONOLIX
4.4.0 and are represented by
AIC = −2LLy(θ) + 2P, (3.46)
and
BIC = −2LLy(θ) + log(N)P, (3.47)
where P represents the total number of parameters to be estimated while N
is the number of subjects. In selecting the best model between two different
models, the model which has the smallest AIC or BIC is chosen as the most
appropriate one.
According to Lavielle (2014), when comparing two models, the LRT uses the
test statistic
LRT = 2(LLy(θˆ1)− LLy(θˆ0)),
where θˆ0 and θˆ1 represent the ML estimates of two models. The distribution
of the LRT could either be a χ2 distribution or a mixture of χ2 and Dirac delta
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(δ) distributions (Lavielle, 2014).
In order to perform the LRTs and compute the information criteria for the
models used, it requires the computation of the log-likelihood
LLy(θˆ1) = log(Ly(θˆ1)) = log(p(y; θˆ)),
where θˆ represents the vector of population parameter estimates for the mod-
el. The log-likelihood can be estimated for the data using the Monte Carlo
approach based on importance sampling. This method provides an unbiased
estimate of the log-likelihood whose variance is controlled by the Monte Carlo
size. Importance sampling is a sampling tool used for Monte Carlo computing.
It refers to a collection of Monte Carlo methods where a mathematical ex-
pectation with respect to a target distribution is approximated by a weighted
average of random draws from another distribution (Tokdar and Kass, 2010).
3.12.7 Model Validation
Model validation is done to examine whether the final model is a good descrip-
tion of the validation data in terms of the proposed application (FDA, 1999).
This can be interpreted as the assessment of the predictability of the developed
model to a validation data set. The data which are not used for building the
model and parameter estimation is referred to as the validation data. Two
model validation types which are often used include external validation and
internal validation.
3.12.7.1 External Validation
This is the application of the final developed model on a different dataset which
is usually from another study.
3.12.7.2 Internal Validation
This technique involves resampling methods (cross-validation and bootstrap-
ping) and data-splitting (FDA,1999). Data splitting is a convenient and use-
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ful internal validation method used to check the predictive performance of a
developed model when it is difficult to collect new data to be used for the
validation process. Another internal validation method is re-sampling. This
process involves cross-validation and bootstrapping. Cross-validation is the
use of repeated data-splitting and is very useful because the size of the model
development data could be larger than in other validation methods and vari-
ability is reduced.
Bootstrapping is another method that is used whenever the sample size is
small. It is used for evaluating the performance of a model when there is no
validation data set.
3.13 Summary
The Chapter provided a detailed description of the data and the variables
that were used in the PopPK model development as identified from previous
research. The steps that were taken in building the PopPK model were dis-
cussed including the data preparation, discussion of the structural and residual
error model as well as the parameter estimation methods. Different model e-
valuation methods were discussed including the AIC, BIC, individual plots,
observation versus prediction plots, plots of residuals, visual predictive checks
plots,etc.
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Chapter 4
Analysis and Results
4.1 Introduction
As discussed in earlier chapters, bioequivalence studies play an important role
in drug development and are conducted primarily by pharmaceutical compa-
nies who want market access for their drugs. This chapter discusses the results
obtained from the various methods recommended by the FDA and other bod-
ies for bioequivalence studies. The techniques that have been used include
ANOVA, CI, TOST, Wilcoxon-Mann-Whitney test and the results from these
methods are presented and discussed in this chapter. Results from ABE and
PBE are presented and discussed comprehensively.
In addition, this chapter discusses the results of the PopPK model and reviews
the model diagnostics generated from the best fitting model. The primary ob-
jective is to get the best model that describes the data adequately. The tech-
niques that have been used to assess the different models developed include
the AIC, BIC and other diagnostic plots which are illustrated in Figures 4.3
to 4.10. The model validation results together with statistical and diagnostic
plots are also provided.
The chapter also presents the results of the SA algorithm which are used to
obtain the optimal sampling times for the blood samples to be drawn from the
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subjects in the study. The optimised sampling times are then used to gener-
ate new concentrations for each subject and bioequivalence testing methods
applied to the optimised data.
4.2 ANOVA Results
In a randomised, single-dose, two-period, two sequence COD, it is assumed
that the within-subject variances are independent of the formulations result-
ing in the ANOVA table. The problem of the 2 × 2 COD concerns unbiased
estimation of the formulation differences in the presence of different carryover
effects. A failure to detect such an effect may lead to a biased estimate of
the formulation difference. Chow and Liu (2008) suggested performing a pre-
liminary test for the presence of different carryover effects before comparing
the formulations. Carryover effects are confounded with sequence effects and
formulation-by-period interaction. Different sequence effects may not bias the
analysis but a difference in carryover effects and a formulation-by-period effect
may lead to a serious problem. In bioequivalence studies, carryover effects
seldom occur if there is an adequate washout period between the periods. Al-
so, since healthy volunteers are recruited, their physical condition is unlikely
to change from one period to another. The pharmacokinetic parameters are
subjected to ANOVA in which the variance is partitioned into components due
to subjects, periods and formulations. The summary of the results from the
log-transformed parameters using ANOVA are presented in Table 4.1:
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Table 4.1: ANOVA table for log-transformed AUC0−t.
Source of Variation DF SS MS F statistics P-value
Between:Subject
Sequence 1 0.1053 0.1053 2.86 0.1129
Subject(Sequence) 14 0.5156 0.0368 3.25 0.0176
Within:Within
Formulation 1 0.0028 0.0028 0.25 0.6260
Period 1 0.0572 0.0572 5.04 0.0415
Residuals 14 0.1589 0.01135
Total 31 0.8398
From Table 4.1, the results indicate no significant effect in the sequence (p-
value=0.1129) but has significant subject effect (p-value=0.0176) at the 5%
level of significance. The significant subject effect therefore suggests that there
are inter-subject dissimilarity in clearance and also in the AUC0−t as well. In
addition, the period effect is also significant (p-value=0.0415) and the formu-
lation effect (p-value=0.6260) is not significant at the 5% level of significance.
This suggests that there are no statistically significant carryover effect or for-
mulation effects in this bioequivalence study. A significant period effect does
not suggest bioinequivalence. The formulation effect test is a secondary test
for the equality of the predicted means against the expected mean difference.
That is:
H0 : exp(µT ) = exp(µR) vs. H1 : exp(µT ) 6= exp(µR).
It is therefore not appropriate to use the formulation effect test for bioequiva-
lence assessment even if it is significant.
The residual variance estimate σˆ2W = MSwithin = 0.011348. This variability
is better expressed as a coefficient of variation (CV) for easy interpretation.
The residual variance estimate for the AUC0−t is 0.011348 (σˆ2W = 0.011348)
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and is proportionate to the within-subject CV of 10.7% assuming that the
formulation variances for the within-subject are equal. Similarly, the between-
subject CV is 11.3%.
Table 4.2: ANOVA table for log-transformed AUC0−∞.
Source of Variation DF SS MS F statistics P-value
Between:Subject
Sequence 1 0.0615 0.0615 2.12 0.1673
Subject(Sequence) 14 0.4060 0.0290 2.06 0.0938
Within:Within
Formulation 1 0.0149 0.0149 1.06 0.3199
Period 1 0.0407 0.0407 2.90 0.1108
Residuals 14 0.1967 0.0140
Total 31 0.7198
Table 4.2 provides the results for the ANOVA of the log-transformed extrapo-
lated AUC (AUC0−∞). The result indicates no significant effect in the sequence
(p-value=0.1673) and also no significant subject effect (p-value=0.0938) at the
5% level of significance. The non-significant subject effect therefore suggests
that there are no inter-subject differences in the AUC0−∞ and the clearance.
In addition, the period effect is not significant (p-value=0.1108) and the for-
mulation effect (p-value=0.3199) as well is not significant at the 5% level of
significance. This suggests that there are no statistically significant carryover
effect, period effect or formulation effects in this bioequivalence study.
The residual variance estimate σˆ2W = MSwithin = 0.014049. This variability
is better expressed as a CV for easy interpretation. The residual variance
approximation for AUC0−∞ is 0.014049 (σˆ2W = 0.014049) and this is equivalent
to the within-subject CV of 11.9% assuming that the formulation variances for
the within-subject are equal. Similarly, the between-subject CV is 8.7%.
Table 4.3 provides the results for the ANOVA of the log-transformed Cmax.
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Table 4.3: ANOVA table for log-transformed Cmax.
Source of Variation DF SS MS F statistics P-value
Between:Subject
Sequence 1 0.6110 0.6110 2.84 0.1140
Subject(Sequence) 14 3.0108 0.2151 1.04 0.4706
Within:Within
Formulation 1 0.0760 0.0760 0.37 0.5538
Period 1 0.0029 0.0029 0.01 0.9072
Residuals 14 2.8924 0.2066
Total 31 6.5932
The results indicate no significant effect in the sequence (p-value= 0.1140)
and the subject effect is also not significant (p-value= 0.4706) at a 5% level
of significance. The non-significant subject effect therefore suggests that there
are no inter-subject contrasts in clearance and in the Cmax as well. To add,
there is a non-significant period effect (p-value= 0.9072) while the formulation
effect is also not significant (p-value=0.5538). This suggests that there are no
statistically significant carryover effect, period effect or formulation effects in
this bioequivalence study.
The residual variance estimate σˆ2W = MSwithin = 0.2066. This variability
is better expressed as a CV for easy interpretation. The residual variance
evaluation for Cmax is 0.014049 (σˆ
2
W = 0.014049) and this is comparable to the
within-subject CV of 47.9% assuming that the formulation variances for the
within-subject are equal. Similarly, the between-subject CV is 6.5%.
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4.3 Statistical Methods for Average Bioequiv-
alence
4.3.1 Confidence Interval Method
The common approach for bioequivalence testing as stated by the FDA is to
construct a 90% CI for the mean difference of the log-transformed responses
of the PK parameters; AUC0−t, AUC0−∞ and Cmax. In order to conclude
that the R and T drugs are bioequivalent, the requirement states that the
confidence interval must be within the range [0.8-1.25].
4.3.1.1 The Classic Confidence Interval
Table 4.4: The mean of the different log-transformed pharmacokinetic param-
eters.
Mean
Parameter Test Reference
AUC0−t 4.115988 4.134758
AUC0−∞ 4.197142 4.240359
Cmax 1.237731 1.140246
Table 4.5: Confidence Interval for the different pharmacokinetic parameters.
AUC0−t AUC0−∞ Cmax
Interval Limits
Lower Upper Lower Upper Lower Upper
Shortest 98.32 100.77 97.65 100.31 89.59 127.51
Table 4.4 presents the mean of the different log-transformed R and T treatment
for each of the pharmacokinetic parameters. Table 4.5 provides the confidence
intervals for the different log-transformed pharmacokinetic parameters.
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The mean AUC0−t values were 4.115988 and 4.134758 for the T and R drugs,
respectively. The mean AUC0−∞ for the T and R drugs were 4.197142 and
4.240359, respectively. The mean Cmax values were 1.237731 and 1.140246 for
the T and R drugs, respectively. The mean AUC0−t and AUC0−∞ for the
R drug is higher than the T drug mean for the same parameters. However,
the mean Cmax for the T drug is higher than that of the R drug. The 90%
confidence interval for AUC0−t and AUC0−∞ were within the 80-125% limit
set by FDA and other regulatory bodies. However, the 90% confidence interval
for the Cmax was not within the 80-125% limit.
Table 4.6 presents the 90% confidence limits and the decisions reached about
bioequivalence between the R and T drugs.
Table 4.6: Confidence Interval and the decision about bioequivalence.
Interval Limits
Parameter Lower Upper Decision
AUC0−t 98.32 100.77 ABE claimed
AUC0−∞ 97.65 100.31 ABE claimed
Cmax 89.59 127.51 ABE not claimed
The 90% confidence interval for the log-transformed AUC0−t is presented as
(98.321,100.771). This confidence interval is within the (80-125) range accord-
ing to the FDA guidelines. Therefore the R drug and the T drug are declared
as average bioequivalent with regards to the AUC0−t.
The associated 90% confidence interval for the AUC0−∞ as presented in Ta-
ble 4.6 is (97.65,100.31) and is well within the interval (80-125) range. The
T and R formulations are therefore average bioequivalent with regards to the
AUC0−∞.
The associated 90% confidence interval for Cmax is (89.59,127.51) which is
not contained within the (80-125) range as per the FDA guidelines. Average
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bioequivalence cannot be concluded as required by the FDA guideliness as the
upper confidence limit exceeds the required upper limit as per FDA guidelines.
However, for Cmax, the WHO, the SAMCC and the EMEA adopt a more
relaxed equivalence interval of (70-133) for Cmax. By virtue of this relaxed
margin used by these organisations, bioequivalence can be claimed.
4.3.1.2 Westlake’s Symmetric Confidence Interval
For any two formulations to be declared as average bioequivalent using the
Westlake symmetric confidence interval, ∆ should be less than 0.2µR, where
∆ is defined in Equation 3.36. From Table 4.7, the ∆ values for AUC0−t
and AUC0−∞ are less than 0.2µR while the ∆ value for Cmax is greater than
0.2µR. Therefore, average bioequivalence is concluded in terms of AUC0−t and
AUC0−∞ but not Cmax.
Table 4.7: Westlake’s CI results for log-transformed AUC0−t, AUC0−∞ and
Cmax.
Parameter Westlake’s ∆ value 0.2µR
AUC0−t 0.07307435 0.8269516
AUC0−∞ 0.1001362 0.8480718
Cmax 0.3242763 0.228048
4.3.1.3 Schuirmann’s TOST Approach
The TOST procedure was introduced by Schuirmann (1987) and is based on
Equation 3.13. Two formulations are considered as bioequivalent if H01 and
H02 from Equation 3.13 are both rejected at a significance level which is pre-
determined.
The TOST results for the following log-transformed PK parameters AUC0−t,
AUC0−∞ and Cmax are presented in Table 4.8.
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Table 4.8: The Schuirmann’s TOST results.
TL TU t(α, n1 + n2 − 2)
AUC0−t 21.458 -22.455 1.761
AUC0−∞ 19.206 -21.269 1.761
Cmax 2.026 -0.812 1.761
From the results, |TL| and |TU | for AUC0−t and AUC0−∞ are both greater
than t(0.05, 14) = 1.761 . Since these values are greater than 1.761, the null
hypotheses (H01 and H02) in Equation 3.13 are both rejected at 5% level of
significance. Bioequivalence can be concluded according to the ±20 rule for
both AUC0−t and AUC0−∞. However, for Cmax, |TL| is greater than 1.761 but
|TU | is less than 1.761. Bioequivalence cannot be claimed using the Cmax.
4.3.2 Non-Parametric TOST Method
4.3.2.1 Wilcoxon-Mann-Whitney Two One-Sided Test for Tmax
Table 4.9 lists the ranks of bhik.
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From Table 4.9, the value of RL and RU are found to be 98 and 37, respectively.
WL = RL − n1(n1 + 1)
2
,
= 98− 8(8 + 1)
2
,
= 62,
and
WU = RU − n1(n1 + 1)
2
,
= 37− 8(8 + 1)
2
,
= 1.
Therefore W (0.95) = 8(8) − 16 = 48 and W (0.05) = 16. Since WL = 62 is
greater than W (0.95) = 48 and WU = 1 is less than W (0.05) = 16, both two
one-sided null hypotheses in Equation 3.19 are rejected at 5% level of signif-
icance. Average bioequivalence can then be concluded for both formulations
using the Tmax.
4.3.3 Power and Sample Size Determination
Bioequivalence studies should be designed properly such that the correct num-
ber of subjects are used to address the objective of the study. When designing
clinical trials, a power of at least 80% is required. The required number of
samples is determined from the design phase for a specific power. The em-
pirical power estimates for specific sample sizes and their associated CVs are
presented in Table 4.10. It is evident that, for any sample size, the power
of TOST increases as the CV decreases and the power decreases as the CV
increases.
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Table 4.10: Values for the index of sensitivity.
Coefficient of variation
N 10 15 20 25 30
8 0.916 0.600 0.300 0.133 0.059
10 0.969 0.742 0.442 0.216 0.096
12 0.988 0.831 0.565 0.314 0.151
14 0.996 0.887 0.664 0.417 0.217
16 0.999 0.926 0.737 0.506 0.293
Figures 4.1 and 4.2 present a graphical representation of the sample size and
power of the TOST used in bioequivalence studies. The graphs indicate that,
as the sample size increases, so does the power of the TOST.
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Figure 4.1: The power of the TOST
with corresponding number of samples.
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Figure 4.2: The power of the TOST
with corresponding number of samples.
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4.4 Population Bioequivalence
For population bioequivalence to be established, Θpop in Equation 2.7 must be
less than the regulatory set value of 1.74483 for the log-transformed AUC0−t,
AUC0−∞ and Cmax. Table 4.11 presents the results of the PBE for three PK
parameters.
Table 4.11: PBE results for logAUC0−t, logAUC0−∞ and logCmax.
Parameter Θpop Decision
AUC0−t 1.107772 PBE claimed
AUC0−∞ 1.010149 PBE claimed
Cmax 1.523058 PBE claimed
From Table 4.11, the Θpop values for all the PK parameters are less than
the 1.74 as per the FDA guidelines. This indicates that the two drugs are
population bioequivalent, implying that a patient can have the option to be
prescribed either the R or the T drug if they have not been using either of the
two.
4.5 Individual Bioequivalence
As stated by various researchers including Jones et al. (1999), IBE is on-
ly conducted for a replicated design so that the within- and between-subject
variability is estimated. IBE enables patients to easily switch from one formu-
lation to another formulation without any therapeutic effects. It is therefore
impossible to perform IBE in this research as the data are a 2× 2 COD.
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4.6 Population Pharmacokinetics
A randomised, single dose, two sequences, two periods crossover study was
performed on the subjects to compare the PK parameters of the T and the
R drug. The treatment periods were well separated and therefore there is no
evidence of carryover effect. The data were analysed with a NLMEM using
the SAEM algorithm which is implemented in MONOLIX 4.4.0. The NLMEM
parameters were estimated using the SAEM algorithm implemented in MONO-
LIX. Two different one-compartment models with first order absorption and
first order elimination were used to describe the data. Different residual er-
ror models were used together with the structural model and the models were
compared using BIC, AIC and VPC to determine the best model fit. The
ideal statistical model corresponds to the one with the smallest BIC and AIC
and also one with a VPC which best represents the data. After fitting the
model to the data, different graphs such as individual fits graphs, observation
versus predictions graphs, normalised prediction distribution errors (NPDE)
graphs, VPC, distribution of the individual parameter graphs, random effects
joint distribution graphs and the SAEM convergence graphs were obtained for
each of the different models. The best model based, on the criteria mentioned
previously, is presented with the model diagnostics and analysed. The VPC
graphs were evaluated using the prediction intervals (PI) for each model.
The best statistical model for the data is the combined error model with two
parameters a for the additive and b for the proportional part together with
the structural model with PK parameters Ka, V and Cl. The model used
has no covariates and the period or sequence effects are also not incorporated.
Table 4.12 displays parameter estimates with their standard errors and root
square errors. Figures 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 4.10 present the spaghetti
plot, the individual and population fits, the prediction vs observation plot, the
residuals, the VPC plots, the parameter distribution plot, the random effect
joint distribution plot and the SAEM convergence plot.
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The pharmacokinetic population modelling was done with MONOLIX version
4.4.0. The parameters of the population were estimated using the SAEM
algorithm and reported in Table 4.12. These parameter values are considered
to be the EBE because they were obtained at the maximum. The relative
standard error (r.s.e) percentage for the parameters Ka, V and Cl are 19%,
10% and 5%, respectively. The residual variability was modelled using different
error models (constant and combined error model). The best error model was
the combined error model for the residual variability using model diagnostics.
The AIC, BIC and log-likelihood of the best model are presented in Table
4.13. The interindividual variability (IIV) for the random effects ωKa , ωV and
ωCl are 39%, 28% and 13%, respectively. The individual parameters follow a
log-normal distribution and are independent as illustrated below:
Cli = 0.234× exp(ηi,Cl) with ηi,Cl ∼ N(0, 0.1362), (4.1)
Vi = 5.97× exp(ηi,V ) with ηi,V ∼ N(0, 0.2812), (4.2)
(Ka)i = 2.76× exp(ηi,Ka) with ηi,Ka ∼ N(0, 0.3912). (4.3)
Table 4.12: Parameter estimates using the combined error model.
Parameter Estimate s.e (stochastic
approximation)
r.s.e (%)
Ka 2.76 0.52 19
V 5.97 0.61 10
Cl 0.234 0.013 5
Omega Ka 0.391 0.18 46
Omega V 0.281 0.073 26
Omega Cl 0.136 0.043 32
a 0.0336 0.0089 27
b 0.164 0.014 9
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Table 4.13: Statistical tools for model selection.
AIC BIC -2 × log-likelihood
33.28 33.92 17.28
Figure 4.3: Spaghetti plot with parameters Ka, V and Cl.
Figure 4.3 shows the concentration time graph (spaghetti plot) for the R drug
with 8 subjects. It is a plot of the concentration time curve for all subjects
plotted on the same panel. This graph represents the distribution of drug ab-
sorption, distribution and elimination for the subjects that received the same
dose of the drug at the same sampling times. From the graph, it is concluded
that almost all the subjects exhibited similar drug kinetics (absorption, dis-
tribution, metabolism, elimination). It can also be concluded from the plot
that the data do not contain experimental errors and no large inter-individual
differences exist with respect to the peak.
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Figure 4.4: The Individual and the population fits for the subjects are plotted
simultaneously on each of these four plots.
Figure 4.4 shows the individual fits and the population fits for subjects with
their estimated individual parameters (lighter line) and the estimated popu-
lation parameters (darker line). Also, the estimated individual parameters for
each subject are indicated. The data are displayed using the crosses. The
population fits is the estimation of the model on each subject based on the
population parameters and the individual fits is the estimation on each subject
based on the individual parameters. The individual parameters are estimated
from the conditional mode or the conditional mean. The individual fits graphs
fit the data well and therefore the proposed PK model is accepted since the
fits seem acceptable. These fits are acceptable for the one-compartment model
which was proposed since the data fit the model.
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Figure 4.5: Observations versus predictions graphs using the population mod-
el(left) and individual model (right).
Figure 4.5 shows the observation versus prediction using the proposed popula-
tion model (left) with population parameters and the individual model (right)
with the individual parameters. The observation versus individual predic-
tion graph indicates that there is no misspecification in the model but the
observation versus population prediction graph indicates a slight model mis-
specification. The data are nicely distributed around the identity line for the
individual predictions. There is a slight deviation away from the line for the
population prediction as indicated in Figure 4.5. It is also evident from the
population prediction graph that there is an inter-individual variability and
residual variability since not all the data points lie on the identity line. How-
ever, the inter-individual variability is small. There is no nonzero prediction
which corresponds to a zero concentration observation which indicates that
there is no delay between the time when the drug was administered and the
time during which it was absorbed. In other words, there is no lag-time. The
amplitude of the residual errors also seem to increase along the predicted con-
centration for both graphs. This indicates that a constant error model is not
the most appropriate model for this type of data.
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Figure 4.6: The IWRES and the NPDE.
From Figure 4.6, the graphs for the IWRES and the NPDE with respect to
time are presented in the top row and the graphs for the IWRES and NPDE
with respect to the prediction are in the middle row as well as the graphs for
presenting the comparison of the empirical and theoretical probability density
function (pdf) of the IWRES and the NPDE are at the bottom. The prediction
intervals are also added on each of the graphs. The IWRES and the NPDE
are expected to be independent standardised normal random variables. The
IWRES and the NPDE histograms also suggest normality for both residuals.
From Figure 4.6, both the IWRES and the NPDE suggest that there is a slight
model misspecification as indicated by the residuals which are outside the
prediction intervals although generally the model is acceptable. The IWRES
are centered around the zero mean line indicating that the one compartment
structural model is the appropriate model for this data. The variance of the
IWRES is constant which also indicates that the error model is appropriate.
The IWRES can then be said to be normally distributed with a mean of zero
and a constant variance. The amplitude of the residuals are not too large.
The 10th, 50th and 90th percentiles which are displayed in Figure 4.6 indicate
a slight misspecification although generally the model predicts the data quite
well. The plot of the NPDE versus predictions tends to disperse the data quite
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well over the range of predictions.
Figure 4.7: Visual predictive check.
From Figure 4.7, there is an indication that the structural model is good except
for between 10 to 19 hours where the model underestimates or under predicts.
In the 10% prediction intervals, the 10th empirical percentile deviates from
the theoretical percentile slightly between 9 to 30 hours although it does not
indicate model misspecification. The 90% prediction interval fits the data quite
well.
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Figure 4.8: Estimated population distributions of the individual parameters
(solid line) and the empirical distributions of the individual parameters simu-
lated with their conditional distributions (histogram).
Figure 4.8 indicates the probability density function which was obtained for
each individual parameter in the model from the estimated population param-
eters as well as the empirical distribution which is indicated by the histogram
of the individual parameters. Each of the individual parameters was simulated
with its own conditional distribution. From Figure 4.8 and from the plots for
Ka, V and Cl, it is clear that that the individual parameters are log-normally
distributed and the shrinkage which was estimated using the simulated param-
eters, is a random variable with a mean of zero and variance close to 1/N . The
shrinkage values (-10%, -5% and 8%) as shown in Figure 4.8 are significantly
different from zero.
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Figure 4.9: Joint distribution of the random effects.
The graphs in Figure 4.9 represent a plot of each pair of simulated random ef-
fects against each other. Regression and spline interpolations are also displayed
to assist in determining the correlation between the random effects. From the
three plots, it is evident that the points are randomly scattered and indicate no
trend. This indicates that there is no correlation between the random effects
which indicates that there is a diagonal variance-covariance matrix. Therefore
Ka, V and Cl are independent of each other.
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Figure 4.10: SAEM convergence for each of the parameters Ka, V andCl.
Figure 4.10 shows the parameter estimates which were computed after each
iteration of SAEM. It shows the convergence of the estimated parameters.
The parameters of the one-compartment model with first-order absorption
and linear elimination are estimated. The vertical lines on each graph indicate
where the algorithm switches from the first phase to the second phase. The
SAEM algorithm converges quite well to the global maximum of the likelihood
for each of the parameters.
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4.7 Model Validation
The fitting of the PopPK model on a portion of the data as well as the estimat-
ed parameters and model diagnostics were discussed in the previous section.
Even though the model diagnostics suggested that the one compartment mod-
el which was fitted on the data described it well, it does not suggest that the
model is highly significant. The developed model has to be validated. The
validation of the final PopPK model was based on statistical and graphical
methods. The parameter estimates are presented in Table 4.14 and the AIC
and BIC values of the validated model are shown in Table 4.15. The model
diagnostics plots are also presented in Appendix B.
Table 4.14: Validation model parameter estimates using the combined error
model.
Parameter Estimate s.e (stochastic
approximation)
r.s.e (%)
Ka 1.96 0.24 12
V 3.33 0.8 24
Cl 0.227 0.0058 3
Omega Ka 0.303 0.098 32
Omega V 0.675 0.17 25
Omega Cl 0.0614 0.021 34
a 0.0424 0.01 24
b 0.0859 0.0082 10
Table 4.15: Statistical tools for model selection.
AIC BIC -2 × log-likelihood
20.53 21.17 4.53
The AIC and BIC values of the validation model in Table 4.15 suggest that
the one compartment model fits the validation data well. The diagnostic plots
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in Figures B.2, B.3, B.4, B.5, B.6, B.7 and B.8 which are shown in Appendix
B also confirm that the model fits the data.
4.8 Simulated Annealing
In certain cases, the individual PK parameters are either not available or
cannot be determined directly. In such situations, the PK parameters are
estimated using modelling. The PK parameters which were estimated with
modelling are used in the simulated annealing algorithm to generate opti-
mised sampling times. The optimisation approach used in the dissertation
uses a one-compartment model with first order absorption as illustrated in E-
quation 2.19. Mostly, the Ka, Ke and V are random variables that change
for every subject but the dose is a fixed and known value. The optimal
sampling times which were obtained from the one-compartment model are
t=(0,0.5,0.71,1.3,1.44,2.10,5.13,5.16,5.36,7.15,8,19.44,24,33.62,34.53,48,72) and
shown in Figure 4.11.
0 10 20 30 40 50 60 70
Dotplot of optimised sampling times
time (hours)
Figure 4.11: Dot plot of optimised sampling times.
These sampling times were obtained from a one-compartment model with
population pharmacokinetic parameters Ka = 0.0393, Ke = 2.71, D = 15,
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V = 0.0863 and F = 1. The parameters have been defined in Equation 2.1.
The concentrations for each subject, the AUC0−t, the AUC0−∞ were obtained
and are presented in Tables 4.16 and 4.17.
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Table 4.16: Log-transformed AUC for the T and R formulations after optimi-
sation.
Subject Sequence Period Formulation AUC0−t AUC0−∞ Cmax
842 1 1 R 67.43587 79.30902 2.002654
858 1 1 R 64.62041 66.45337 2.990088
860 1 1 R 63.25278 72.97602 1.908576
861 1 1 R 53.91614 54.42014 3.205287
862 1 1 R 51.74834 56.07939 1.860115
864 1 1 R 62.15424 75.20628 1.732339
869 1 1 R 60.51894 61.10355 3.475313
870 1 1 R 51.95971 53.83509 2.322062
842 1 2 T 65.86338 69.09776 2.66777
858 1 2 T 61.14068 64.37372 2.43851
860 1 2 T 71.41448 73.86414 3.13272
861 1 2 T 58.21259 59.55591 2.813054
862 1 2 T 44.36431 48.88173 1.519091
864 1 2 T 72.333 77.75346 2.631034
869 1 2 T 63.45344 73.11628 1.922489
870 1 2 T 63.17753 67.89929 2.312708
827 2 1 T 58.80359 58.81331 5.714009
843 2 1 T 60.86652 62.05818 3.003115
844 2 1 T 61.41677 69.94059 1.919448
857 2 1 T 65.92797 68.02171 2.953064
859 2 1 T 67.94529 67.94547 8.545359
863 2 1 T 68.45833 68.45838 9.849732
866 2 1 T 66.2853 71.80288 2.366139
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Table 4.17: Log-transformed AUC for the T and R formulations after optimi-
sation.
Subject Sequence Period Formulation AUC0−t AUC0−∞ Cmax
985 2 1 T 65.02689 70.92395 2.270761
827 2 2 R 58.21236 71.60807 1.565088
843 2 2 R 72.3221 73.32932 3.794461
844 2 2 R 70.19283 72.04327 3.239377
857 2 2 R 71.18192 71.18194 10.3222
859 2 2 R 88.02288 93.19436 3.379288
863 2 2 R 73.97729 81.16862 3.126044
866 2 2 R 61.17458 75.12056 1.647895
985 2 2 R 66.62649 70.44845 2.580378
The AUC data obtained after the optimisation is used to test for BE stud-
ies and the results are presented. The summary of the results from the log-
transformed parameters using ANOVA are presented in Table 4.18.
Table 4.18: ANOVA table for the log-transformed AUC0−t.
Source of Variation DF SS MS F statistics P-value
Between:Subject
Sequence 1 0.0812 0.0812 3.98 0.0659
Subject(Sequence) 14 0.2855 0.02039 3.25 0.0174
Within:Within
Formulation 1 0.00269 0.00269 0.43 0.5230
Period 1 0.0320 0.0320 5.11 0.0402
Residuals 14 0.0878 0.0063
Total 31 0.4892
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From 4.18, the results indicate no significant effect in the sequence (p-value
= 0.0659) but has significant subject effect (p-value=0.0174) at the 5% level
of significance. The significant subject effect therefore suggests that there are
inter-subject dissimilarity in clearance and also in the AUC0−t as well. In ad-
dition,the period effect is also significant (p-value=0.0402) and the formulation
effect (p-value=0.5230) is not significant at the 5% level of significance. This
suggests that there are no statistically significant carryover effect, period effect
or formulation effects in this bioequivalence study. The formulation effect test
is a secondary test for the equality of the predicted means against the expected
mean difference. That is,
H0 : exp(µT ) = exp(µR) vs. H1 : exp(µT ) 6= exp(µR).
It is therefore not appropriate to use the formulation effect test for bioequiva-
lence assessment even if it is significant.
The residual variance estimate σˆ2W = MSwithin = 0.0063. This variability
is better expressed as a CV for easy interpretation. The residual variance
estimate for the AUC0−t is 0.0063 (σˆ2W = 0.0063) and is proportionate to the
within-subject CV of 7.92% assuming that the formulation variances for the
within-subject are equal. Similarly, the between-subject CV is 6.6%.
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Table 4.19: ANOVA table for the log-transformed AUC0−∞.
Source of Variation DF SS MS F statistics P-value
Between:Subject
Sequence 1 0.0630 0.0630 2.83 0.1149
Subject(Sequence) 14 0.312 0.022 2.95 0.0260
Within:Within
Formulation 1 0.0163 0.0163 2.16 0.1634
Period 1 0.0453 0.0453 5.99 0.0282
Residuals 14 0.1058 0.00756
Total 31 0.5424
Table 4.19 gives the ANOVA results of the log-transformed AUC0−∞.
The results indicate no significant effect in the sequence (p-value=0.1149) and
also a significant subject effect (p-value=0.0260) at the 5% level of signif-
icance. The significant subject effect therefore suggests that there are inter-
subject dissimilarity in clearance and also in the AUC0−∞ as well. In addition,
the period effect is significant (p-value=0.0282) and the formulation effect (p-
value=0.1634) is not significant at the 5% level of significance.This suggests
that there are no statistically significant carryover effect, period effect or for-
mulation effects in this bioequivalence study.
The residual variance estimate σˆ2W = MSwithin = 0.00756. This variability
is better expressed as a CV for easy interpretation. The residual variance
approximation for AUC0−∞ is 0.00756 (σˆ2W = 0.00756) and this is equivalent
to the within-subject CV of 8.7% assuming that the formulation variances for
the within-subject are equal. Similarly, the between-subject CV is 11.5%.
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Table 4.20: ANOVA table for the log-transformed Cmax.
Source of Variation DF SS MS F statistics P-value
Between:Subject
Sequence 1 1.126 1.126 5.17 0.0393
Subject(Sequence) 14 2.8362 0.2026 0.87 0.6021
Within:Within
Formulation 1 0.0864 0.0864 0.37 0.5525
Period 1 0.0730 0.0730 0.31 0.5847
Residuals 14 3.265 0.233
Total 31 7.3867
Table 4.20 gives the ANOVA of the log-transformed Cmax. The result in-
dicates a significant effect in the sequence (p-value=0.0393) and the subject
effect is also not significant (p-value=0.6021) at a 5% level of significance. The
non-significant subject effect therefore suggests that there are no inter-subject
contrast in clearance and in the Cmax as well. In addition, there is a non-
significant period effect (p-value=0.5847) while the formulation effect is also
not significant (p-value=0.5525). This suggests that there are no statistically
significant carryover effect, period effect or formulation effects in this bioequiv-
alence study.
The residual variance estimate σˆ2W = MSwithin = 0.233. This variability is bet-
ter expressed as a CV for easy interpretation. The residual variance evaluation
for Cmax is 0.233 (σˆ
2
W = 0.233) and this is comparable to the within-subject
CV of 48.3% assuming that the formulation variances for the within-subject
are equal. Similarly, the between-subject CV is 3.9%.
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4.8.1 The Classic Confidence Interval
Table 4.21: The mean of the log-transformed pharmacokinetic parameters.
Mean
Parameter Test Reference
AUC0−t 4.1441 4.1625
AUC0−∞ 4.1995 4.2448
Cmax 1.1011 0.9972
Table 4.21 presents the mean for the R and the T treatment for each of the
pharmacokinetic parameters. Table 4.22 provides the 90% confidence intervals
for the different pharmacokinetic parameters. The mean AUC0−t values were
4.1441 and 4.1625 for the T and R drugs, respectively. The mean AUC0−∞
for the T and R drugs were 4.1995 and 4.2448, respectively. The mean Cmax
values were 1.1011 and 0.9972 for the T and R drugs, respectively. The mean
AUC0−t and AUC0−∞ for the T drug is lower than the R drug mean for the
same parameters. However, the mean Cmax for the T drug is higher than that
of the R drug. The 90% confidence interval for AUC0−t and AUC0−∞ were
within the 80-125% limit set by FDA and other regulatory bodies. However,
the 90% confidence interval for the Cmax was not within the 80-125% limit.
Table 4.22: 90% CI for the different pharmacokinetic parameters.
AUC0−t AUC0−∞ Cmax
Interval Limits
Lower Upper Lower Upper Lower Upper
Shortest 98.65 100.46 97.96 99.91 87.49 133.00
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Table 4.23: 90% CI and the decision about bioequivalence.
Interval Limits
Parameter Lower Upper Decision
AUC0−t 98.65 100.46 ABE claimed
AUC0−∞ 97.96 99.91 ABE claimed
Cmax 87.49 133.00 ABE not claimed
The 90% CI for the log-transformed AUC0−t is given as (98.65,100.46). This
CI is within the (80-125) range as per the FDA guidelines. Therefore the R
drug and the T drug are declared as average bioequivalent with respect to the
AUC0−t.
The associated 90% CI for theAUC0−∞ as indicated in Table 4.23 is (97.96,99.91)
and is well within the interval (80-125). The T and R formulations are there-
fore average bioequivalent for the AUC0−∞.
The associated 90% CI for Cmax is (87.49,133) which is not contained within
the (80-125) range as per the FDA guidelines. ABE cannot be concluded
as required by the FDA guidelines as the upper confidence limit is above the
required upper limit as per the FDA guidelines. However, for Cmax, the WHO,
the SAMCC and the EMEA adopt a more relaxed equivalence interval of (70-
133) for Cmax. By virtue of this relaxed range used by these organisations,
average bioequivalence can be claimed.
4.8.2 Westlake’s Symmetric Confidence Interval
For any two formulations to be declared as average bioequivalent using the
Westlake symmetric CI, ∆ should be less than 0.2µR where ∆ is defined in
Equation 3.36.
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Table 4.24: Westlake’s CI results for log-transformed AUC0−t, AUC0−∞ and
Cmax.
Parameter Westlake’s ∆ value 0.2µR
AUC0−t 0.05754786 0.8325
AUC0−∞ 0.0866167 0.84896
Cmax 0.3448097 0.19944
From Table 4.24, the ∆ values for the PK parameters AUC0−t and AUC0−∞ are
less than 0.2µR. However, the ∆ value for Cmax is greater than 0.2µR. There-
fore, average bioequivalence is concluded in terms of AUC0−t and AUC0−∞
but not Cmax.
4.8.3 Schuirmann’s TOST Approach
The TOST procedure was introduced by Schuirmann (1987) and was based
on Equation 3.13. Two formulations are considered as bioequivalent if H01
and H02 from Equation 3.13 are both rejected at a significance level which is
predetermined.
Table 4.25: The Schuirmann’s TOST results for log-transformed PK parame-
ters.
TL TU t(α, n1 + n2 − 2)
AUC0−t 29.08393 -37.82908 1.761
AUC0−∞ 26.15258 -36.00039 1.761
Cmax 1.776692 -0.8514206 1.761
The Schuirmann’s TOST results are shown in Table 4.25 for the following PK
parameters AUC0−t, AUC0−∞ and Cmax. From the results, |TL| and |TU | for
AUC0−t and AUC0−∞ are both greater than t(0.05, 14) = 1.761 . Since these
values are greater than 1.761, the null hypotheses (H01 and H02) in Equation
3.13 are both rejected at 5% level of significance. We can conclude bioequiva-
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lence according to the ±20 rule for both AUC0−t and AUC0−∞. However, for
Cmax, |TL| is greater than 1.761 but |TU | is less than 1.761. Bioequivalence
cannot be claimed using the Cmax.
4.9 Comparing optimal and regular design
During the sampling times, the general rule of thumb is to collect more blood
samples during the absorption phase and peak phase and collect less during
the elimination phase. However, the number of samples and the time intervals
are generally chosen by the pharmacokineticist and not based on any rule.
The regular design of sampling is done without any recognised algorithm and
not taking the characteristics of the drug into consideration while the optimal
design considers the various characteristics of the drug and uses an algorithm
to compute the different times the blood samples are to be collected.
It is very important to verify the quantity of AUC0−t that is missed when the
trapezoidal method is used to calculate the AUC0−t using the regular design.
The AUC0−t for the regular design and optimal design are presented in Tables
4.26 and 4.27. The second column in Tables 4.26 and 4.27 report the AUC0−t
from time 0 to 72 hours for the regular design while column 3 reports the
AUC0−t from time 0 to 72 hours for the optimal design. The AUC0−t for the
regular design was obtained using the linear interpolation method as explained
in Section 2.5 while the AUC0−t for the optimal design was obtained using
Equation 2.16 after optimising the sampling times. Column 4 presents the
percentage of the unexplained AUC0−t when using the regular design.
140
Table 4.26: AUC0−t for regular and optimal design.
Subject AUC0−t(Regular) AUC0−t(Optimal) % difference
842 62.4935 67.43587 7.328993
858 60.244 64.62041 6.772489
860 65.0565 63.25278 -2.85161
861 50.333 53.91614 6.645765
862 49.2165 51.74834 4.892601
864 60.549 62.15424 2.582672
869 57.7215 60.51894 4.622421
870 49.312 51.95971 5.095698
842 53.378 65.86338 18.95648
858 63.4214 61.14068 -3.73028
860 78.4096 71.41448 -9.7951
861 56.0545 58.21259 3.707256
862 38.5985 44.36431 12.99651
864 78.99 72.333 -9.20327
869 71.838 63.45344 -13.2137
870 54.3085 63.17753 14.03827
827 56.264 58.80359 4.318767
843 61.1015 60.86652 -0.38606
844 59.2165 61.41677 3.582523
857 60.798 65.92797 7.781174
859 68.9234 67.94529 -1.43956
863 67.7175 68.45833 1.082162
866 66.153 66.2853 0.199592
141
Table 4.27: AUC0−t for regular and optimal design.
Subject AUC (Regular) AUC (Optimal) % difference
985 58.9715 65.02689 9.312132
827 55.291 58.21236 5.018453
843 73.1955 72.3221 -1.20765
844 72.3501 70.19283 -3.07335
857 66.7527 71.18192 6.222395
859 85.6995 88.02288 2.639518
863 77.544 73.97729 -4.82136
866 59.1085 61.17458 3.377351
985 67.0836 66.62649 -0.68608
The mean percentage of the unexplained AUC0−t while using the regular de-
sign is 2.523912 % and a standard deviation of 6.79962 %. The range of the
percentage difference is [-13.21372%, 18.95648 %]. The results show that the
trapezoidal approximation of the AUC0−t from time 0 to 72 hours for the opti-
mal design is an improvement over the regular design which was used originally.
However, there were a few exceptions where the regular design performed bet-
ter than the optimal design for the subjects. This is an indication that the
optimal design could still be improved.
4.10 Summary
This Chapter provided results for the ANOVA, CI, TOST, SA, Wilcoxon-
Mann-Whitney test and PopPK model for the blood concentrations which
were collected from pigs. The results as discussed in the Chapter indicated
that the T drug formulation is average bioequivalent and population bioequiv-
alent to the R drug formulation using the three metrics AUC0−t, AUC0−∞
and Cmax. The results of the Wilcoxon-Mann-Whitney test on the Tmax also
indicated bioequivalence between the T and R drug formulations.
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The second part of the Chapter discussed the development of the PopPK mod-
el using a one compartment model with first-order absorption and first-order
elimination rate. The model was built using the SAEM algorithm which, ac-
cording to literature, performs very well. Empirical results and the model di-
agnostics indicate that the PopPK model is a better fitting model for the data.
The third part of the Chapter discussed the SA algorithm which used the
parameter estimates from the PopPK model to obtain optimal sampling times.
The empirical results show that the optimal sampling points on average were
better than the regular design method of collecting the blood concentrations.
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Chapter 5
Conclusion and
Recommendations
5.1 Conclusion
The procedures for assessment of bioequivalence testing have been in existence
for the past decades. The methods of bioequivalence assessment have been
constantly updated over the years to provide an efficient assessment. These
procedures are very important to the pharmaceutical industry as well as the
regulatory bodies so that the T drugs could be approved as a replacement for
the R drugs which are generally quite expensive. Advances in biopharmaceuti-
cal studies made it possible to develop improved drug formulations to enhance
efficacy while improving safety and also to create inexpensive drug products
which can be marketed once the patent on the R drug product expires. The
T drugs have become so important because they are cost effective and help to
reduce the medical costs for governments and private consumers.
This dissertation explores several avenues in bioequivalence studies such as
the design of the study, different methods of assessment of bioequivalence and
where such methods are implemented in drug development. The science of
biopharmaceutical studies focuses on differentiating between drug products in
order to provide new and improved treatments for the benefit of the public.
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Statistical techniques namely the TOST, Westlake’s CI, classic CI approach
and the Wilcoxon-Mann-Whitney TOST were used to determine ABE between
the T and the R drugs. Also, PBE was used to determine if the two drug prod-
ucts were bioequivalent.
In this dissertation, ABE was established between the T and R drug formula-
tions using the AUC since the 90% CI was within the FDA range of acceptance.
ABE could not be established under the FDA regulations using the Cmax since
the upper limit of the 90% CI exceeded the FDA CI limits. However, using the
regulatory requirements of the EMEA and the SMCC, ABE was established
between the T and the R drug formulations since they have a wider CI for
the Cmax. The results of the Wilcoxon-Mann-Whitney TOST using the Tmax
demonstrated ABE between the R and the T drug formulations.
From the hypothesis in Equation 2.9, the null hypothesis is rejected thereby
confirming the R and the T drug formulations are population bioequivalent us-
ing both the AUC and Cmax. From the findings in this dissertation, it can be
concluded that BE studies play a very important role in health care especially
in the developing countries and for those who cannot afford the R drugs. If
this concept is embraced and the relevant bodies instituted, the cost of health
care will reduce drastically as shown in the literature. The regulatory bodies
play a vital role to ensure that even though the T drugs are less expensive
and could reduce health care cost as discussed in Chapter 2, T drugs are also
as safe and effective as their R drug counterparts in curing their respective
illness. This ensures cheap and quality T drugs to be marketed.
However, from the literature, there are limitations to the use of ABE as the
sole measure of assessment. It has been stated that it is not enough to prove
that two drugs are average bioequivalent but also to use other approaches such
as the PBE and IBE to address the limitations of ABE.
145
5.2 Recommendations
It is recommended that a replicate design study should be used for drugs
which are highly variable (intra-subject coefficient of variation greater than
30%) in demonstrating ABE. The use of a replicate design reduces the sample
size needed. Also, during the design phase of BE studies, the nature of the
drug product should be taken into consideration and should also consider the
inter-subject variance homogeneity assumption. The subject-by-formulation
interaction variance is assumed to be null during the design stage of the study.
However, the variance may not be null. The replicate design offers a benefit
that this variance may be separated from intra-subject variation which leads
to better understanding of the study outcome.
The pharmacokinetic properties of the drugs should be carefully considered
when selecting subjects for the study. Clinical practice should be standardised
and conducted in accordance with good practice (time of meals, time of drug
administration, etc.).
Also, information on some demographic factors should be provided since they
may differ between populations and affect the results. When these assump-
tions are violated, the power to demonstrate BE would be reduced (Patterson,
2003). BE studies are mostly faced with lack of resources and therefore a s-
mall sample of subjects is advised as well as a two-period COD. However, to
make a meaningful statistical inference which could lead to a definitive study,
a replicate design is preferred which will result in IBE.
Covariate modelling should also be considered as one of the modelling ap-
proaches in PopPK modelling, which makes the design of the BE important
to include the covariates in the design of the BE study.
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Appendix A
The CTC for the subjects and
data for calculating AUC0−∞
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Figure A.1: Concentration pro-
file for T and R formulation in
sequence 1
0 10 20 30 40 50 60 70
0
1
2
3
4
5
Subject 858
Time (hours)
Co
nc
en
tra
tio
n 
(m
g/k
g)
Reference
Test
Figure A.2: Concentration pro-
file for T and R formulation in
sequence 1
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Figure A.3: Concentration pro-
file for T and R formulation in
sequence 1
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Figure A.4: Concentration pro-
file for T and R formulation in
sequence 1
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Figure A.5: Concentration pro-
file for T and R formulation in
sequence 1
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Figure A.6: Concentration pro-
file for T and R formulation in
sequence 1
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Figure A.7: Concentration pro-
file for T and R formulation in
sequence 1
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Figure A.8: Concentration pro-
file for T and R formulation in
sequence 1
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Figure A.9: Concentration pro-
file for T and R formulation in
sequence 2
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Figure A.10: Concentration
profile for T and R formulation
in sequence 2
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Figure A.11: Concentration
profile for T and R formulation
in sequence 2
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Figure A.12: Concentration
profile for T and R formulation
in sequence 2
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Figure A.13: Concentration
profile for T and R formulation
in sequence 2
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Figure A.14: Concentration
profile for T and R formulation
in sequence 2
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Figure A.15: Concentration
profile for T and R formulation
in sequence 2
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Figure A.16: Concentration
profile for T and R formulation
in sequence 2
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Appendix B
Diagnostic plots from
population Pharmacokinetic
Modelling
Figure B.1: Spaghetti plot with parameters Ka, V and Cl
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Figure B.2: Individual and population fits for subjects
Figure B.3: Observation versus predictions
168
Figure B.4: Individual weighted residuals and NPDE
Figure B.5: Visual predictive check
169
Figure B.6: Population distribution of the estimated individual parameters
and the empirical distributions of the individual parameters simulated with
conditional distributions
Figure B.7: Joint distribution of the random effects
170
Figure B.8: SAEM convergence
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Appendix C
R and MATLAB codes
R code f o r ABE and PBE
chow$Sequence<−as . f a c t o r ( chow$Sequence )
chow$Period<−as . f a c t o r ( chow$Period )
chow$Subject<−as . f a c t o r ( chow$Subject )
###conver t ing AUC and Conc to natura l l og in chow−−−−#
f o r ( i in 1 : nrow ( chow )){
chow$lnAUCT [ i ]<−( l og (chow$AUCT[ i ] ) )
}
f o r ( i in 1 : nrow ( chow )){
chow$lnAUCINF [ i ]<−( l og (chow$AUCINF [ i ] ) )
}
f o r ( i in 1 : nrow ( chow )){
chow$lnCMAX [ i ]<−( l og (chow$CMAX[ i ] ) )
}
c l c
c l e a r a l l
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format long g
t =[0 0 .5 1 1 .5 2 2 .5 3 4 5 6 8 12 24 24 30 48 7 2 ] ;
ka =0.0393; k =2.71; D=15; V=0.0868;F=1;
c=ka∗F∗D/(V∗( ka−k ) ) ;
f=@( t ) c . ∗ ( exp(−k .∗ t)−exp(−ka .∗ t ) ) ;
T=20;
[ a , b]= s i z e ( t ) ;
m=b−2;
f o r i =2:24
omega=f ( t ) ;
T=T/ log ( i ) ;
k1=randi ( [ 2 ,m] , 1 ) ;
tnew1=[ t ( k1−1) , t ( k1 +1) ] ;
r=un i f rnd ( t ( k1−1) , t ( k1 +1)) ;
tnew=t ;
tnew ( k1)=r ;
sigma=f ( tnew ) ;
p=min ( [ exp(−(sigma−omega ) . /T) , 1 ] ) ;
u=rand ;
i f u<=p
t=tnew ;
e l s e
end
end
d i sp l ay ( t ’ )
p l o t ( t , f ( t ) )
x l a b e l ( ’ time ( hours ) ’ )
y l a b e l ( ’ concent ra t i on (mg/kg ) ’ )
g r i d on
c l c
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c l e a r a l l
format long g
ka =0.0393; k =2.71; D=15; V=0.0868;F=1;
c=ka∗F∗D/(V∗( ka−k ) ) ;
f=@( t ) c . ∗ ( exp(−k .∗ t)−exp(−ka .∗ t ) ) ;
proc glm
data=WORK.DATA1;
c l a s s Formulation Period Sequence Subject ;
model lnAUC= Sequence Subject ( Sequence ) Period Formulation ;
random Subject / t e s t ;
lsmeans Formulation / p d i f f c l alpha =0.1 ;
run ;
proc mixed
data=WORK.DATA1;
c l a s s Subject Sequence Period Formulation ;
model lnAUC=Sequence Period Formulation ;
random Subject ( Sequence ) ;
lsmeans Formulation / p d i f f c l alpha =0.1 ;
e s t imate ’T/R’ Formulation 1 2 / c l alpha =0.1 ;
run ;
setwd (”C:\\ Users \\Administrator \\Desktop\\ opt im i sa t i on ”)
chow= read . csv (”C:\\ Users \\Administrator \\Desktop\\ opt im i sa t i on \\chow . csv ”)
chow$Sequence<−as . f a c t o r ( chow$Sequence )
chow$Period<−as . f a c t o r ( chow$Period )
chow$Subject<−as . f a c t o r ( chow$Subject )
###conver t ing AUC and Conc to natura l l og in chow−−−−#
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f o r ( i in 1 : nrow ( chow )){
chow$lnAUCT [ i ]<−( l og (chow$AUCT[ i ] ) )
}
f o r ( i in 1 : nrow ( chow )){
chow$lnAUCINF [ i ]<−( l og (chow$AUCINF [ i ] ) )
}
f o r ( i in 1 : nrow ( chow )){
chow$lnCMAX [ i ]<−( l og (chow$CMAX[ i ] ) )
}
tab . n<−aggregate (chow$lnAUCT , l i s t ( Sequence=chow$Sequence , Per iod=chow$Period ) , l ength )
n1<−tab . n [ tab . n$Sequence==1 & tab . n$Period ==1,]$x
n2<−tab . n [ tab . n$Sequence==2 & tab . n$Period ==1,]$x
n<−n1+n2
####−−−−−car ryove r e f f e c t−−−−−−−−−##
uik<−aggregate (chow$lnAUCT , l i s t ( Sequence=chow$Sequence , Subject=chow$Subject ) , sum)
colnames ( uik)<−c (” Sequence ” ,” Subject ” ,” uik ”)
muk<−aggregate ( uik$uik , l i s t ( Sequence=uik$Sequence ) , mean)
colnames (muk)<−c (” Sequence ” ,”muk”)
p r i n t (muk)
hatc<−muk[2 ,2 ]−muk [ 1 , 2 ]
hatc
du<−merge ( uik ,muk)
s igu2<−sum ( ( du$uik−du$muk)ˆ2/( n1+n2−2))
se . s igu<−s q r t ( s i gu2 ∗ ( (1/ n1)+(1/n2 ) ) )
TC<−hatc / se . s i gu
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TC
pc<−2∗(1−pt ( abs (TC) , n1+n2−2))
pc
###−−−f o rmulat ion e f f e c t−−−−###
dik<−aggregate (chow$lnAUCT , l i s t ( Subject=chow$Subject , Sequence=chow$Sequence ) , d i f f )
dik$x<−dik$x /2
colnames ( dik)<−c (” sub j e c t ” ,” Sequence ” ,” dik ”)
mdk<−aggregate ( dik$dik , l i s t ( Sequence=dik$Sequence ) , mean)
colnames (mdk)<−c (” Sequence ” ,”mdk”)
hatF<−mdk[1 ,2 ]−mdk [ 2 , 2 ]
dF=merge ( dik ,mdk)
s igd2<−sum ( ( dF$dik−dF$mdk)ˆ2 )/ ( n1+n2−2)
s i gd2
se . s igd<−s q r t ( s i gd2 ∗ ( (1/ n1)+(1/n2 ) ) )
TF<−hatF/ se . s i gd
TF
pf<−2∗(1−pt ( abs (TF) , n1+n2−2))
pf
mdrug<−tapply (chow$lnAUCT , l i s t ( Formulation=chow$Formulation ) , mean)
ybarT<−mdrug [ ”T” ]
ybarR<−mdrug [ ”R” ]
##−−−−−Confidence i n t e r v a l−−−−##
alphaCI<−0.1
qt . alpha<−qt(1−alphaCI , n1+n2−2)
#sigd2<−anova (mdlnAUCT) [ 5 , 3 ] / 2
low1<−(ybarT−ybarR)−qt . alpha∗ s q r t ( s i gd2 )∗ s q r t ( ( ( 1/ n1)+(1/n2 ) ) )
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up1<−(ybarT−ybarR)+qt . alpha∗ s q r t ( s i gd2 )∗ s q r t ( ( ( 1/ n1)+(1/n2 ) ) )
cat (”The c l a s s i c a l CI1=(” , round ( low1 , 6 ) , ” , ” , round ( up1 , 6 ) , ” ) ” , sep =”” ,”\n\n”)
low2<−((low1/ybarR)+1)∗100
up2<−((up1/ybarR)+1)∗100
cat (”The Ratio CI2=(” , round ( low2 , 5 ) , ” , ” , round ( up2 , 5 ) , ” ) ” , sep =”” ,”\n\n”)
##−−−west lake−−−##
mdrug<−tapply (chow$lnAUCT , l i s t ( Formulation=chow$Formulation ) , mean)
ybarT<−mdrug [ ”T” ]
ybarR<−mdrug [ ”R” ]
k12<−2∗(ybarR−ybarT )/ s q r t ( s i gd2 ∗ ( ( (1/ n1)+(1/n2 ) ) ) )
k2<−un i roo t ( func t i on ( k2 ) pt ( k12−k2 , n1+n2−2)−pt ( k2 , n1+n2−2)−(1−alphaCI ) , lower=−10,upper =10, t o l =0.0001) $root
k1<−k12−k2
cat (” the west lake k1=”,k1 , ” and k2=”,k2 , sep =”” ,”\n\n”)
low . west<−k2∗ s q r t ( s i gd2 ∗(1/ n1+1/n2))−(ybarR−ybarT )
up . west<−k1∗ s q r t ( s i gd2 ∗(1/ n1+1/n2))−(ybarR−ybarT )
cat (”The west lake CI f o r mu T−Mu A i s (” , low . west , ” , ” , up . west , ” , ” , sep =”” ,”\n\n”)
##−−two 0ne−s ided−−−##
theta . L<− −0.2∗ybarR
theta .U<− 0 .25∗ ybarR
#theta .U<− 0 .25∗ ybarR
TL<−(ybarT−ybarR−theta . L)/ s q r t ( s i gd2 ∗ ( (1/ n1)+(1/n2 ) ) )
TU<−(ybarT−ybarR−theta .U)/ s q r t ( s i gd2 ∗ ( (1/ n1)+(1/n2 ) ) )
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